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1 Introduction and goals 
Amino acids are classified as non-proteinogenic amino acids (NPAAs) when they are not part of the 
22 standard α-amino acids that are translated into proteins by the genetic code.[1] NPAAs occur in 
nature and can be chemically designed and synthesized as well.[2] Among 700 known NPAAs, around 
300 are found in plants. The significant role of NPAA in plants and soil was recently reviewed.[3] 
Thus, NPAAs could be considered as an important store of organic nitrogen in many ecosystems, as 
metabolites, as allelopathic substances. For instance, (R)-β-tyrosine 1, a β-amino acid which is 
enzymatically produced from (S)-α-tyrosine, is an interesting allelopathic compound with potential 
to suppress weeds in rice fields.[4] Moreover, NPAAs are involved in plant defense against insect 
herbivores.[5] 
Since NPAAs, i.e. proteomimetic amino acids, were found in proteins, the investigation of the 
significance of this in drug discovery and peptide synthesis gained close attention as NPAAs can 
possess interesting biological activity and can substitute the original α-amino acids in polypeptide 
chains in order to modulate their structure and activity.[6] Moreover, protein misfolding and protein 
aggregation may cause diseases such as amyotrophic lateral sclerosis, Parkinson’s and Alzheimer’s 
diseases and neurodegenerative neurolathyrism.[7] The role of protein aggregation could be 
accelerated by the incorporation of proteomimetic amino acids into proteins as an environmental 
factor. Important examples of such toxins are β-N-methylamino-L-alanine 2 (BMAA) and β-N-
oxalyl-L-α,β-diaminopropionic acid 3 (β-ODAP) (Figure 1).[8] 
 
Figure 1 
BMAA was first isolated from seeds of Cycas circinalis and reported as neurotoxic to “higher 
animals”.[9] BMAA is produced by the majority of cyanobacterial isolates,[10] and has been found in 
cycad seeds, plausibly derived from symbiotic cyanobacteria in coralloid roots (Cyca micronesica) 
as well as in species of free-living marine cyanobacteria, which may bioaccumulate in the marine 
food web.[11] Moreover, BMAA was recently found in shark fins.[12] This proteomimetic amino acid 
has the potential to be a major environmental factor capable of causing amyotrophic lateral sclerosis 
(ALS) and other neurodegenerative diseases.[13] The toxicity of BMAA is connected with 
amyotrophic lateral sclerosis and the parkinsonism-dementia complex (ALS-PDC), because a high 
rate of this disease was observed among Chamorro people from Guam.[14] First, it was suggested that 
consumption of the cycad flour by Chamorro people of Guam is a main source of BMAA, however, 
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this hypothesis was initially disputed because the level of the neurotoxin in cycad flour after 
processing is too low to be a cause of neurofibrillary degeneration of nerve cells observed in ALS-
PDC of Guam.[15] However, recently the association between BMAA and ALS disease regained 
attention because it was demonstrated that BMAA can become protein-associated, leading to 
increases in human BMAA levels and providing a potential mechanism for slow release.[16] 
Additionally, it was shown that BMAA is biomagnified via the food chain from the cyanobacteria 
symbionts on cycad plants to the flying foxes, which are present in the Chamorro people diet.[17] The 
univocal mechanism of BMAA toxicity was not established and chronic toxicity might be 
mechanistically differ from acute toxicity, but several suggestions were made. In the first proposal, 
the toxicity of BMAA was based on its action as an agonist for glutamate receptors (NMDA, 
mGluR5).[18] Another suggestion was based on the effect of BMAA on system xc- (cystine/glutamate 
antiporter),[19] inducing oxidative stress and increase of extracellular glutamate.[20] Recently, the 
Rodgers research group found that BMAA can be misincorporated in place of L-serine in human 
proteins in vitro, with subsequent protein misfolding, what can be a putative explanation of the 
toxicity of BMAA 2.[21] Noteworthy, the described misincorporation can be inhibited by L-serine.  
Another neurotoxin, β-ODAP 3, was found in the seeds of grass peas (Lathyrus sativus L. family 
Fabaceae syn. Leguminosae) and was proposed to be responsible for the neurodegenerative disease 
neurolathyrism.[22] The clinical syndrome of the latter disease is attributed to the excessive 
consumption of grass pea seeds as survival food in some regions of Africa and Asia due to the hardy 
and drought tolerant nature of the plants.[23] Albeit numerous studies were performed in order to 
establish the mechanism of initiation of neurolathyrism by β-ODAP, understanding the precise 
mechanism of toxicity remains challenging.[24] Moreover, β-ODAP was reported as an inhibitor of 
tyrosine aminotransferase (TAT) and as activator of protein kinase C (PKC).[25] Another example of 
a NPAA is α,γ-diaminobutyric acid 4 (DABA, or 2,4-diaminobutanoic acid) which was found in 
Lathyrus species.[26] DABA is highly toxic and, as β-ODAP, could cause a type of neurolathyrism 
(Figure 1).[27] 
An important example of a cyclic NPAA is azetidine-2-carboxylic acid (Aze) 5 (Figure 2) which 
mimics proline and could be incorporated into polypeptides promoting irreversible abnormal protein 
conformation, which could also result in neurodegeneration, multiple sclerosis and autoimmune 
disorders.[28] Additionally, derivatives of Aze 5 are known as active pharmaceutical ingredients, as 
for example the withdrawn thrombin inhibitor melagatran 6 (Figure 2).[29] 





The design and synthesis of new peptides with discrete and predictable folding propensities 
(“foldamers”) is one of the essential topics both in academia and in the pharmaceutical industry.[30] 
Peptides, constructed of α-amino acids, have some disadvantages such as low bioavailability and 
susceptibility to enzymatic degradation as well as flexibility of the peptide backbone, hampering the 
definition of the bioactive conformation. One of the possible solutions to these problems is the use 
of β-amino acids instead for the synthesis of oligomers (so called β-peptides).[31] The most interesting 
properties of β-peptides are folding in a predictable way and stability to cleavage by peptidases. The 
conformationally restricted alicyclic analogues of β-amino acids represent even more advantages for 
the chemistry of β-peptides.[32] Thus, trans-2-aminocyclohexanecarboxylic acid 7 (trans-ACHC) and 
trans-2-aminocyclopentanecarboxylic acid 8 (trans-ACPC) formed predictable peptide 14- and 12-
helices, respectively, what is unprecedented among α-peptides (Figure 3).[33] 
 
Figure 3 
On the other hand, azacyclic β-amino acids allowed to generate peptides with sheet conformation. 
For instance, nipecotic acid 9 was incorporated in a short peptide 10 that appeared to adopt well-
defined conformations (Figure 3).[34] It was suggested that dinipecotic acid segments are useful for 
the development of β-turn mimics for biological application[35] and for the creation of hairpin-shaped 
catalysts for asymmetric reactions.[36] Moreover, homooligomers of (S)-nipecotic acid are able to 
adopt non-hydrogen-bonded secondary structures such as the polyproline II helix (PPII).[37]  
In view of the importance of the aforementioned classes of non-proteinogenic amino acids in 
different fields of biological study, the aim of the present PhD-work is to expand on the synthesis of 
some of these amino acids and their analogues via different new pathways, involving diversity 
oriented synthesis (DOS) as major approach. Initially, (chiral) building blocks will be prepared which 
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are suited for subsequent (stereoselective) coupling reactions and final functional group 
transformations or cyclization. The focus of DOS is on efficient synthesis of collections of small 
molecules with skeletal and stereochemical diversity.[38] Both acyclic and cyclic α- and β-amino acid 
derivatives functionalized with diverse groups will be prepared. Such compounds can serve as 
analytical or biological tools in research regarding NPAAs or as building blocks in functional 
peptidomimetic foldamers. 
In the first part, it is envisioned that the addition of 1-(methylenamino)pyrrolidine 12, which 
possesses nucleophilic properties associated to its aza-enamine character,[39] across N-sulfinyl- or N-
sulfonyliminoesters 11 would lead to the formation of adducts 15 (Scheme 1). The N-sulfinylimino 
ester 11 (R = S*OtBu) was previously represented as a versatile reagent for the asymmetric synthesis 
of α- amino acids.[40] The N-sulfinyl substituent in iminoacetate 11 exerts a powerful stereodirecting 
effect and activates the C=N bond for nucleophilic addition and could be easily deprotected as well 
by simple acid hydrolysis.[41] N-sulfonyl imines 11 (R = Bus) also proved to be useful synthons in 
organic chemistry, including cycloadditions and nucleophilic reactions.[42] Adducts 15 could be 
foreseen as precursors for the synthesis of α,β-diamino acid derivatives. Thus, reduction of the C=N 
bond in 15 and subsequent N-N cleavage (for example, with BH3·THF)[43] could provide the 
diaminopropanoic acid derivatives 16 which could be elaborated towards ODAP 3 (Scheme 1). 
Noteworthy, this synthetic pathway would provide an advantageous chiral synthesis of diamino acid 
3 as opposed to the previously described methods. The latter were mainly based on chiral pool 
synthesis, having a lack of efficiency or requiring harsh reaction conditions.[22a, 44] Additionally, the 
chiral N-sulfinyl iminoacetate 11 (R = SROtBu) will be explored as electrophilic substrate in addition 
reactions of imidates 13 or α,α- dichloroketimines 14 in order to obtain the adducts 17 and 18, 
respectively. Adducts 17 could serve as precursor for the synthesis of enantiomerically pure α,γ-
diamino acid derivatives 19. Moreover, substrates 17 and 18 could be transformed into substituted 
azetidine-2-carboxylic acid derivatives 21 via elaboration of the imino and imidate moiety towards 
possible leaving groups. 3,3-Dichloroazetidines 21 (R5 = R6 = Cl) form a rather unknown class of 
strained azaheterocycles and their synthesis is rarely reported in the literature.[45] Moreover, the 
asymmetric synthesis of these dichloroazetidines was not previously described. The 3,3-
dichlorinated azetidines 11 represent valuable substrates towards a broad range of reactivities, 
including formation of 2-azetines and its further transformations (i.e. ring constructions or ring 
opening).[45b, 46] 





Previous research at the Department of Sustainable Organic Chemistry and Technology (UGent) has 
shown that the addition of α-chloro N-sulfinyl imidates across N-tosyl aldimines proceeds with high 
anti-diastereoselectivity, affording enantiomerically pure imidates, which were elaborated towards 
chiral 3-chloro-2-arylazetidines 22.[47] In the present research, further transformations of those 
azetidines 22 (Scheme 2), involving oxidation of aromatic C-2 substituent and nucleophilic 
substitution of the chloride at C-3, will be attempted in order to synthesize the 3-aminoazetidine-2-
carboxylic acid derivative 25. The latter azetidine 25 can be used as azacyclic β-amino acid derivative 
for the synthesis of β-peptides or to develop functional chemical probes for use in the study the 
relevance of azetidine-2-carboxylic acid 5 in neurodegenerative diseases.[32a] 
 
Scheme 2 
Moreover, it is envisioned that the use of δ-chloro-N-sulfinyl imidates 26 in the addition reaction 
across aromatic aldimines 27 could afford the new chiral β-aryl-δ-chloro-substituted β-amino acid 
derivatives 28 as potential building blocks for the synthesis of enantiopure 2,3-difunctionalized 
piperidines 29-33 (Scheme 3). The latter piperidines and their derivatives are a well-known class of 
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organic compounds due to their natural occurrence and their presence in pharmacologically active 
compounds (vide infra). 
 
Scheme 3 
Fluorinated analogues of bioactive compounds find increasing interest since fluorine often improves 
the bioactivity and bioavailability of drug molecules.[48] Recently, the diastereoselective synthesis 
cis-α-bromo-α-fluoro-β-lactams 36 (Scheme 4) was reported using the diethylzinc-promoted 
Reformatsky-type reaction of ethyl dibromofluoroacetate 34 with aromatic aldimines 35.[49] The β-
lactams 36 are envisioned as attractive precursors for the synthesis of new 2-aryl-3-bromo-3-
fluoroazetidines 37 via reduction of the carbonyl functionality. Because of incorporation of bromide 
and fluoride at the C-3 position of the azetidine ring, the investigation of the reactivity of azetidines 
37 is in the focus of the following research. Indeed, the nucleophilic substitution of bromide with 
functional groups such as azide or cyanide would provide valuable precursors 38 towards fluorinated 
3-aminoazetidines 40 or azetidine-3-carboxylic acid derivatives 41. Additionally, the elaboration of 
azetidines 37 via a halogen-exchange strategy will be attempted pursuing the synthesis of cyclic 
amino acid derivatives 41. Moreover, the scope of the Reformatsky-type reaction will be extended 
towards the use of a broad range of aldimines, including aliphatic aldimines and aldimines bearing 
an electron-withdrawing group on nitrogen. 





In the last part of this thesis, the research will further elaborate on a preliminary study of the reactivity 
of alkyl N-tosyl-2-(aminomethyl)acrylate.[50] The pool of N-substituted alkyl 2-
(aminomethyl)acrylates 42 (Scheme 5) will be extended and their transformations towards a diverse 
range of α- and β-amino acid derivatives, including of alkyl 2-(aminomethyl)oxirane-2-carboxylates 
44, alkyl aziridine-2-carboxylates 45 and alkyl azetidine-3-carboxylates 46, will be investigated. 
Elaboration of the azetidines 46 towards the 3-aminoazetidine-3-carboxylates 47 and 3-
azidoazetidine-3-carboxylic acids 48 would provide new Cα-tetrasubstituted amino acid derivatives. 
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2 Literature overview 
The objective of this literature overview is to give a general summary concerning the azacyclic non-
proteinogenic α- and β-amino acid derivatives, their significance and synthesis. The present research 
is mainly devoted to the synthesis of cyclic amino acid derivatives, in particular, with a four- and 
six-membered heterocyclic core. Therefore, the latter amino acids 5, 9, 49, 50 and their derivatives 
are the focus of the present report (Figure 4). The synthetic approaches of the last years (2010-2015) 
are highlighted. The earlier work was summarized in previous reviews.[52] 
 
Figure 4 
2.1 Significance of α- and β-amino acids with a piperidine and azetidine 
skeleton 
2.1.1 Pipecolic acid and its derivatives 
Pipecolic acid 49 is a naturally occurring non-proteinogenic amino acid which can be found in 
plants.[53] Numerous natural or synthetic derivatives of pipecolic acid 49 possess interesting 
biological activity, including anesthetic,[54] NMDA antagonistic, antibiotic,[55] or glycosidase and 
dehydrogenase inhibition.[56] Furthermore, the pipecolic acid core is a part of complex biologically 
active molecules. For instance, a pipecolic acid derivative is part of the structure of compounds such 
as anti-tumor antibiotic tetrazomine 51,[57] rapamycin 52, which was originally identified as 
antifungal agent and later recognized as a potent immunosuppressant,[58] allosteric modulator PNU-
69176E 53 of the serotonine (5-HT) 5-HT2C receptor (5-HT2CR),[59] and palinavir 54 or its analogue 






Moreover, pipecolic acid has been used in peptide chemistry.[61] Additionally, anti-HIV 
cyclodepsipeptide, homophymine A 55, isolated from a New Caledonian collection of the marine 
sponge Homophymia sp, contains a pipecolic acid moiety in the structure (Figure 6).[62] 
 
Figure 6 
Addtionally, L-pipecolic acid derived N-formamides were applied as basic organocatalysts for 
enantioselective synthesis.[63] Some metal complexes of racemic pipecolic acid exhibit anticancer 
activity.[64] 
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2.1.2 Nipecotic acid and its derivatives 
Recently, the development of a new series of piperidine-base renin inhibitors 56 and its analogues 
has gained close attention due to high in vitro potency toward human renin with good off-target 
selectivity and dose-depended blood pressure lowering effects (Figure 7).[65] A necessity for the 
design of new renin inhibitors, different from direct renin inhibitors (DRIs), is the lack of oral 
bioactivity of the DRIs. Also, nipecotic acid can be considered as a conformationally restricted γ-
aminobutyric acid (GABA) analogue, as exemplified by Tiagabine 57 (Gabitril®).[66]  
 
Figure 7 
As pipecolic acid 49, nipecotic acid 9 presents great potential in peptide chemistry.[31c] Functionalized 
piperidine-3-carboxylic acids are conformationally restricted azacyclic analogues of β-amino acids, 
which are known to be useful building blocks for the synthesis of peptides with modified and 
improved biological activities such as stability to metabolization, slow microbial degradation, 
stability to proteases and peptidases.[32c, 32d, 33e, 58a, 67] It has also been established that nipecotic acid 
can be incorporated into short homochiral peptides that appear to adopt well-defined conformations. 
Nipecotic acid-containing heterochiral dipeptides also strongly stabilize reverse-turn formation.[32e, 
34, 37] Additionally, piperidine-3-carboxylic acid derivatives were envisioned as potent activators of 
TrkB receptors in mammalian neurons,[68] as inhibitors of Rho/MKL1/SRF-mediated gene 
transcription that inhibits invasion of PC-3 prostate cancer cells,[69] and as anti-diabetic[70] and anti-
staphyloccocal agents.[71] 
2.1.3 Azetidine-2-carboxylic acid and its derivatives 
L-Azetidine-2-carboxylic acid (Aze) 5 is a naturally occurring plant non-proteinogenic amino acid 
and can be regarded as the lower homolog of proline.[28e] Aze is readily misincorporated in proteins 
in place of proline in different species, including humans, and causes toxic effects as well as 
congenital malformations.[28a, 28d, 72] Aze 5 is also a valuable building block for peptide synthesis.[73] 
Azetidine-2-carboxylic acid derivatives are incorporated in a wide range of biologically and 




Natural products with an Aze moiety in their structure were isolated, including nicotianamine 58,[74] 




Among the bioactive compounds, the Aze 5 part can be found in hepatitis C virus NS3 protease 
inhibitors 63,[78] in agonist 64 of Takeda G-protein receptors (TGR5) associated with diabetes, 
metabolic syndrome, and autoimmune disease,[79] and in the withdrawn thrombin inhibitors 
melagatran® 6 or exanta® 65 (Figure 9).[80] 
 
Figure 9 
Additionally, enantiopure azetidine-2-carboxylic acid derivatives could be used as organocatalysts 
for asymmetric reactions.[81] 
2.1.4 Azetidine-3-carboxylic acid and its derivatives 
Azetidine-3-carboxylic acid 50 (Figure 4) is a non-proteinogenic azacyclic β-amino acid which is, 
similar to its 6-membered analogue 9, of interest for use in peptide chemistry (vide supra). Since β-
peptides possess higher metabolic stability, they could be applied in some cases where the use of 
azetidine-2-carboxylic acid derivatives failed due to lack of stability.[82] Azetidine-3-carboxylic acid 
50 is used for the preparation of biologically and pharmaceutically valuable compounds. For 
instance, AMG 369 66[83] and BAF312 67[84] and their analogues,[83, 85] were discovered as agonists 
of S1P1 and S1P5 (Figure 10). Compound 68 showed antibacterial and anticancer properties 
comparable to the marketed drugs Linezolid and Ciprofloxacin (Figure 10).[86] 





2.2 Synthesis of pipecolic acid and its derivatives 
2.2.1 Chiral pool synthesis 
Recently, the synthesis of pipecolic acid derivatives based on chiral pool synthesis, using chiral 
starting materials such as serine, phenylglycinol, glutamic acid, proline, glyceraldehyde, glucose, 
mandelic acid and 1,2-amino alcohols was well reviewed.[52d] Therefore, the following overview will 
be focused on the most relevant new synthesis of piperidine-2-carboxylic acid derivatives. 
2.2.1.1 Synthesis from L-(+)-tartaric acid 
L-(+)-Tartaric acid 69 is a naturally abundant and cheap starting material. Chavan et al. reported two 
pathways applying L-(+)-tartaric acid 69.[87] In the first route, aldehyde 70 was prepared from tartaric 
acid 69 via a known procedure[88] and was subsequently used for Wittig olefination (Scheme 6). 
Alkene 71 was transformed to five-membered butyrolactone 72 via deprotection of the acetonide and 
TBS group. The reduction of the double bond and further selective protection of the primary alcohol 
with TBSCl led to formation of lactone 73. Furthermore, azido functionality was introduced using 
Mitsunobu reaction conditions to furnish azide 74. After the reduction of azide 74, the obtained 
compound 75 was treated with sodium methoxide to accomplish the cyclization towards lactam 76. 
Following reduction, the TBS-deprotection was carried out using TBAF in THF, affording the 






A second approach, reported by the same author, towards the synthesis of pipecolic acid derivatives 
based on tartaric acid 69 included less steps and was more convenient (Scheme 7).[90] Esterification 
of tartrate 69 afforded ethyl tartrate 79, which was treated with thionyl chloride to furnish sulfite 80. 
Opening of sulfite 80 with sodium azide and subsequent selective reduction of the ester group of 
substrate 81 gave β,γ-diol 82. The protection of diol 82 with a TBS group and further selective 
primary TBS deprotection furnished azido alcohol 83 which was oxidized using 2-iodobenzoic acid 
(IBX). The aldehyde was used for Wittig reaction, affording α,β-unsaturated ester 84. The reductive 
lactamization was performed by using hydrogen and Pd/C as catalyst, affording 6-oxopiperidine 85. 
The latter was subjected to selective reduction of the amide group to provide amino ester 86, which 
was hydrolyzed towards the target (2S,3S)-3-hydroxypipecolic acid trans-78. 





2.2.1.2 Synthesis from L-aspartic acid 
The direct synthesis of cis- and trans-2,6-disubstituted-4-oxo-L-pipecolic acid derivatives from L-
aspartic acid, where the stereochemical outcome depended on the presence or absence of a N-
protective group, was reported.[91] The starting enones 90 were prepared from L-aspartic acid 87 
(Scheme 8). The latter was converted to N-trityl L-aspartate dimethyl ester 88 under standard 
conditions. The phosphonate ester 89 was prepared by reaction of ester 88 with the anion of dimethyl 
methylphosphonate. Horner-Wadsworth-Emmons reaction of ester 89 with different aldehydes gave 
exclusively E-enones 90. 
 
Scheme 8 
The synthesis of trans-2,6-disubstituted-4-oxo-L-pipecolic acid derivatives 91 was achieved from 
enones 90 via tandem reductive amination/6-endo-trig cyclization mediated by sodium 
cyanoborohydride (Scheme 9).[91a] In turn, the synthesis of cis-2,6-disubstituted-4-oxo-L-pipecolic 




deprotection of enone 90 prior to the base-mediated 6-endo-trig cyclization.[91b] The optimal results 
were obtained using Hunig’s base (Scheme 9). Noteworthy, the second approach led to formation of 
minor product trans-91 in a cis-93/trans-91 ratio of 75/25 and the main isomer could be easily 
isolated via column chromatography. 
 
Scheme 9 
Subsequent stereoselective reduction of the keto functionality of the 4-piperidones 91 and 93 using 
sodium borohydride (for 91) or sodium triacetoxyborohydride (for 93) afforded methyl 4,6-
disubstituted piperidine-2-carboxylates 92 and 94, respectively, in good yield (Scheme 9). 
The Gouault research group also reported the synthesis of pipecolic acid derivatives based on 
(S)- aspartic acid (Scheme 10).[92] As key step of their method, the gold-catalyzed cyclization of 
ynone-containing α-amino esters 97 was accomplished. Weinreb amide 96, obtained from protected 
(S)- aspartic acid 95, was treated with lithium propylacetylide and lithium phenylacetylide, affording 
ynones 97a,b. The treatment of amide 96 with ethynylmagnesium bromide furnished 97c. 
Subsequent cyclization towards compounds 98 was performed using (triphenylphosphane)gold(I) 
bis(trifluoromethanesulfonyl)imide (for 98a and 98b) and using (triphenylphosphane)gold(I) triflate 
(for 98c). 





The enantiopure dihydropyridone-2-carboxylates 98 were revealed as key intermediates to undergo 
conversions into various 6-substituted 4-hydroxypipecolic acid derivatives 99. 
2.2.1.3 Synthesis from D-glycals 
The recent application of D-glycals for the formal synthesis of functionalized compounds with a 
piperidine core was reported by Mallick et al. (Scheme 11).[93] The synthesis of functionalized cis-
/trans-pipecolic acids 78 started from 3,4,6-tri-O-acetyl- D-glycals 100a,b, which were converted to 
azido derivatives 101a,b.[94] Reduction of 101a,b with lithium aluminum hydride followed by N-Boc 
protection of acyclic amino alcohols led to formation of derivatives 102a,b. Furthermore, the free 
hydroxyl groups were converted into the corresponding mesylates 103a,b. Because the direct 
cyclization of the latter substrates failed, the N-deprotection was performed in first instance followed 
by base-mediated cyclization towards functionalized piperidines 104a,b. Finally, target molecules 
trans- and cis-78 could be obtained via simple transformations of piperidines 104a and 104b, 






2.2.1.4 Synthesis from (R)-α-aminoadipic acid 
The Sewald research group provided a simple asymmetric synthesis of (R)-pipecolic acid 49 starting 
from (R)-α-aminoadipic acid 105 (Scheme 12).[95] Protection of the amino moiety with the 
benzyloxycarbonyl group followed by selective esterification at the α-position afforded compound 
106.[96] The reductive cyclization of intermediate 106 using BH3·Me2S afforded the protected 
pipecolic acid 107. Simple hydrogenation of piperidine 107 gave the target (R)-pipecolic acid 49. 
 
Scheme 12 
2.2.2 Ring transformation 
The Haufe research group reported an acid-catalyzed cascade reaction starting from the fluorovinylic 
compound 110a leading to the rearranged 4-oxopipecolic acid derivate 112 (Scheme 13).[97] The 
starting tert-butyl 2-tert-butyl-5-(2-haloallyl)-3-methyl-4-oxoimidazolidine-1-carboxylates 110a-c 
were prepared via asymmetric alkylation of Boc-protected imidazolidinone 108 with different 
electrophiles 109a-c. Treatment of substrate 110a with 4M HCl in methanol afforded the fluorinated 
amino acid derivative 111a and 4-oxopipecolic acid derivative 112. Noteworthy, the use of the 
chloro- or bromovinyl compounds 110b,c exclusively led to formation of the halogenated amino acid 
derivatives 111b,c. This supported the idea that the presence of a fluorovinyl group in 110a promoted 
the molecular rearrangement towards the formation of six-membered heterocycle 112. 





Product 112 was converted into (2S,4R,6R)-6-tert-butyl-4-hydroxypiperidine-2-carboxylic acid 114 
in two steps, including selective reduction with sodium borohydride and subsequent hydrolysis with 
HCl (Scheme 14). 
 
Scheme 14 
2.2.3 Enantioselective organocatalytic synthesis  
2.2.3.1 Enantioselective organocatalytic vinylogous aldol reaction 
The direct vinylogous aldol reaction of commercially available γ-crotonolactone 115 and 
benzaldehyde in the presence of aminosquaramide 116 as catalyst afforded aldol product 117 as a 
diastereomeric mixture of anti/syn in a ratio of 8/1 (Scheme 15).[98] Hydrogenation of the latter, 
subsequent mesylation of the secondary alcohol and substitution of the mesylate by azide (with 
inversion of configuration) yielded the azidobutyrolactone 118. Reduction of the azide 118 in the 
presence of a base (K2CO3) accomplished the rearrangement towards the piperidone 119. The major 
cis-isomer was easily separated via column chromatography and was used in further transformations. 
Reduction of the piperidone cis- 119 with borane and further N-Boc protection of the obtained 
piperidine afforded derivative 120, which was used as substrate for the synthesis of pipecolic acid 
derivative cis-78 via oxidative cleavage of the 2-aryl group. Noteworthy, the changing of the N-
substituent in piperidine 120 had a crucial effect on the oxidation of the 2-aryl substituent with 
RuCl3/NaIO4. The oxidation of the N-Boc protected piperidine 120 failed whereas the reaction of N-
trifluoroacetyl substituted piperidine 121 proceeded smoothly to provide, after methanolysis of the 
trifluoroacetamide, the corresponding carboxylic acid 78. In order to synthesize substrate 121, 
(2R,3R)-2-phenyl-3-hydroxypiperidine 120 was first converted to the N,O-bis trifluoroacetyl 






2.2.3.2 Proline-catalyzed cascade reaction 
Proline and its derivatives have been proven to be efficient catalysts in asymmetric synthesis.[99] 
An efficient one-pot cascade reaction towards the synthesis of functionalized piperidine 125 involved 
a proline 124-catalyzed Mannich reaction of glutaraldehyde 122 with imine 123 and acid-mediated 




2.2.3.3 Chiral phosphonic acid catalysis 
Chiral phosphonic acids 128 are a catalyst class widely used in organic chemistry.[101] 
Recently, an enantioselective organocatalytic synthesis of 4,6-bis(1H-indole-3-yl)piperidine-2-
carboxylate 129, using 3-vinylindole 126 and imino ester 127 in the presence of the chiral phosphoric 
acid 128 as catalyst, was reported (Scheme 17).[102] The product 129 was obtained under mild reaction 
conditions in good yield (64%) and high enantiomeric excess (94%). 





2.2.4 Ring closure metathesis 
The diastereoselective synthesis of 4-methylpipecolic esters 135 and 136 based on ring closure 
metathesis (RCM) reaction and conjugate Michael addition was described via precursor 131 which 
was obtained as diastereomeric mixture from (S)-(-)-phenylethylamine 130 in 5 steps (Scheme 
18).[103] This mixture was subjected to a RCM reaction, giving a diastereomeric mixture of 
unsaturated esters 132 and 133 in diastereomeric ratio of 70/30. The diastereomeric mixture was 
separated and the absolute configuration of C-6 atom of the piperidine core was determined as (R) 
for 132 and (S) for 133. Furthermore, the conjugate addition of methylcuprate to the major (R)-132 
afforded the desired cis-4-methylpiperidine-2-on-6-carboxylate 134 as major diastereomer. The 
reduction/N-deprotection/N-protection sequence afforded pipecolic acid derivative 135. The minor 
isomer (S)-133 was subjected to the same transformations as 132 in order to obtain the 1,3-
disubstituted piperidine 136. 
 
Scheme 18 
2.3 Synthesis of nipecotic acid derivatives 
In this part, the methods to synthesize piperidine-3-carboxylic acid derivatives, mainly based on one-




drawn considerable attention due to their efficiency towards the preparation of complex molecules, 
in particular, polysubstituted piperidines. 
2.3.1 Formal [4+2]-cycloaddition of donor-acceptor cyclobutanes with imines 
The Pagenkopf research group has reported ytterbium triflate-catalyzed stereoselective synthesis of 
donor-acceptor cyclobutane 139 and its [4+2]-cycloaddition with imines 140 (Scheme 1).[104] The 
[2+2] reaction of ethyl methylidene malonate 138 with dihydropyran 137 in the presence of 10 mol% 
of ytterbium triflate afforded the intermediate cyclobutane 139. Although the synthesis of this class 
of cyclobutanes was reported in 1986,[105] the use of these substrates in dipolar cycloaddition was not 
investigated. Subsequently, a CH2Cl2 solution of Schiff bases 140 was added to a concentrated 
solution of the in situ formed cyclobutane 139 and adducts 141 were formed in yields ranging from 
77 to 84%. The obtained dihydropyridines 141 could serve as versatile precursors for the synthesis 
of piperidine-3,3-dicarboxylic acid derivatives. 
 
Scheme 19 
Moreover, this methodology was applied for different substrates. Thus, the ability of Yb(OTf)3 to 
catalyze the synthesis of cyclobutanes with carbon-donating groups was demonstrated. The reaction 
of methylidene malonate 138 with p-vinylanisol 142 gave cyclobutane 143 (Scheme 20). 
Noteworthy, the adducts 143 could be isolated in good yield. Further addition of the obtained 
cyclobutane 143 across imines 140 afforded the highly substituted piperidine-3,3-dicarboxylates 144 
in good yields (59-86%) and exclusively as the trans-diastereomers. 
 
Scheme 20 
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2.3.2  [N+2+3]-cyclization strategy 
Harada et al. reported an asymmetric one-pot [N+2+3] cyclization strategy towards the synthesis of 
six membered azaheterocycles.[106] The procedure started with the chiral diether 147-controlled 
asymmetric conjugate addition reaction of lithium amide 145 across tert-butyl cinnamate 146 in 
toluene, followed by treatment with 1-chloro-3-iodopropane 148 in DMPU for 2 hours and then with 
tetrabutylammonium fluoride giving cis-2,3-disubstituted piperidine cis-149 in good yield (dr >99/1, 
ee 97%) (Scheme 21). Noteworthy, the trans-isomer trans-149 was easily obtained from cis-isomer 
by heating in xylene in the presence of sodium methoxide. 
 
Scheme 21 
2.3.3 Multicomponent reactions (MCRs) 
Multicomponent reactions (MCRs) starting from simple starting materials are interesting approaches 
due to their practical value and accessibility.[107] 
In a first study, the four-component one-pot reaction between substituted nitrostyrenes 153, aromatic 
aldehydes 155, dialkyl malonates 152 and ammonium acetate 154 led to formation of a wide range 
of polysubstituted piperidinone derivatives (only one example 156 is presented) (Scheme 22).[108] 
The proposed pathway includes three steps, namely: the Michael addition of dimethyl malonate 152 
to the substituted nitrostyrene 153 to form 2-(1-aryl-2-nitroethyl)malonate 158, followed by nitro-
Mannich nucleophilic addition to afford intermediate 159, and finally, intramolecular cyclization 
with elimination of methanol to give the cyclic amide 156 (Scheme 23). The piperidinone 156 could 
be foreseen as precursor for the synthesis of polysubstituted piperidine-3-carboxylic acid derivatives 









Another multicomponent synthesis of functionalized piperidines concerned the reaction between 
primary amines 162, α,β-unsaturated aldehydes 160, β-dicarbonyl compounds 161 and alcohols in 
the presence of cerium(IV) ammonium nitrate (CAN) as a Lewis acid affording the 1,4-
dihydropyridine-3-carboxylates 163 which were subsequently reduced towards functionalized 
nipecotic acid derivatives 164 (Scheme 24).[110] The reaction mechanism was explained. via β-
enaminone 165 which underwent Michael addition across α,β-unsaturated aldehyde 160 to give 
intermediate 166 (Scheme 25). The 6-exo-trig cyclization of the latter afforded enaminoester 167, 
presumably in equilibrium with iminium ion 168 which was deprotonated to dehydropyridine 163. 
More than 20 derivatives of 163 were prepared via this cascade reaction in 55-78% yields. 







Asymmetric synthesis of piperidines 173a,b was accomplished via reduction of enantiomerically 
enriched 1,4-dihydropyridines 172 (Scheme 26). The latter were prepared via an organocatalytic 
asymmetric aza-ene-type cascade reaction, developed by Noole et al.[111] The conjugate addition of 
β-enamino esters 170 across α,β-unsaturated aldehydes 169 (cinnamaldehyde derivatives) in the 
presence of (S)-diarylprolinol-TMS ether 171 and benzoic acid afforded the 1,4-dihydropyridines 
172a,b in good yields (62-70%) and enantiomeric excess of 83-89%. Subsequently, these 
dihydropyridine derivatives 172 were subjected to reduction with NaBH4, giving highly 






2.4 Synthesis of azetidine-2-carboxylic acid derivatives 
An overview of the latest synthetic approaches was prepared below with main focus on asymmetric 
synthesis of azetidine-2-carboxylic acid derivatives. 
2.4.1 Synthesis starting from chiral substrates 
2.4.1.1 From (R)-phenylglycinol 
A straightforward synthesis of enantiopure α-trifluoromethylated azetidine-2-carboxylic acid 
derivatives 181 and 182 was recently reported, starting from (R)-phenylglycinol 175 and ethyl 4,4,4-
trifluoroacetoacetate 174 (Scheme 27).[112] The starting fluorinated oxazolidine 176 was prepared via 
condensation of phenylglycinol 175 and acetate 174. Subsequent reduction with NaBH4 afforded 
alcohol 177 without any degradation of the oxazolidine moiety. The synthesis of the bicyclic 
compound 179 was realized via cyclization of the iodo derivative 178 using sodium hydride in THF 
under reflux. The introduction of the nitrile group was accomplished via Strecker-type reaction 
across iminium ion 180. A diastereomeric mixture of 2,2-disubstituted azetidines 181 and 182 was 
formed and the two diastereomers were conveniently separated by silica gel chromatography to give 
(R,R)-182 and (R,S)-181 in 58% and 41% yield, respectively. 
 
Scheme 27 
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The hydrolysis of the nitrile group of major isomers (R,R)-182 under basic conditions afforded the 
azetidine-2-carboxylic acid derivatives 183 (Scheme 28). The direct hydrogenolysis of compound 
183 in order to remove the N-protection failed, leading to the degradation of starting material. 
Therefore, substrate 183 was subjected toward esterification reaction giving ester 185. Finally, the 




2.4.1.2 From chiral glyceraldehyde derivatives 
As a continuation of previous research, the Chattopadhyay group envisioned the homoallylic amines 
191 and 193 as precursors for the synthesis of N-protected azetidine-2-carboxylic acid derivatives 
199 and 200 (Schemes 30 and 31).[113] The starting amines 191 and 193 were prepared via allylation 
of imine 189 derived from (R)-2,3-cyclohexylideneglyceraldehyde 187 (Scheme 29). When imine 
189 was treated with allylmagnesium bromide 190, syn-adduct 191 was obtained. The reversal of 
stereoselectivity was observed when allylation was performed with allylzinc bromide 192, affording 
amine anti-193. The Cbz-protected amine derived from amine 191 was subjected to ozonolysis and 
in situ reduction of the resulting aldehyde delivered primary alcohol 194 (Scheme 30). The removal 
of Cbz and benzyl groups from 194 produced amine 195. N-Heterocyclization of substrate 195 using 
TosCl-KOH led to the formation of the azetidine derivative 196. Acid-mediated deprotection of the 
cyclohexylidene acetal in azetidine 196 and subsequent transformation of the diol functionality into 
a carboxylic acid function using NaIO4 and a catalytic amount of RuCl3, followed by esterification, 
afforded (R)-azetidine-2-carboxylic acid derivative (R)-199. In the same manner, the anti-











Recently, the synthesis of 3-aminoazetidine-2-carboxylic acid derivative 210 was described in a 
patent, starting from azido dioxolan-4-yl acetate 201 (Scheme 32).[114] Deprotection of the dimethyl 
acetal 201 and subsequent selective protection of the primary hydroxyl group with TBDPSCl 
afforded monoprotected methyl α-azido-β-hydroxybutanoate 202. The ester function of the latter was 
reduced towards a primary hydroxy group. Subsequently, bis-mesylation of the hydroxyl groups in 
the obtained azido alcohol gave the compound 203. The addition of benzylamine to substrate 203 
followed by intramolecular 4-exo-tet cyclization led to the formation of 2,3-disubstituted azetidine 
204. A Staudinger reduction of the azido azetidine 204 and subsequent acylation of the amino 
functionality followed by removal of the benzyl group afforded azetidine 205. The addition of 
azetidine 205 across 3-chloroquinoxalin-2(1H)-one derivative 206 gave the adduct 207 in good yield. 
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Two subsequent oxidation reactions, a Swern oxidation followed by a Pinnik oxidation, transformed 
the 2-hydroxymethyl functionality of azetidine 207 to a carboxylic acid to give functionalized 3-
aminoazetidine-3-carboxylic acid 210 in moderate yield. 
 
Scheme 32 
2.4.1.3 From Boc-protected chiral allylic amines 
Pradhan et al. reported the synthesis of cis-2,3-disubstituted azetidines via diastereoselective 
hydrozirconation of the C=C bond of allylamine 211.[115] First, chiral allylamine 211 was treated with 
Schwartz reagent, Cp2Zr(H)Cl, followed by treatment of the hydrozirconated intermediate with 
iodine, affording the iodocarbamate 212 (Scheme 33). Subsequent treatment of intermediate 212 with 
NaHMDS in THF promoted the cyclization towards cis-2,3-disubstituted azetidine 213 in 65% yield 
and dr of 92/8. Further transformation of the obtained azetidine 213 via alcohol deprotection and 
ruthenium-based oxidation led to the formation of the N-Boc-protected 3-methylazetidine-2-






2.4.1.4 Synthesis based on chiral α-chloro-N-sulfinylimines 
Another approach towards chiral 3-aminoazetidine-2-carboxylic acid derivatives was developed at 
the Department of Sustainable Organic Chemistry and Technology (UGent) based on enantiopure α-
chloro-N-sulfinylimine 217.[116] The latter was prepared by condensation of α-
chloroisobutyraldehyde 215 with (S)-p-toluenesulfinamide 216 (Scheme 34).  
 
Scheme 34 
The stereoselective Mannich-type addition of N-protected glycine ester 218 across chiral α-chloro-
N-sulfinylimine 217 gave the anti-adduct 219 when LDA was used for the deprotonation of the 
glycine ester 218 (Scheme 35). The anti-addition product 219 was cyclized to the corresponding N-
sulfinylaziridine 220 in good yield and diastereomeric ratio of 81/19. Furthermore, the p-
toluenesulfinyl group of N-sulfinylaziridine anti-220 was selectively oxidized with mCPBA, 
resulting in N-sulfonylaziridine 221. The reduction of the N-diphenylmethylene moiety of the 
aziridine 221 gave the N-sulfonylaziridine 222. The ring transformation of the latter towards trans-
3-(N-tosylamino)azetidine-2-carboxylate 223 was performed via simple heating in CH3CN under 
microwave conditions. 





Moreover, the enantiomerically pure 3-aminoazetidine-2-carboxylic acid derivative 223 was 
subjected to deprotection reactions, including the removal of the diphenylmethyl moiety and 




2.4.2 Organocatalytic asymmetric synthesis 
The catalytic asymmetric C-alkylation of glycine ester derivative 227 using dibromoethane 228 in 
the presence of a chiral phase transfer catalyst (S)-229 and subsequent intramolecular N-alkylation 
afforded 2-substituted azetidine-2-carboxylic acid derivative 231 in 39% yield and enantiomeric 
excess of 98% (Scheme 37, A).[117] Noteworthy, this methodology was also applied for the synthesis 
of enantiomerically pure pipecolic acid derivative 233 by switching of the dihaloalkane to 1-chloro-






2.4.3 Ring contraction of functionalized pyrrolidinones 
A simple one-pot nucleophilic addition-ring contraction strategy was applied for the synthesis of a 
broad scope of highly functionalized azetidine-2-carboxylic acid derivatives 237 (Scheme 39).[118] 
The starting α-bromo N-sulfonylpyrrolidinones 235a-g were obtained via the selective 
monobromination of N-sulfonylpyrrolidinones 234 (Scheme 38). Nucleophilic addition of methanol 
across substrates 235 in acetonitrile in the presence of potassium carbonate and subsequent 4-exo-tet 









2.4.4 Pd-catalyzed intramolecular amination 
The reaction of picolinamide protected amine substrates 238 and PhI(OAc)2 as oxidant under 
palladium catalysis resulted in intramolecular amination of γ-C(sp3)-H bond, affording azetidine-2-
carboxylic acid derivatives 240 (Scheme 40).[119] Noteworthy, the absence of β-substituents in the 
substrate 238b disfavored the cyclization towards azetidine 240b, giving non-cyclic acetoxylated 
compound 241b as major product. 
 
Scheme 40 
2.4.5  [2+2]-cycloaddition strategy 
The synthesis azetidine-2-carboxylates via a [2+2]-cycloaddition strategy starting from 
commercially available 6-azauracil 243 was reported by the Aitken research group.[120] A solution of 
azauracil 243 was irradiated with a 400 W Hg lamp and ethylene 242 was bubbled through the 
mixture, affording [2+2] adduct 244 (Scheme 41). Treatment of adduct 244 with NaOH provided 
semicarbazide 245 which was hydrolyzed to the hydrazino acid 246, however, in a low yield of 10%. 
Therefore, another route from adduct 244 was applied, which included selective N1-Boc protection, 
cleavage of the heterocyclic ring in 247 and Boc-deprotection of azetidine 248, leading to the 




asymmetric synthesis of acid 246 was accomplished via chiral resolution of the intermediate 248 
using (S)-benzyloxazolidin-2-one (Scheme 42). The activated carboxylic acid 248 as its tert-butyl 
anhydride reacted with the lithium salt of (S)-benzyloxazolidin-2-one 249 to provide the 
diastereomeric mixture which was separated via column chromatography, affording diastereomers 
250 and 251 in 36% and 33% yield, respectively. The cleavage of the oxazolidinone auxiliary in 
derivatives 250 and 251 with LiOOH and subsequent TFA-mediated Boc removal afforded the two 





In another report, selective [2+2]-cycloaddition of 2-(N-benzoylamino)malonate 252 with chalcone 
253 via phase transfer catalyzed solvent free Michael addition and a PhIO/Bu4NBr-mediated 
oxidative cyclization led to formation of highly substituted diethyl azetidine-2,2-dicarboxylate trans-
254 (Scheme 43).[121] A library of 24 derivatives of azetidine 254 was created using the 
aforementioned method (structures are not presented). The presumed pathway includes the formation 
of adduct 255. The latter reacts with an iodine species, generated in situ from iodosobenzene and 
tetrabutylammonium bromide, via a ligand exchange to form intermediate 256, which readily 
undergoes an intramolecular reductive elimination to afford azetidine 254. 





2.4.6 TiCl4-promoted formal [3+3]-cycloaddition 
The Lewis acid-promoted transformation of cyclopropane-1,1-diesters 258 with azides 257 afforded 
the functionalized triazines 259, which were easily transformed towards azetidine-2,2-dicarboxylic 
acid derivatives 260 by means of simple thermolysis (Scheme 44).[122] A plausible pathway of the 
formation of triazines 259 includes the TiCl4-mediated ring opening of the cyclopropane ring 258, 
affording 1,3-zwitterionic intermediates 261. Then, a nucleophilic attack of an azide occurs to form 
a zwitterion 262, which undergoes an intramolecular nucleophilic attack to afford the triazines 259. 
The elimination of N2 from 259 under reflux gave azetidines 260. 
 
Scheme 44 
2.4.7 Cyclization of glycine derivatives 
As extension of the application of sulfonium triflate,[123] the cyclization of derivatives 264 to 
functionalized azetidine-2-carboxylic acid derivatives 269 using (2-bromoethyl)sulfonium triflate 




following steps: nucleophilic addition of ester 264 across the vinylsulfonium salt 266, generated in 
situ from sulfonium triflate 265 and base, gave the ylide intermediate 267 and, after proton transfer, 
formed enolate 268, which underwent intramolecular attack to furnish the azetidine ring. 
Noteworthy, the use of derivative 264b as starting material furnished the azetidine-2,2-dicarboxylic 
acid derivative 269b in good yield of 78%. 
 
Scheme 45 
2.5 Synthesis of azetidine-3-carboxylic acid derivatives 
The synthetic approaches towards azetidine-3-carboxylic acid and its derivatives are not so diverse 
as for azetidine-2-carboxylic acid. 
In a first example, one-pot diastereoselective annulation of Baylis-Hillman adducts 272 with N-
arylphosphoramidates 270 afforded trans-1,2-disubstituted azetidine-3-carbonitriles/carboxylates 
276, which are the precursors of azetidine-3-carboxylic acids (Scheme 46).[125] Diethyl N-
arylphosphoramidates 270 were treated with sodium hydride to generate anions 271 in situ, which 
underwent aza-Michael addition across Baylis-Hillman adducts 272 followed by cyclization of 
adduct 273 to afford the azetidine-3-carbonitriles/carboxylates 276 in 84–93% yield. The formation 
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Several other methods for the synthesis of azetidine-3-carboxylic acids 278 included the 
functionalization of the double bond of allylamine derivatives 277 as a key step (Scheme 47). 
 
Scheme 47 
The synthesis of 3-fluoroazetidine-3-carboxylic acid 287 was reported by the research group at the 
Department of Sustainable Organic Chemistry and Technology (UGent) (Scheme 48).[126] 
Preparation of the starting allylamine 281 was performed via reaction of 3-chloro-2-
chloromethylpropene 279 with 4-methoxyphenol in the presence of KOtBu, and subsequent reaction 
of the obtained 3-chloro-2-(4-methoxyphenoxymethyl)propene 280 with ammonia in methanol in a 
pressure vessel. Transimination of imine 282 with allylamine 281 gave imine 283, which was 
regioselectively bromofluorinated using triethylamine trihydrofluoride and NBS in dichloromethane. 
Furthermore, imine 284 was subjected to reductive cyclization using sodium cyanoborohydride in 
the presence of acetic acid to form fluorinated azetidine 285. After hydrogenolysis of the N-
protecting group of azetidine 285, reaction with Boc2O and cleavage of the O-protecting group, the 
efficient oxidation of 3-fluoro-3-hydroxymethylazetidine 286 using NaIO4/RuCl3.3H2O towards 3-
fluoroazetidine- 3-carboxylic acid 287 was accomplished. 
 
Scheme 48 
The same research group developed the synthesis of azetidine-3-carboxylates 290 and 293 from 
allylamines 288 (Scheme 49).[127] The dihalogenation of the double bond in 288 afforded substrates 
289 and 292 which were cyclized towards azetidines 290 and 293, respectively, under basic 
conditions. When dibromo derivatives 289 were used as starting material, formation of aziridines 




azetidines 290 occurred under heating in DMSO in a highest yield of 50%. The base-promoted ring 
closure of dichlorinated ester 292 was less efficient, giving a mixture of starting material 292 and 
product 293.[127c] However, the aziridines 291 were transformed to the desired 3-chloroazetidines 293 




The 3-bromoazetidine-3-carboxylates 290 have proven to be suitable precursors for the synthesis of 
Cα-tetrasubstituted α-amino acid derivatives which appeared to be a β-turn inducer in peptides.[51a] 
Transformation of substituted azetidines 290 via nucleophilic substitution of bromide with azide gave 
3-azidoazetidines 294. Subsequent elaboration of the carboxylic group and amino group afforded 3-
aminoazetidine-3-carboxylic acid derivatives 295 and 296 which are of intrest for an application in 




In conclusion, the discussed N-heterocycles, i.e. azetidine- and piperidinecarboxylic acid derivatives, 
are some of the most important building blocks. Due to their role as potential pharmaceuticals, 
continuous attempts towards developing new efficient synthetic methods constantly appear in the 
literature. Asymmetric synthesis of enantiomerically pure derivatives of these azacyclic amino acids 
are mainly based on chiral pool approaches, which often requires inefficient multi-step 
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transformations. Some other methods that were accomplished use expensive/exclusive 
reagents/catalysts. Therefore, the development of new efficient synthetic methods for the 
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3 Results and discussion 
3.1 Synthesis and elaborations of N-(sulfinyl)iminoacetates 297 and N-
(sulfonyl)iminoacetates 298 towards diamino acid derivatives 
In the first chapter, N-(sulfinyl)- and N-(sulfonyl)iminoacetates 297 and 298 were explored as key 
substrates for the synthesis of diamino acid derivatives which possess interesting biological activity 
(see Introduction and Goals). Previously reported synthesis of β-ODAP 3 were mainly based on 
chiral pool synthesis. For instance, synthesis from aspartic acid involved a step with in situ formed 
highly explosive hydrazoic acid from sodium azide and sulfuric acid.[128] Another synthesis starting 
from tosyl-L-asparagine displayed a lack of reproducibility as well as a low yields of the desired acid 
3.[44] Additionally, the preparation of β-ODAP 3 from the copper chelate of L-2,3-diaminopropionic 
acid and various oxalate esters is not economically viable due to poor yields.[22a, 129] Several formal 
syntheses of BMAA 2 were reported. For example, an inefficient synthesis of BMAA hydrochloride 
from methylamine and acetamidoacrylic acid followed by enzymatic enantioselective hydrolysis of 
the acetamide group was reported.[130] Other approaches were based on transformations of protected 
L-serine.[131] [132] Among synthetic methods towards diaminobutyric acid 4 (DABA), Curtius,[133] 
Schmidt[134] or Hofmann[135] degradations from (S)-glutamic acid and the ring opening of γ-
butyrolactone derivatives with potassium phthalimide[136] could be highlighted. Moreover, 
asymmetric synthesis of both enantiomers of DABA was performed using 2-hydroxypinan-3-one as 
inducer of chirality, however, with lack of diastereoselectivity.[137] Therefore, the development of 
new synthetic routes towards aforementioned amino acids remains challenging. Thus, it was 
envisioned that the condensation of α-iminoacetates 297 and 298 with different nucleophiles, such 
as 1- (methylenamino)pyrrolidine 12, N-sulfinyl imidates 13 or 3,3-dichloro-1-azaallylic anions 302 
could result in a short synthetic pathway towards new derivatives of diamino acids (Scheme 51). 





3.1.1 Addition reactions of 1-(methylenamino)pyrrolidine 12 across N-(sulfinyl)- and 
N-(sulfonyl)iminoacetates 297 and 298 
Enantioselective addition reactions of 1-(methylenamino)pyrrolidine 12 across N-substituted 
aromatic aldimines 304 have been reported (Scheme 52).[39, 138] However, to the best of my 
knowledge, the addition of pyrrolidine 12 across α-iminoacetates has not been described. 
 
Scheme 52 
The synthesis of starting (R)-ethyl 2-(tert-butylsulfinyl)iminoacetate 297 and 1-
(methylenamino)pyrrolidine 12 was performed following literature procedures. The condensation of 
(RS)-tert-butanesulfinamide 306 and ethyl glyoxalate 307 in dichloromethane in the presence of 
molecular sieves for 48 hours at room temperature afforded iminoacetate 297 in 83% yield (Scheme 
53).[40] (tert-Butylsulfinyl)iminoacetate 297 was observed exclusively as E-isomer.[139] 
 
Scheme 53 
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1-(Methylenamino)pyrrolidine 12 was prepared from commercially available N-nitrosopyrrolidine 
308 via reduction with LiAlH4 followed by addition of paraformaldehyde to the prepared 1-
aminopyrrolidine (Scheme 54).[140]  
 
Scheme 54 
Next, the addition reaction of hydrazone 12 across imine 297 was attempted (Table 1). In a first 
attempt, the reaction was performed without catalyst in chloroform for 8 hours at room temperature, 
giving no reaction (Table 1, entry 1). The gradual increase of the reaction temperature and elongation 
of the reaction time resulted in the degradation of starting materials to unidentified side products 
(Table 1, entry 1). The use of Brønsted acid (BINOL)[138] (Table 1, entry 2) as well as different Lewis 
acids, such as BF3·OEt2, ZnCl2, Cu(OTf)2 (Table 1, entries 3-11),[141] did not lead to the formation of 
the desired ethyl 2-((tert-butylsulfinyl)amino)-3-(pyrrolidin-1-ylimino)propanoate 299. The 
variation of the solvents (CDCl3, CH2Cl2 or THF), temperatures and reaction times, unfortunately, 
did not positively influence the reaction outcome and only very complex mixtures were obtained 
which were not further analyzed (Table 1, entry 3-10). 
Table 1. The addition reaction of hydrazone 12 across imine 297. 
 
Entry Equiv 12 Catalyst/equiv Temp (oC)/ 
Time (h) 
Solvent Results a 








2 0.5 BINOL/20%mol r.t./0.75 CDCl3 No reaction 







3 1.5 BF3·OEt2/2 r.t./0.75 CH2Cl2 No reaction b 
4 1.5 BF3·OEt2/2 0/75 
+r.t./48 
CH2Cl2 No reaction 
-c,d 
5 1.5 BF3·OEt2/2 0/7 
+r.t./48 
THF No reaction 
-c,d 
6 1 BF3·OEt2/1 0/3.5 
+r.t./21 
+r.t./21 
CH2Cl2 No reaction 
-c,d 
-c,e 
7 1.5 BF3·OEt2/1 0/3.5 
+r.t./21 
CH2Cl2 No reaction 
-c 
8 2 BF3·OEt2/2 0/3.5 
+r.t./21 
CH2Cl2 No reaction 
-c 
9 1 ZnCl2/1 r.t./24 CH2Cl2 -c 
10 1.5 Cu(OTf)2/1.1 r.t./30-48  -c,e 
a Based on 1H NMR and TLC analysis of the crude reaction mixture. b Starting product 297 is present. 
Degradation of 12 which is thought to form complex with BF3·OEt2. c Complex reaction mixture. d Small 
amount of starting product 297 is still present. e After flash chromatography no products could be identified 
by 1H NMR and LC-MS analysis. 
 
In the next part, the addition of hydrazone 12 across the more electrophilic sulfonyl iminoacetate 298 
was attempted. The starting imine 298 was synthesized from 1,2-di-tert-butyldisulfane 309 in five 
steps following a literature procedure (Scheme 55).[142] 





The addition of hydrazone 12 across imine 298 was performed at room temperature in chloroform, 
affording an equilibrium mixture of adducts 300 and 313 in a ratio 76/24 determined via 1H NMR 
analysis of the crude reaction mixture. Purification of the crude mixture by column chromatography 
afforded the mixture 300/313 in the same ratio of 76/24 in 87% yield (Scheme 56).  
 
Scheme 56 
With the mixture of ethyl (E)-2-((1,1-dimethylethyl)sulfonamido)-3-(pyrrolidin-1-
ylimino)propanoate 300 and ethyl 2-((1,1-dimethylethyl)sulfonamido)-3-(pyrrolidin-1-
ylamino)acrylate 313 in hand, the reactivity of the addition products was investigated (Scheme 57). 
The attempts are listed in Table 2. Oxidation of the pyrrolidin-1-ylimino moiety of substrate 300 
with magnesium monoperoxyphthalate hexahydrate (MMPP·6H2O) towards the corresponding 
nitrile adduct 314 failed, giving a complex mixture (Table 2, entries 1-2). Furthermore, compounds 
300/313 were explored in an oxidative cleavage with ozone or manganese(IV) oxide in order to 
obtain the oxopropanoate 315 which could serve as a versatile building block for further elaborations 
(Table 2, entries 3-5). Unfortunately, only formation of unidentified side products was detected. The 
attempts to establish the structure of those side products by means of purification via column 
chromatography or preparative thin layer chromatography were not successful. Unsatisfactory results 
were obtained when substrates 300/313 were treated with catecholborane,[143] di-isobutylaluminium 
hydride or lithium aluminium hydride towards the synthesis of diamino acid derivative 316 or amino 
alcohol 317 (Table 2, entries 6-10). 





Table 2. Investigation of reactivity of the tautomeric mixture 300/313. 
 
Despite the multiple attempts to reduce the double bond in compounds 300/313, some additional 
variations of the reaction conditions could be foreseen for future research. For instance, use of sodium 
cyanoborohydride as reducing agent which was efficient towards reduction of the C=N bond in 
hydrazone-containing derivative of ethyl 3-hydroxyacrylate.[144] Moreover, reduction under milder 
conditions, involving the use of sodium borohydride, could be promising. Additionally, 
Entry  Reagent/ equiv T(oC) /t(h) Solvent Results 
1 MMPP·6H2Oa/ 2.5 0/ 1  MeOH -b 
2 MMPP·6H2Oa/ 5 0/ 0.08 MeOH -b 
3 O3 (gas) -78/ 0.5 THF -b 
4 MnO2/ 2.5 ∆/ 3 CH2Cl2 -b 
5 MnO2/ 5.0 rt/ 1 CH2Cl2 -b 
6 DIBAL-H b/ 1.0 0/ 0.5 to r.t./15  EtO2 -b 
7 Catecholborane/ 2.0 0/ 0.5 to r.t./16 EtO2 -b 
8 Catecholborane/ 2.5 0/ 0.5 to r.t./16 EtO2 -b 
9 Catecholborane c/ 2.0 0/ 0.5 to r.t./24 THF -b 
10 LiAlH4/ 1.05 0/ 2 THF -b 
a Magnesium bis(monoperoxyphthalate) hexahydrate. b 1M solution in heptane. c 1M solution in THF. b Complex 
reaction mixture. 
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hydrogenation of both tautomers could be performed with catalytic hydrogenation under phase 
transfer conditions. 
Further investigation of the reactivity of the obtained compounds 300/313 was not conducted due to 
their instability and the goal of developing new pathways towards diamino acid derivatives could not 
be realized via these unstable compounds. Nevertheless, the application of N,N-dialkylhydrazones 
has proven to be an useful synthetic tool.[39, 138, 145] Therefore, the addition reactions of 
methylenaminopyrrolidine 12 across iminoacetates 297 and 298 is still potentially of interest. Further 
optimizations could involve the modification of the electrophile[146] and/or the potential use of 
different catalysts.[147] 
3.1.2 Addition of the (RS)-imidates 13 across N-(tert-butylsulfinyl)iminoacetate 297 
In the next part of this research, the reactivity of (R)-ethyl 2-(tert-butylsulfinyl)iminoacetate 297 
towards Mannich-type reaction with chiral (RS)-imidates 13 was studied (Scheme 58).  
The addition reaction of imidate (RS)-13a across iminoacetate (RS)-297 was optimized by 
systematically changing the reaction conditions in the synthesis of ethyl 2-(sulfinylamino)-4-
(sulfinylimino)-4-methoxy-3-methylbutanoate 301a (Table 3). In a first attempt, the use of one 
equivalent of LiHMDS at -78 oC to deprotonate imidate 13a resulted after addition of iminoacetate 
297 in the formation of imidate 301a with good diastereoselectivity, but with incomplete conversion 
of the starting imidate 13a after one hour (Table 3, entry 1). Next, similar conditions were applied, 
however, the reaction time after addition of iminoacetate 297 was extended to two hours, affording 
adduct 301a with a slight decrease of the diastereoselectivity (Table 3, entry 2). Full conversion of 
imidate 13a and moderate diastereoselectivity (major/minor 67/33) of imidate 301a was achieved 
when 1.2 equivalents of LiHMDS were used and the reaction was performed at -78 oC for one hour. 
Column chromatography allowed to separate two diastereomers although in low yields of 18% (dr 
>99/1) and 9% (dr >99/1), probably caused by instability of compound 301a. Further modification 
of the reaction conditions by means of variation of the base (KHMDS, NaHMDS, LDA) (Table 3, 
entries 4-6), addition of ZnCl2 as Lewis acid (Table 3, entry 7), change of solvent (Table 3, entry 8), 
or performing the reaction at -97 oC (Table 3, entry 9) did not result in improved diastereomeric 
ratios and/or conversion. An additional experiment was performed starting from imidate 13b. The 
addition reaction was performed under optimized conditions, namely: deprotonation of imidate 13b 
with 1.2 equiv LiHMDS in THF at -78 oC for 45 minutes followed by addition of 1.2 equivalents 
iminoacetate 297 at -78 oC and stirring the reaction mixture at the same temperature for one hour. 
Two diastereomers were formed in a ratio of major/minor 71/29 and isolation of single diastereomers 
by column chromatography afforded two isomers of adduct 301b in 8% and 6% yield.  
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However, due to insufficient selectivity and low yield of adducts 301, further transformations were 




Table 3. Addition reaction of imidates (RS)-13 across iminoacetate (RS)-297. 






Conversion of 13 (%) 
a 
Result dr of 301 a 
1 LiHMDS/ 1 13a 1 -78/1 94 301a 71/29 
2 LiHMDS/ 1 13a 1 -78/2 99 301a 67/33 
3 LiHMDS/1.2 13a 1.2 -78/1 100 301a 67/33 b 
4 KHDMS/ 1 13a 1 -78/1 87 301a 53/45 
5 NaHMDS/ 1 13a 1 -78/1 82 301a 63/32 
6 LDA/ 1.1 13a 1 -78/1 100  301a 60/30 
7 LDA/ 1.1 c 13a 1 -78/1 60 301a 63/37 
8 LDA/ 1.1 13a 1 -78/1 d 97 301a 55/44 
9  LDA/ 1.3 13a 1 -97/1 0 - - 
10 LiHMDS/1.2 13b 1.2 -78/1 100  301b 71/29 e 
a Determined via 1H NMR analysis of the crude reaction mixture. b After column chromatography two 
diastereomers 301a were isolated in 18% and 9% yield. c 1.05 equiv of ZnCl2 was added after deprotonation 
at -78 oC for 15 min. d Reaction was performed in dry Et2O instead of dry THF. e After flash chromatography 
two diastereomers 301b were isolated in 8% and 6% yield. 
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3.1.3 Reaction of α-iminoacete 297 with 3,3-dichloro-1-azaallylic anions 
In a last part, α-iminoacetate 297 was subjected to reaction with 3,3-dichloro-1-azaallylic anions 302, 
generated by deprotonation of α,α-dichloroketimines 14 with lithium diisopropylamide,[148] to 
produce the Mannich-type products ethyl 2-(tert-butylsulfinylamino)-3,3-dichloro-4-
(isopropylimino)-4-arylbutanoates 303 (Scheme 59). The condensation reaction of α,α-dichlorinated 
imines 14 with N-sulfonylaldimines has been reported in literature.[149] The resulting adducts proved 
to be useful substrates towards hydrolysis of the imino functionality and diastereoselective ring 
closure to the corresponding functionalized aziridines. Therefore, it was of interest to explore this 
methodology on chiral substrates. α,α-Dichloroketimines 14a,b were prepared by condensation of 
the corresponding α,α-dichloroketones 318 with primary amine in the presence of titanium(IV) 
chloride in diethyl ether (Scheme 59).[150] Deprotonation of α,α-dichloroketimines 14 with 1.1 
equivalents of lithium diisopropylamide in THF at 0 oC for 40 minutes afforded 3,3-dichloro-1-
azaallylic anions 302, which reacted as nucleophiles with (RS)-iminoacetate 297 at -40 oC for one 
hour. Notheworthy, the diastereoselectivity of the reaction was divergent for different substrates 303. 
Thus, a diastereomeric ratio of >99/1 for adduct 303a was determined via 1H NMR analysis of the 
crude reaction mixture, while a ratio of 70/30 for adduct 303b was obtained. Further elaborations 
were performed with substrate 303a, which was isolated by column chromatography in 80% yield. 
 
Scheme 59 
The imino functionality of adduct 303a was hydrolyzed in aqueous hydrochloric acid, resulting in 
the ketone 319 in 91% crude yield (Scheme 60). The elimination of hydrogen chloride occurred 
during purification via flash chromatography and compound 320 was isolated as a mixture of E/Z-
isomers in a ratio of 2/1 (or vice versa) in 51% yield. Noteworthy, ketone 319 underwent also 
elimination of hydrogen chloride when stored at room temperature. 
 
Scheme 60 
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Finally, the base-induced ring closure of compound 319 was attempted towards aziridine 321, 
unfortunately, with no success (Scheme 61). The selective reduction of ketone 319 to the amino 
alcohol 322 was tried with different reducing agents (NaBH4, LiBH4, NaCNBH3/CH3COOH). 
However, only complex mixtures were formed which contained no desired product 322 (Scheme 61). 
 
Scheme 61 
In conclusion, the reactivity of iminoacetates 297 and 298 towards nucleophilic addition of 
1- (methylenamino)pyrrolidine 12, N-sulfinyl imidates 13 and anions of α,α-dichloroketimines 302 
was investigated. Adducts obtained from aforementioned additions in sufficient yields were 
subjected to different transformations, including reduction, hydrolysis and oxidation, showing a lack 
of selective reactivity, however.  
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3.2 Synthesis of N-sulfinyl imidates and their transformation towards four- 
and six-membered azaheterocycles 
In this part, the synthesis of chiral azetidine-2-carboxylic acid derivatives from 2-aryl-3-
chloroazetidines 22 via oxidation of the aryl substituent was attempted. Asymmetric synthesis of 
precursors 22 was previously developed at the Department of Sustainable Organic Chemistry and 
Technology, UGent (Scheme 62).[47] This method includes the synthesis of N-tert-butanesulfinyl α-
chloro-β-sulfonylaminoimidates 325 via the highly anti-diastereoselective Mannich-type addition of 
N-tert-butanesulfinyl α-chloro acetimidate 324 across aromatic aldimines 27 as a key step.[47] 
Secondly, the synthesis of new N-tert-butanesulfinyl δ-chloro-β-sulfonylaminoimidates 339-340 was 
investigated. The latter were studied for the synthesis of enantiomerically pure N-(de)protected 2,3-
functionalized piperidines. 
The asymmetric Mannich reaction is a very important method for the preparation of β-amino 
carbonyl compounds.[151] The Kobayashi group developed a (super)base-catalyzed addition reaction 
of N-sulfonylimidates with activated aromatic or aliphatic aldimines leading to racemic adducts with 
high anti-diastereoselectivity.[152] 
Over the last decade, chiral N-sulfinamides have proven to be among the most efficient classes of 
auxiliaries in asymmetric synthesis.[47, 123a, 153] In particular, N-(tert-butanesulfinyl)imidates are very 
useful chiral enolate precursors for Michael addition,[154] α-alkylation[155] and aldol addition.[156] 
Recently, our group elaborated the asymmetric, highly anti-selective Mannich-type reactions of 
α-methyl- and α-chloro-N-sulfinyl imidates across N-tosyl aldimines.[47, 153e] These imidates were 
used in the synthesis of enantiopure β-sulfonylamino amides and esters as new chiral β-amino acid 
derivatives. 
3.2.1 Synthesis of 2-aryl-3-chloroazetidines 22 and their attempted transformation 
towards azetidine-2-carboxylic acid derivatives 
The synthesis of 2-aryl-3-chloroazetidines 22 was performed via a method developed at the 
Department of Sustainable Organic Chemistry and Technology, UGent. Starting α-chloro N-sulfinyl 
imidate 324 was synthesized via condensation of (RS)-tert-butanesulfinamide 306 and orthoester 323 
without solvent at 100 oC for 4 hours. Subsequently, anti-selective Mannich-type reaction of N-
sulfinyl imidate 324 and aromatic aldimines 27 afforded N-tert-butanesulfinyl α-chloro-β-
sulfonylaminoimidates 325a and 325b. The reaction was performed under optimized reaction 
conditions, namely, deprotonation of N-sulfinyl imidate (RS)-324 by means of LiHMDS in THF at -
78 oC for 45 minutes, followed by addition of aldimines 27a and 27b with reaction at -78 oC for 30 
minutes. The formation of four diastereomers 325 was detected by 1H NMR analysis of the crude 
reaction mixture, namely, major-(RS,R,R)-325/minor-325=(RS,S,S)-325+(RS,S,R)-325+(RS,R,S)-325 
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in 91/9 (for 325a) and 95/5 (for 325b) ratio. Major isomers (RS,R,R)-325a,b were separated by 
column chromatography and were subjected to the next steps. N-Deprotection of the N-sulfinyl group 
towards esters 326, reduction of ester 326 to the primary alcohols 327, and subsequent cyclization 




With enantiomerically pure azetidines 22 in hand, further transformation towards azetidine-2-
carboxylic acid derivatives 23 and 25 was attempted (Scheme 63). 
 
Scheme 63 
Oxidation was attempted by catalytic oxidation of the aromatic substituent with ruthenium(VIII) 
oxide in a biphasic solvent system consisting of water, acetonitrile and tetrachloromethane or in 
anhydrous conditions.[157] Periodic acid was used as co-oxidant based on several literature 
procedures.[158] Initially, the 3-chloro-2-phenylazetidine 22a was treated with ruthenium(III) chloride 
and H5IO6 in tetrachloromethane and acetonitrile at room temperature for 2.5 hours. However, only 
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a complex mixture was observed and attempts to determine the composition of the mixture failed 
(Table 4, entry 1). Next, two times less equivalents of oxidizing agent under anhydrous conditions at 
0 oC for 15 minutes were applied, leading to the formation of a mixture of unidentified products 
(Table 4, entry 2). Unsatisfying results were obtained upon applying CH3CN/CCl4/H2O 1/1/1 as 
solvent system at 0 oC or at room temperature, following literature procedure (Table 4, entries 3 and 
4).[158b] When 3-chloro-2-(4-methoxyphenyl)-1-tosylazetidine 22b was subjected to the oxidation 
with RuCl3/H5IO6 in a solvent system of CH3CN/CCl4/H2O at room temperature for 2.5 hours, only 
side product 328b resulting from a ring opening/oxidation sequence was isolated in a poor yield of 
10% (Table 4, entry 5).  
Table 4. Attempted oxidation of the 2-aryl substituent of azetidines 22 towards a carboxylic group. 
Entry X Equiv of H5IO6 Solvent system time, h/Temp  Result 
1 H 10.0 CH3CN/CCl4 (1/1) 0.5/0 oC 
+2.5/r.t. 
-a 
2 H 5.0 CH3CN/CCl4 (1/1) 0.25/ 0 ºC -a 
3 H 10.0 CH3CN/CCl4/H2O (1/1/1) 0.75/ 0 ºC -a 
4 H 15.0 CH3CN/CCl4/H2O (1/1/1) 24/r.t. -a 
5 OMe 10.0 CH3CN/CCl4/H2O (1/1/1) 2.5/r.t. 328b (10%) b 
a Complex reaction mixture. b Yield after column chromatography. 
 
Based on the attempted conditions it may be concluded that the use of RuCl3/H5IO6 has a lack of 
reactivity and selectivity towards the desired oxidation. In future research, the oxidation of the 
aromatic ring could be performed prior to cyclization in ester 326 in order to avoid side reactions 
such as the formation of ring opened products 328. 
Additionally, nucleophilic substitution of chloride from azetidine 22a with azide was tested (Scheme 
63). Unfortunately, attempted substitution with 1.1-2.0 equivalents of sodium azide in acetone at 
50-60 oC for 17-24 hours failed (Table 5, entries 1 and 2). The performance of the reaction in DMF 
or DMSO at 60 oC for 5 hours (Table 5, entries 3 and 4) gave no reaction while use of harsher 
conditions resulted in complex reaction mixtures which were not further analyzed (Table 5, entries 
5 and 6). 
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Table 5. Attempted substitution reaction of 3-chloroazetidine 22a with NaN3. 
Entry Reaction conditions Result 
1 1.1 equiv NaN3, acetone, 50 °C, 17 h No reaction 
2 2.0 equiv NaN3, acetone, 60 °C, 24 h No reaction 
3 1.5 equiv NaN3, DMF, 60 °C, 5 h No reaction 
4 2.0 equiv NaN3, DMSO, 60 °C, 5 h No reaction 
5 4.0 equiv NaN3, DMSO, 110 °C, 15 h Complex reaction mixture 
6 3.0 equiv NaN3, 3.0 equiv NaI, DMSO, 80 °C, 16 h Complex reaction mixture 
 
3.2.2 Attempted synthesis of 3-chloro-2-(3,5-dimethoxyphenyl)-1-tosylazetidine 
Due to the reactivity of 2-aryl-3-chloroazetidine 22b towards the ring opening process, a 
modification of the aromatic unit to a 3,5-dimethoxyphenyl moiety was suggested to facilitate the 
oxidation process prior of ring opening.[159]  
Starting aldimine 330 was synthesized via condensation of 3,5-dimethoxybenzaldehyde 329 and p-
toluenesulfonamide in toluene at reflux for 72 hours (Scheme 64).[160] After filtration of the reaction 
mixture over Celite®, evaporation of the solvent in vacuo and recrystallization from ethyl acetate, N-
(3,5-dimethoxybenzylidene)-4-methylbenzenesulfonamide 330 was obtained in 85% yield. 
 
Scheme 64 
Next, the addition reaction of α-chloro N-sulfinyl imidate 324 across imine 300 was initially 
performed under optimized reaction conditions (Table 6, entry 1). However, the selectivity of the 
reaction dropped dramatically. Additionally, conversion of starting substrate 324 was only 37%. 
Then, 1.5 equivalents of imidate 324 was deprotonated with 1.5 equivalents of LiHMDS in THF at -
78 oC for 45 minutes, followed by addition of one equivalent of aldimine 330 (Table 6, entry 2). 
Again, only moderate selectivity could be achieved (major-(RS,R,R)-325c/minor-325c=(RS,S,S)-
325c+(RS,S,R)-325c+(RS,R,S)-325c = 73/27). The relative and absolute stereochemistry was assumed 
in analogy with previous results.[47] The crude mixture was purified by column chromatography, 
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affording the single diastereomer methyl (RS)-N-(tert-butylsulfinyl)-2R-chloro-3R-(3,5-
dimethoxyphenyl)-3-(p-toluenesulfonylamino)propanimidate (RS,R,R)-325c in a moderate yield of 
33%. 
Table 6. Addition reaction of imidate (RS)-334 across imine 27d. 
 
Entry n Conversion of 324 dr of 325ca Yield of (RS,R,R)-325c (%) 
1 1.8 37 325c (68/10/13/9) - 
2 1.5 92 325c (73/11/6/10)  33 (dr > 99/1)b 
a Determined via 1H NMR analysis of the crude reaction mixture. b After purification via flash 
chromatography. 
 
Deprotection of N-sulfinyl β-amino-α-chloro imidate (RS,R,R)-325c with HCl in methanol led to 
formation of a mixture of ester 326c and amide 331 in a ratio of 30/70 (Scheme 65). The individual 
compounds 326c and 331 were isolated by column chromatography in 23% and 67% yield, 
respectively. A second attempted deprotection of imidate 325c was carried out by means of HCl (3M 
solution in dioxane) in diethyl ether at room temperature for one hour. Evaporation of the solvents 




Due to the low efficiency of the key step of the formation of the imidate 325c, as well as the lack of 
selectivity towards the formation of desired ester 326c, further synthesis of the corresponding 
functionalized enantiomerically pure azetidine was abandoned at this stage. 
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3.2.3 Synthesis of δ-chloro N-sulfinyl imidates 26 and their elaboration towards the 
synthesis of substituted piperidines 
The present chapter presents the results towards the synthesis of new methyl N-sulfinyl-5-
chloropentanimidates 26 and their elaboration towards the synthesis of new δ-chloro N-sulfinyl 
imidates 339 and 340 via anti-diastereoselective Mannich-type addition. The latter were investigated 
as versatile building blocks for the preparation of enantiomerically pure 2,3-disubstituted piperidines. 
3.2.3.1 Introduction.  
Functionalized piperidines and their derivatives form a well-known class of organic compounds due 
to their natural occurrence in various bioactive alkaloids.[161] Piperidine motifs are also found in 
pharmaceuticals and synthetic intermediates.[162] Particular attention has been given to 2,3-
disubstituted piperidines as the basic skeleton of many pharmacologically active compounds.[52d, 163] 
For example, piperidines 332 and 333 (Figure 11) and their analogues are nonpeptide antagonists of 
substance P which has been implicated in the pathophysiology of a wide range of diseases including 
neurogenic inflammation, transmission of pain and depression.[164] Cis- and trans-piperidine-2,3-
dicarboxylic acids 334 and 335 are cyclic analogues of N-methyl-D-aspartic acid 336 (NMDA) 
which are intensively studied in view of their interactions with amino acid neuromediated receptors 
(Figure 11).[52d, 165]  
 
Figure 11. 2,3-Disubstituted piperidines 1, 2 as antagonists of substance P and 3, 4 as analogues of NMDA 5. 
Both the relative configuration and the absolute configuration of the chiral centres of the piperidine 
ring have an influence on the biological activity.[165d, 166] Moreover, chiral functionalized piperidine-
3-carboxylic acids are conformationally restricted azacyclic analogues of alicyclic β-amino acids, 
which are known to be useful building blocks for the synthesis of peptides with modified and 
improved pharmacological activities.[32c, 32d, 33e, 58a, 67, 167] It has also been established that piperidine-
3-carboxylic acid (nipecotic acid) 9 can be incorporated into short homochiral peptides that appear 
to adopt well-defined conformations. Nipecotic acid-containing heterochiral dipeptides also strongly 
stabilize reverse-turn formation.[32e, 34, 37] 
A number of asymmetric approaches for the synthesis of 2,3-disubstituted piperidines are based on 
chiral pool syntheses starting with readily available amino acids[165e, 168] and diols[169] through a 
multistep synthesis. Among other methods, ring expansion[164d, 170] and domino reactions starting 
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from Baylis-Hillman adducts using lithium amide[106, 166a, 171] have been reported recently. The 
development of new simple and efficient methods towards the synthesis of functionalized piperidines 
with controlled diastereo- and enantioselectivity keeps to attract the continuous attention of organic 
chemists.  
Therefore, it was envisioned that the use of δ-chloro N-sulfinyl imidates in the addition reaction 
across aromatic aldimines could lead to the synthesis of new chiral β-aryl-δ-chloro-substituted β-
amino acid derivatives as potential building blocks of enantiopure functionalized piperidines. 
3.2.3.2 Synthesis of N-sulfinyl δ-chloro-β-sulfonylamino imidates 339 and 340 
The synthesis of δ-chloro N-sulfinyl imidates 26 was achieved via a modified literature 
procedure.[155a, 155b] Condensation of sulfinamides 306, 337a,b and orthoester 338 with a catalytic 
amount of pTosOH without solvent afforded imidates 26a-c in high yields of 76-87% (Scheme 66). 
A single isomer was observed which is supposed to have E-configuration based on recent literature 
data.[156] Additionally, several NOESY experiments were performed for imidate (RS)-26a, however, 
giving no conclusive results due to the lack of strong NOE’s. 
 
Scheme 66 
The imidate 26d was synthesized via condensation of (SS)-p-toluenesulfinamide (SS)-216 with 
orthoester 338 in the presence of MgSO4 in CH2Cl2 at reflux for 3.5 hours. Purification via flash 
chromatography afforded chiral N-p-toluenesulfinyl imidate (SS)-26d in 61% yield (Scheme 67).[155a] 
 
Scheme 67 
Examination of the addition reaction of imidate (RS)-26a across N-tosyl aldimine 27a was carried out 
by systematic variation of the reaction conditions (Table 7). Screening of the reaction conditions 
showed that deprotonation of imidate (RS)-26 with 1.8 equivalents LiHMDS in THF at -78 ºC 
followed by addition of N-tosyl aldimine 27a at -78 °C provided the desired adduct 339a and 340a 
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in good yield with a high relative stereocontrol (dr > 99/1) and moderate absolute stereocontrol 
((RS,S,R)-anti-339a/(RS,R,S)-anti-340a = 72/28) (Table 7, entry 1). Separation of the two 
diastereoisomers via flash chromatography afforded the optically pure δ-chloro-β-amino-N-sulfinyl 
imidates (RS,S,R)-anti-339a and (RS,R,S)-anti-340a in 58% and 24% yield, respectively. The 
selectivity could not be improved by means of changing the ratio reagent/base (Table 7, entries 2-6). 
The use of KHMDS, NaHMDS or LDA led to a decrease in absolute stereocontrol while relative 
stereocontrol was exclusively anti (Table 7, entries 7-10). Furthermore, the reaction was repeated 
with 1.2 equivalents LiHMDS at -78 °C for one hour, followed by 16 hours at room temperature 
leading to a decline of the stereoselectivity (Table 7, entry 11) indicating reversibility of the addition 
reaction. Reversed stereocontrol was observed ((RS,S,R)-anti-339a/(RS,R,S)-anti-340a = 24/76) when 
the reaction was repeated at -78 °C for one hour, followed by reflux for one hour with an overall 
crude yield of only 44% which indicated the possible degradation of (RS,S,R)-anti-339a under strong 
basic conditions (Table 7, entry 12) and only a trace of the cyclization product 344a and 345a was 
observed via LC-MS analysis. The changing of solvents to toluene or hexane did not lead to enhanced 
stereoselectivity (Table 7, entries 13 and 14). In a last attempt to improve the selectivity of the 
addition reaction, some Lewis acids were tested. The addition of ZnCl2 led to a reversal of absolute 
anti-stereocontrol ((RS,S,R)-anti-339a/(RS,R,S)-anti-340a = 47/53) (Table 7, entry 15), whereas the 
addition of MgBr2 gave no conversion of the starting imidate (RS)-26a (Table 7, entry 16). 













anti/sync Yield (%)d 




2 1.2 1.0 LiHMDS (1.2) e THF -78/1 64/36 > 99/1 - 
3 1.5 1.0 LiHMDS (1.5) e THF -78/1 67/33 > 99/1 - 
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4 1.0 2.0 LiHMDS (1.2) e THF -78/1 58/42 > 99/1 - 
5 1.5 1.0 LiHMDS (2.0) e THF -78/1 52/48 > 99/1 - 
6 1.0 1.5 LiHMDS (1.5) e THF -78/1 65/35 > 99/1 - 
























10 1.2 1.0 LDA (1.3) e THF -78/1 - - - 
















13 1.2 1.0 LiHMDS (1.2) f Toluene -78/1 69/31 > 99/1 - 
14 1.2 1.0 LiHMDS (1.2) g Hexane -78/1 65/35 > 99/1 - 
15 1.8 1.0 LiHMDS (1.8) e,h THF -78/1 47/53 > 99/1 - 
16 1.8 1.0 LiHMDS (1.8) e i THF -78/1 - - - 
a Determined by 1H NMR analysis with Pirkle’s alcohol. b Determined via 1H NMR analysis of the purified compound. 
c Determined via 1H NMR analysis of the crude reaction mixture. d Yield of a single diastereomers after flash 
chromatography. e Deprotonation was performed at -78 ºC for 45 min in THF (f in toluene, g in hexane). h 1.2 equiv of 
ZnCl2 or i MgBr2 was added after deprotonation at -78 ºC. 
 
Analogously, several other new chiral imidates 339 and 340 were prepared via the optimized reaction 
conditions with excellent anti-diastereoselectivity (anti/syn > 99/1) and good overall yield (69-83%) 
(Table 8, entries 1 and 2). Noteworthy, the reaction of imidate (RS)-26a with aldimine 27b (Ar = 
4-MeOC6H4) resulted in the formation of N-sulfinyl imidates (RS,R,S)-anti-340b as major 
diastereomer obtained in enantiomerically pure form by recrystallization in 69% yield. 
Unfortunately, the minor diastereomer (RS,S,R)-anti-339b could not be isolated in diastereomerically 
pure form and only a mixture of (RS,S,R)-anti-339b/(RS,R,S)-anti-340b = 74/26 in 10% yield was 
obtained which was not applied in further transformations. In case of the addition of imidate 26a 
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across aldimine 27c, optically pure imidates (RS,S,R)-anti-339c and (RS,R,S)-anti-340c were isolated 
after flash chromatography in 45% and 38% yield, respectively. 
In order to improve the facial selectivity, more sterically hindered substrates 26b-d and 330 or 341 
were tested. When addition of imidate 26a across N-(3,5-dimethoxybenzylidene)-4-
methylbenzenesulfonamide 330 was performed under optimized reaction conditions, the 
diastereomeric ratio 339d/340d was of 57/43 (Table 8, entry 3). The addition of methyl 5-chloro-N-
((2,4,6-triisopropylphenyl)sulfinyl)pentanimidate (RS)-26b across aldimines 26a and 26b resulted in 
the formation of adducts (RS,S,R)-anti-339e/(RS,R,S)-anti-340e in a ratio of 35/65 (Table 8, entry 4) 
and (RS,S,R)-anti-339f/(RS,R,S)-anti-340f in a ratio of 15/85 (Table 8, entry 5), respectively. The only 
negligible improvement of the diastereomeric ratio was observed when imidate 26b was reacted with 
aldimine 27b. Due to the reduced commercial availability and the low impact on the reaction outcome 
upon use of substrate 26b, further research was based on the use of imidate 26a. 
In a next attempt, imidate 26a and N-tert-butyl[phenyl(phenylsulfonyl)methyl]carbamate 341 were 
reacted under optimized reaction conditions (Table 8, entry 6). Formation of four diastereomers was 
observed via 1H NMR analysis of the crude reaction mixture, which could not be isolated in pure 








  Results and discussion 
61 
 
Table 8. Extension of the addition reaction N-sulfinyl imidates 26a,b across aldimines 27, 330 and 341. 
 
Entry Imidate 26 Aldimine 27 (RS,S,R)-339/ 
(RS,R,S)-340 a 
anti/syn a Yield (%) b 
1 (RS)-26a 27b 17/83 > 99/1 (RS,S,R)-339b (-) 
(RS,R,S)-340b (69) 
2 (RS)-26a 27c 60/40 > 99/1 (RS,S,R)-339c (45) 
(RS,R,S)-340c (38) 
3 (RS)-26a 330 57/43 > 99/1 - 
4 (RS)-26b 27a 35/65 > 99/1 - 
5 (RS)-26b 27b 15/85 > 99/1 - 
6 (RS)-26a 341 5/7/84/4c - - 
a Determined via 1H NMR analysis of the crude reaction mixture. b Yield of a single diastereomers after 
flash chromatography. c A mixture of four unidentified diastereomers was observed via 1H NMR analysis 
of the crude reaction mixture 
 
In a last attempt, the imidates (SS)-26c and (SS)-26d, with S-configuration of the sulfur atom, were 
applied towards Mannich-type reaction under optimized reaction conditions and results are listed in 
Table 9. Unfortunately, no significant improvements in the reaction outcome were observed with 
these substrates (Table 9, entries 1-3). 
Results and discussion 
62 
 
Table 9. Extension of the addition reaction N-sulfinyl imidates 26c,d across aldimines 27a,b. 
 
Entry Imidate 26 Aldimine 27 (SS,R,S)-339/ 
(SS,S,R)-340 a 
anti/syn a Yield (%) b 
1 (SS)-26c 27a 40/60 > 99/1 - c 
2 (SS)-26c 27b 14/86 > 99/1 (SS,R,S)-339i (10) 
(SS,S,R)-340i (70) 
3 (SS)-26d 27a 45/55 > 99/1 - c 
a Determined via 1H NMR analysis of the crude reaction mixture. b Yield of a single diastereomers after flash 
chromatography. c Single diastereomers were not isolated. 
 
3.2.3.3 Proposed transition state of formation of adducts 339 and 340 
The relative diastereoselectivity of the addition reaction of N-sulfinyl imidate 26a across N-sulfonyl 
aldimines 27 can be rationalized with a model in which the reaction proceeds via transition states 
TS-1 and TS-2 (Figure 12) with poor facial selectivity. Upon deprotonation of imidate 26,[152c, 153e] 
the E-enolate will be preferably formed with the chloropropyl group and the N-tert-butylsulfinyl 
group at opposite sides of the C–C double bond, while the N-sulfonyl aldimines 27 adopt an E-
configuration. Due to the steric repulsion between the sulfinyl group of imidate 26a and the aryl 
group of aldimines 27 and between the chloropropyl substituent and the arylsulfonyl group in 
transition state TS-3 it is concluded that transition states TS-1 and TS-2 are favored to give (RS,S,R)-
anti- and (RS,R,S)-anti products, respectively (Figure 12). It is worth noting that currently the halogen 
does not play a role in this stereochemical outcome, contrary to a halogen at the β-position of the 
enolate which influences the E/Z ratio of the metal enolates.[47, 172] 




Figure 12. Proposed transition state model. 
To confirm the anti-stereochemistry of adducts 339 and 340, additional investigation was carried 
out. The structure and stereochemistry of (RS,R,S)-anti-339c was confirmed by X-ray diffraction 
analysis (Figure 13). Noteworthy, the crystal data of adduct (RS,R,S)-anti-340c also supports the 
suggestion about E-configuration of the imidates 26. Furthermore, the oxidation of the sulfinyl group 
of imidates 339a and 340a to a sulfonyl group with mCPBA led to the formation of N-sulfonyl 
imidates (S,R)-342 and (R,S)-343 which demonstrate identical sets of chemical shifts in 1H and 13C 
NMR (Scheme 68). This result allowed to conclude that the two starting N-sulfinyl imidates 339a 





Figure 13. Asymmetric unit of the crystal structure of (RS,R,S)-anti-340c, showing thermal displacement ellipsoids at the 
50% probability level. The intramolecular H-bond between NH and S=O is indicated. 





3.2.3.4 Synthesis of 2,3-disubstituted piperidines 344-359 
For the further transformations towards substituted piperidines, compounds 339a-c and 340a-c were 
chosen in order to demonstrate the applicability of the new imidates. 
First, the chiral imidates 339 and 340 were evaluated for intramolecular cyclization to the 
corresponding piperidines 344 and 345 (Scheme 69).[173] Initial attempts to carry out a base-induced 
cyclization at room temperature resulted in poor conversion of N-sulfinyl imidate 339a. Treatment 
of imidate (RS,S,R)-anti-339a with three equivalents of potassium carbonate in acetonitrile under 
reflux for 20 hours resulted in full conversion of δ-chloro imidate 339a into piperidine (RS,2R,3S)-
cis-344a, which was isolated in an excellent yield of 92%. 
Other piperidines 344 and 345 were prepared in the same manner in good to excellent yields (87-
97%) without any isomerization reactions being observed. The relative configuration of the 
synthesized methyl 2-aryl-1-sulfonylpiperidine-3-N-(tert-butylsulfinyl)carbimidates 344 and 345 
was established as cis based on observed coupling constants of 6.1-6.2 Hz (1H NMR, CDCl3) between 
the protons at C-2 and C-3, whereas the corresponding trans-2,3-disubstituted piperidines have larger 
coupling constants (average 9.0-10.0 Hz).[174] The relative and absolute configurations were 
determined by means of X-ray diffraction analysis of the corresponding piperidines 344 and 345, 
namely, (RS,2R,3S)-cis-344a, (RS,2S,3R)-cis-345a, and (RS,2S,3R)-cis-345b (Figure 14). 
Noteworthy, the aryl substituent in the 2-position of N-protected piperidines 344 and 345 occupies 
an axial position, presumably, to minimize A1,3 interactions of the 2-substituent with the substituent 
at nitrogen which is sp2 hybridized.[175] 


















Figure 14. Asymmetric units of the crystal structures of piperidines (RS,2R,3S)-cis-344a, (RS,2S,3R)-cis-345a and 
(RS,2S,3R)-cis-345b, showing thermal displacement ellipsoids at the 50% probability level. 
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Furthermore, simple N-deprotection of the chiral piperidine-3-N-(tert-butylsulfinyl)carbimidates 344 
and 345 with 3M HCl in dioxane afforded the corresponding new optically pure N-
sulfonylpiperidine-3-carboxamides cis-347 and cis-348 in excellent yields (94-99%) (Scheme 70). 
Noteworthy, the use of diethyl ether as solvent led to formation of a mixture of N-sulfonylpiperidines 
cis-347a or 348a and piperidinecarbimidate hydrochlorides 346 in 1/1 ratio. The latter can be easily 
transformed to piperidine-3-carboxamides cis-347a and cis-348a in chloroform under reflux for 16 
hours, albeit, with lower yields of 78-84% (Scheme 70, A). The absolute and relative stereochemistry 
of the obtained amides 347 and 348 was determined by X-ray diffraction analysis (Figure 15), and 
the enantiomeric excess of >98% ee was measured via chiral HPLC analysis and based on NMR 
















Figure 15. Asymmetric units of the crystal structures of piperidine-3-carboxamides (2R,3S)-cis-347a, (2S,3R)-cis-348a 
and (2S,3R)-cis-348b, showing thermal displacement ellipsoids at the 50% probability level. Solvent water molecules are 
omitted for clarity. For (2S,3R)-cis-348b, only one molecule of the asymmetric unit is shown. 
  Results and discussion 
69 
 
Noteworthy, when deprotection of the N-sulfinyl group was performed prior to cyclization, the yield 
of piperidine-3-carboxamide 347a dropped dramatically (Scheme 71). 
 
Scheme 71 
Next, the successfully synthesized chiral piperidine-3-carboxamides cis-347a and cis-348b were 
converted by Hofmann rearrangement into the corresponding amines [i.e., (2S,3S)-cis-350 and 
(2R,3R)-cis-351] in good yields (60-75%) and with a diastereomeric ratio of >99/1 (Table 10, entries 
1 and 2).[176] The use of a prolonged reaction time and excess of NaOH (6.0 equivalents) caused the 
isomerization of cis-3-aminopiperidine 350 to trans-350 in a ratio cis/trans of 92/8 (Table 10, entry 
3), whereas the formed piperidine 351 was not prone to isomerization when excess of base was 
increased to 6.0 equivalents (Table 10, entry 4). 
Table 10. Optimization of the reaction conditions for the Hofmann rearrangement. 
 
Entry X Reaction conditions Result, dr a 
1 H 1.1 equiv Br2, 2.5 equiv NaOH, CH3CN/H2O = 2/1, 55 °C, 1 
h 
350, dr > 99/1 (60%)b 
2 OMe 1.1 equiv Br2, 2.5 equiv NaOH, CH3CN/H2O = 2/1, 55 °C, 1 
h 
351, dr > 99/1 (75%)b 
3 H 1.1 equiv Br2, 6 equiv NaOH, CH3CN/H2O = 2/1, 55 °C, 4 h 350, dr 92/8 
4 OMe 1.1 equiv Br2, 6 equiv NaOH, CH3CN/H2O = 2/1, 55 °C, 4 h 351, dr > 99/1 
a Determined via 1H NMR analysis of the crude reaction mixture. b Yield after preparative thin layer 
chromatography. 
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The enantiomer of compound cis-350, namely (2R,3R)-cis-3-amino-2-phenyl-1-tosylpiperidine 350, 
is a reported compound in the literature.[170b] A comparison of optical rotations, however, did not 
give a results consistent with literature data [[α]D (2S,3S)-350 -17.0 (c 0.33, CH2Cl2) vs lit. (2R,3R)-
350 -71 (c 0.16, CH2Cl2, 89% ee)], and this prompted us to carry out additional experiments in order 
to confirm the structure of piperidine 350. 
Thus, (S)- and (R)-Mosher amides 352 and 353 were synthesized from 3-aminopiperidine 350 and 
(R)- and (S)-α-methoxy-α-(trifluoromethyl)phenylacetyl chlorides (MTPA-Cl), respectively, 
following a reported protocol (Scheme 72).[177] The analysis of (S)- and (R)-Mosher amide 352 and 
353 confirmed the S-configuration of the stereogenic center at C-3 (Figure 16). The relative 
stereochemistry of 350 was assigned as cis based on the coupling constant of 6.2 Hz (1H NMR, 
CDCl3) between the protons at C-2 and C-3.[170] Additionally, 19F and 1H NMR analysis of (S)- and 




Figure 16. Schematic outcome of the Mosher analysis of (S)- and (R)-amides 352 and 353. 
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When the deprotection reaction of N-sulfonylpiperidine-3-N-(tert-butylsulfinyl)carbimidates 344 
and 345 was carried out with 3M solution of HCl in methanol, esters 354 and 355 were obtained in 
moderate yields (54-68%) (Scheme 73). 
 
Scheme 73 
In the next step, N-deprotection of N-sulfonylpiperidine-3-carboxylates cis-354 and cis-355 by 
sonication with Mg in MeOH at 40 °C afforded the chiral piperidines 356 and 357 in 35-52% yield 
(Scheme 74). Noteworthy, the deprotection of N-phenylsulfonylpiperidines (2R,3S)-354c and 
(2S,3R)-355c was complete within 1.5 hours after sonication with 20 equivalents of Mg, whereas for 
N-tosylpiperidines 354a and 355a,b a prolonged reaction time and 60 equivalents of Mg had to be 
used for full conversion of the starting esters into the desired chiral piperidines 356a and 357a,b to 
be achieved. Additionally, 2-arylpiperidine-3-carboxylates 356 and 357 are not only useful building 
blocks for peptide synthesis but could also serve as precursor for the synthesis of biologically relevant 
piperidine-2,3-dicarboxylic acids via possible oxidation of the phenyl group at C-2. 
 
Scheme 74 
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Finally, piperidine (2R,3S)-cis-356a was treated with benzyl bromide and triethylamine in THF for 
18 hours at room temperature, giving N-protected piperidine 358 (Scheme 10). The relative 
stereochemistry of piperidine 358 was assigned as cis based on the coupling constant of 5.6 Hz 
between the protons at C-2 and C-3. When methyl N-benzyl piperidine-3-carboxylate 358 was treated 
with 1M solution of KOtBu in THF and t-butyl acetate at room temperature for 48 hours, the trans-
2,3-disubstituted piperidine 359 was obtained in 43% yield (Scheme 75). The assignment of the 
relative stereochemistry as trans was based on the coupling constant of 10.1 Hz between the protons 
at C-2 and C-3.[106] 
 
Scheme 75 
The aforementioned transformations of piperidine 356a towards cis- and trans-piperidines 358 and 
359 were performed in order to demonstrate the potential use of piperidines 356 for further 
elaborations. However, the optimization of the reaction conditions is the object of following research. 
Noteworthy, the aryl substituent in the 2-position of N-(de)protected piperidines 356-359 occupies 
an equatorial position to avoid unfavorable 1,3-diaxal interactions between the aryl group at C-2 and 
the hydrogens at C-4 and C-6, in contrast to piperidines bearing a tosyl group on nitrogen (i.e. 344-
355) where the strong A1,3 strain results in the aryl substituent at C-2 to occupy the axial position.[175] 
In conclusion, the reactivity of the enantiomerically pure 2-aryl-3-chloroazetidines 22 towards the 
synthesis of azetidine-2-carboxylic acid derivatives 25 was studied. Unfortunately, all 
transformations of 2-arylazetidines 22 to the desired azetidine-2-carboxylic acids 23, 25 failed. In 
the second part, it was demonstrated that δ-chloro-β-amino-N-sulfinyl imidates 339 and 340 were 
readily prepared via highly anti-selective Mannich-type reactions of δ-chloro-N-sulfinyl imidates 26 
across aromatic N-sulfonyl aldimines 27. The absolute anti-diastereoselectivity obtained in the newly 
synthesized δ-chloro-β-amino-N-sulfinyl imidates 339, 340 is in agreement with the stereochemical 
outcome observed for α-methyl-substituted imidates.[153e] Subsequent cyclization and deprotection 
reactions led to the formation of various chiral 2,3-disubstituted piperidines such as 3-amino-2-
arylpiperidines 350-351 and 2-arylpiperidine-3-carboxylic acid derivatives 354-357 which belong to 
a class of compounds with potent biological activity or are of interest as valuable building blocks for 
the preparation of β-peptides with well-defined conformations. 
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3.3 Synthesis of fluorinated azetidines and study of their transformations 
3.3.1 Introduction 
Fluorine chemistry interfaces with different fields of research including agrochemical industry, 
medicinal chemistry, synthetic organic chemistry, organometallic chemistry and catalysis, peptide 
chemistry, and chemical biology, due to the extraordinary potential of fluorine-containing 
biologically relevant compounds.[178] Incorporation of fluorine atoms into heterocycles can lead to 
spectacular changes in the molecular properties, including their stability, hydrogen bonding ability, 
their conformational behaviour and basicity.[179] For instance, enhancement of thermal stability of 
collagen was observed by replacement of (4R)-hydroxyproline or proline residues in the polypeptide 
chain of collagen with (4R)-fluoroproline.[180] All of this is associated with specificity of the C-F 
bond which can be briefly characterized as short, strong, polarized and unreactive. A large amount 
of research has been devoted to study the nature and influence of the C-F bond, involving 
experimental and computational methods.[181] 
Particular interest in (3,)3-(di)fluorinated azetidines grows because of their ability to inhibit specific 
enzymes such as dipeptidyl peptidase IV what can be applied in the treatment of type 2 diabetes.[182] 
Another class of fluorinated small-membered rings are 2-fluoroaziridines which are even more rarely 
reported in literature although their non-fluorinated analogues gain great attention due to their utility 
as building blocks for diverse functionalized nitrogen-containing target compounds.[183] Noteworthy, 
synthetic methods towards 2-fluoroaziridine-2-carboxylates, with fluorine directly attached to the 
aziridine ring, are scantily described in literature.[184] 
In this chapter, results are described on the synthesis and study of the reactivity of 3-bromo-3-
fluoroazetidines as well as on the synthesis of 3-alkyl- and 3-aryl-2-fluoroaziridine-2-carboxylates 
with an electron-withdrawing/donating group at nitrogen. 
3.3.2 Reformatsky-type reaction of ethyl dibromofluoroacetate 34 across imines 362 
Starting aldimines 362 were synthesized via condensation of aldehydes 360 with the corresponding 
amines 361 in tetrahydrofuran in the presence of magnesium sulfate as drying agent at reflux for 0.5-
2 hours (Scheme 76).[185] 





Next, aldimines 362 were subjected to the diastereoselective synthesis of α-bromo-α-fluoro-β-
lactams 363 following a literature procedure.[49] The diethylzinc-mediated Reformatsky-type reaction 
of ethyl dibromofluoroacetate 34 across imines 362 in diethyl ether at -10 oC for one hour afforded 
diastereomerically pure cis-β-lactams 363 in good yields (Scheme 77). 
 
Scheme 77 
Furthermore, an attempt was made to extend the application of this Reformatsky-type reaction 
towards a broad range of aldimines, including aliphatic aldimines 365a and 365b and aldimine 27a, 
which bears an electron-withdrawing group at nitrogen.[184] 
First, aliphatic aldimines 365a,b were prepared via condensation of aldehydes 364a,b and 
benzylamine 361a in dichloromethane at 0 oC for one hour (Scheme 78). 
 
Scheme 78 
Imines 365a and 365b were immediately subjected to further reaction without purification due to 
their instability. When addition of ethyl dibromofluoroacetate 34 was carried out across N-
(ethylidene)benzylamine 365a under diethylzinc-mediated conditions, aziridine trans-366 was 
obtained in a yield of 37% (Scheme 79). The relative trans-stereochemistry of aziridine 366 was 
assigned based on analysis of the coupling constants of the C-3 proton of the aziridine ring (J3H,F = 
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Reaction of N-(ethylidene)benzylamine 365b and dibromofluoroacetate 34 led to the formation of a 
mixture of β-lactam 363f, ethyl 2-bromo-2-fluoro-3-(phenethylamino)-3-phenylpropanoate 367 and 
aziridine 368. The formation of compounds 363f, 367 and 368 might be rationalized by the 
isomerization of starting N-benzylaldimine 365b towards N-phenethylaldimine 369 via a base-
catalyzed 1,3-proton shift in the imine 365b (Scheme 80).[187] 
 
Scheme 80 
Compounds 363f, 367 and 368 were separated via column chromatography and the relative 
stereochemistry of these molecules was assigned based on the coupling constants between proton 
and fluorine (for cis-363f J3H,F = 10.3 Hz, for syn-367 J
3
H,F = 23.1 Hz, for cis-368 J
3
H,F = 4.4 Hz).[186] 
Noteworthy, the reaction proceeds regioselectively albeit with poor chemoselectivity. 
In the next attempt, aldimine 27a, bearing an electron-withdrawing group on nitrogen, was subjected 
to the Reformatsky-type reaction (Scheme 81). Only the open form adduct 370 was detected. 
Noteworthy, the stereoselectivity of this reaction was completely lost, giving a non-separable mixture 
of syn/anti isomers 370 in a ratio of 1/1.  






Subsequent treatment of ester 370 with potassium carbonate in CH3CN at room temperature for one 
hour gave a mixture of substituted ethyl 2-fluoroaziridine-2-carboxylates cis-371 and trans-372 in a 
ratio of 20/80 (Scheme 82). However, isolation of the pure diastereomers could not be achieved and 
two mixtures of isomers were isolated in 12% (372/371 34/66) and 17% (372/371 97/3) yield. The 
relative stereochemistry of the diastereomers was assigned based on analysis of the coupling 
constants of the C- 3 proton of the aziridine ring (trans: J3H,F = 8.1 Hz; cis: J
3
H,F = 2.5 Hz). 
 
Scheme 82 
3.3.3 Synthesis of 2-aryl-3-bromo-3-fluoroazetidines 373 and investigation of their 
reactivity 
With β-lactams 363 in hands, synthesis of 3-bromo-3-fluoroazetidines 373 was achieved via 
reduction of the carbonyl group with chloroalane (AlH2Cl) in diethyl ether at reflux for four hours in 
good yields (85-98%) (Scheme 83). The choice of chloroalane as a reducing agent relied on 
previously reported research on reduction of 3,3-dichloro-2-azetidinones.[45b] The relative 
configuration of the synthesized azetidines 373 was established as cis based on the observed coupling 
constants of 21-22 Hz between the proton at C-2 and fluorine at C-3.[188] 
 
Scheme 83 
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3.3.3.1 Investigation of nucleophilic substitutions in 2-aryl-3-bromo-3-fluoroazetidines 373 
In this part, the reactivity of 3-bromo-3-fluoroazetidines 373 towards nucleophilic substitution was 
investigated. The main interest was to investigate a direct approach to the synthesis of fluorinated 3-
aminoazetidines 374 or azetidine-3-carboxylic acid derivatives 375 (Scheme 84). 
 
Scheme 84 
In Table 11, the evaluated reaction conditions are enlisted. Initially, the introduction of an azido 
group on the azetidine ring via treatment of starting substrate 373a and 373b with sodium azide (1.5-
10 equiv) in different solvents (DMSO, DMF, acetone, MeOH) failed and only starting material was 
recovered via column chromatography (Table 11, entries 1, 3-8). Variations of temperature and 
reaction time, as well as substrates 373, did not lead to conversion of the starting material. Only 
degradation product was observed when 10 equivalents of sodium azide and prolonged reaction time 
was applied (Table 11, entry 2). In the next attempts, azetidines 373c,d,e were treated with three 
equivalents sodium iodide and three equivalents sodium azide in DMSO in order to substitute 
bromide with iodide, which might promote reactivity towards nucleophilic substitution (Table 11, 
entries 9-11). However, the addition of sodium iodide did not result in conversion of the starting 
material. Analogously, attempts at the substitution of bromide with iodide by reaction of 373b with 
sodium iodide also failed (Table 11, entries 13 and 14). 
Table 11.. Attempted nucleophilic substitution of azetidines 373. 
 
Entry R X Nu/ equiv Solvent T, °C/ t  Result (yield, %) a dr of 377 
b 
1 Bn H NaN3/3 DMSO 100/4.5 h (-) c,d  
2 Bn H NaN3/10 DMSO 100/24 h (-) e  
3 Bn H NaN3/1.5-3 DMF 60-100/3-24 
h 
(-) c,d  
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4 Bn H NaN3/3 acetone ∆/24 h (-) c,d  
5 Bn H NaN3/3 MeOH ∆/24 h (-) c,d  
6 Bn OMe NaN3/3 DMF ∆/24 h (-) c,d  
7 Bn OMe NaN3/3 acetone ∆/24 h (-) c,d  
8 Bn OMe NaN3/3 MeOH ∆/24 h (-) c,d  
9 Bn Cl NaN3-NaI/3-3 DMSO 100/24 h (-) c,d  
10 Bn CF3 NaN3-NaI/3-3 DMSO 100/24 h (-) c,d  
11 CHPh2 H NaN3-NaI/3-3 DMSO 100/24 h (-) c,d  
13 Bn OMe NaI/3 DMSO 60-90/3-20 h (-) c,d  
14 Bn OMe NaI/3 DMF 60-90/3-20 h (-) c,d  
15 Bn H KCN/3 DMF ∆/20 h (-) c,d  
16 Bn H NaCN/3 EtOH ∆/6 h 377a/373a = 55/45 
b 
53/47 
17 Bn H NaCN/3 DMSO 100/6 h 377a  34/66 
18 Bn H KCN/2+2 DMSO 100/20 h 377a (34%) 74/26 
19 Bn H KSCN/4 DMSO 100/24 h (-) c,d  
20 Bn H KCN/1 DMSO 125/10 min f 377a/373a = 70/30 
b 
79/21 
21 Bn H KCN/1 DMSO 135/10 min f (-) e  
22 Bn H KCN/2 DMSO 125/10 min f 377a (24%) 84/16 
23 Bn H KCN/4.3 MeOH 100/30 min f 377a (46%) 
378a (37%) 
84/16 
24 Bn OMe KCN/4.3 MeOH 125/45 min f 377b(36%) 
378b(41%) 
85/15 










26 Bn H KCN/4 EtOH 125/30 min f (-) c,d  
27 Bn H KCN/4 DMF 125/30 min f (-) e  
28 Bn H KCN/2-5 Toluene 125/30 min f (-) e  
29 Bn H Acetone 
cyanohydrine/2 
MeOH 100/1-8 h 
(press.vial) 
(-) e  
30 Bn H Acetone 
cyanohydrine/1 
CH2Cl2 100/30 min f (-) c  
31 Bn H Acetone 
cyanohydrine/3 
CH2Cl2 100/30 min f (-) e  
a Isolated yield after column chromatography or preparative TLC. b Determined based on 1H NMR analysis 
of crude reaction mixture. c No reaction. d Starting material was recovered. e Complex reaction mixture. f 
Microwave assisted synthesis. 
 
Furthermore, the introduction of a cyano group into 3-bromo-3-fluoroazetidines 373 was evaluated 
by use of different nucleophilic reagents, such as sodium cyanide, potassium cyanide and acetone 
cyanohydrine. At first, the reaction of azetidine 373a with potassium cyanide in DMF at reflux for 
20 hours did not result in any conversion of starting material (Table 11, entry 15). Next, treatment of 
azetidine 373a with three equivalents of sodium cyanide in EtOH at reflux for six hours afforded a 
mixture of 2-cyano-3-fluoroazetidine 377a and starting material 373a in a ratio of 55/45 (Table 11, 
entry 16). Noteworthy, formation of 3-cyano-3-fluoroazetidine 376a was not detected. After analysis 
of 1H and 19F NMR spectroscopic data, it was concluded that two diastereomers of 2-cyano-3-
fluoroazetidine 377a were formed in a ratio of 53/47. When the reaction was performed in DMSO at 
100 oC for six hours, full conversion of starting material was achieved and the ratio of diastereomers 
of 377a was 34/66 (Table 11, entry 17). When two equivalents of potassium cyanide in DMSO at 
100 oC for six hours were used, the starting material was not fully converted. Subsequently, two more 
equivalents of potassium cyanide were added and the reaction time was extended to 20 hours, 
affording full conversion of azetidine 373a based on TLC and LC-MS analyses (Table 11, entry 18). 
Purification via column chromatography gave N-benzyl 2-cyano-3-fluoro-2-phenylazetidine 377a as 
a 74/26 mixture of major/minor isomers in 34% yield. On the other hand, substitution with potassium 
thiocyanate failed (Table 11, entry 19). Next, a series of microwave-assisted experiments towards 
nucleophilic substitution were performed. In a first attempt, the use of one equivalent of potassium 
cyanide in DMSO at 80 oC for 10 minutes did not lead to conversion of starting material 373a, and 
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a gradual increase of the temperature to 125 oC afforded a mixture of product 377a (major/minor = 
79/21) and starting material 373a in a ratio of 70/30 (Table 11, entry 20). An increase of the 
temperature up to 135 oC led to a very complex mixture which was not further analysed (Table 11, 
entry 21). Conversion of starting azetidine 373a was complete when two equivalents of potassium 
cyanide were used in DMSO at 125 oC for 10 minutes under microwave irradiation, affording 2-
cyano-3-fluoroazetidine 377a in 24% yield after chromatography in a ratio 84/16 of major/minor 
isomer (Table 11, entry 22). Furthermore, also MeOH was evaluated as a solvent. After several test 
reactions, the use of 4.3 equivalents of KCN in MeOH at 100 oC for 30 minutes under microwave 
irradiation afforded azetidine 377a in 46% yield and the side product 3,3-dimethoxyazetidine 378a 
in 37% yield (Table 11, entry 23). Noteworthy, azetidine 377a was isolated as a mixture of major 
and minor isomer in a ratio of 84/16 similar to the ratio that was observed for other experiments with 
potassium cyanide. These optimized conditions were applied on substrate 373b, giving similar 
results, although, the reaction time was prolonged to 45 minutes in order to get full conversion of 
starting azetidine 373b (Table 11, entry 24). Analysis of the relative configuration of major and minor 
diastereomers 377 was performed via a NOESY experiment of azetidine 377b based on the 
assumption that the proton at the C-3 atom of the azetidine ring and the protons at C-2/C-6 atoms of 
the 2-(4-methoxyphenyl)-substituent must give a cross-peak when these protons are positioned on 
the same side of the azetidine ring. In a NOESY experiment on 377b, the aforementioned cross-peak 
was observed only for the major isomer which led to the conclusion that the aromatic substituent at 
C-2 and the proton at C-3 are on the same side what corresponds with cis-2-cyano-3-fluoro-2-(4-
methoxyphenyl)azetidine 377b (Figure 18). Thus, in the minor isomer, the fluoro atom is trans-
oriented with respect to the cyano group. Due to the similarity of azetidines 377a and 377b, it was 
assumed that the major isomer of 377a had cis-configuration and the minor 377a is trans. 
 
Figure 18. Arrow lines show NOE’s in NOESY spectrum (CDCl3) of 377b. 
Several additional microwave-assisted experiments were performed in search of a better control of 
the nucleophilic substitution of azetidine 373a with cyanide. However, the use of different solvents 
(tBuOH, EtOH, DMF, toluene) (Table 11, entries 25-28) as well as changing the source of cyanide 
to acetone cyanohydrine in MeOH or CH2Cl2 (Table 11, entries 29-31) did not give any 
improvements, and mainly complex reaction mixtures were formed which were not further analysed 
in detail. 
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A tentative pathway for the formation 3-fluoroazetidines 377 is shown in Scheme 85. Elimination of 
hydrogen bromide generates an unstable 2-azetine 379 which subsequently undergoes attack by the 
cyanide-anion. A related conversion of 3,3-dichloroazetidines into aziridines proceeding via 
elimination of hydrogen chloride, generating the corresponding 2-azetines, followed by addition of 
methanol has been described.[45b] 
 
Scheme 85 
3.3.3.2 Elaboration of 2-aryl-3-bromo-3-fluoroazetidines 373 via halogen-lithium exchange 
In this part of the research, 2-aryl-3-bromo-3-fluoroazetidines 373 were used as substrates in a 
halogen-lithium exchange strategy and the results are presented in Table 12. Optimization of the 
reaction conditions was performed for azetidine 373b. In a first attempt, 2-aryl-3-bromo-3-
fluoroazetidine 373b was treated with n-butyllithium in THF at -78 oC for 45 minutes and was 
subsequently quenched by the addition of water as an electrophile (Table 12, entry 1). Analysis of 
the crude reaction mixture by means of 1H and 19F NMR revealed the formation of 3-fluoroazetidine 
380b along with several unidentified nonfluorinated side products. Attempts to isolate and 
characterize the side products failed. Further optimization of reaction conditions by variations of the 
Li-source, temperature and time was carried out and the results are summarized in Table 12, entries 
2-13. The optimum reaction conditions were determined to be as follows: addition of 1.4 equivalents 
of sec-BuLi at -90 oC in THF and stirring for 30 minutes, followed by the addition of 5 equivalents 
of water and subsequent stirring at room temperature for two hours gave a mixture of azetidine 380b, 
which was isolated in 27% yield, and a tentative identified product (381b) in a ratio of 40/60 (Table 
2, entry 12). Though the ratio of desired product 380b to side product (381b) was higher when using 
the conditions described in Table 12, entry 5 (380b/(381b) = 66/34), the crude reaction mixture 
appeared to be more complex and azetidine 380b was isolated in only 12% yield. Isolation of side 
products failed. The optimized reaction conditions were applied for substrates 373c and 373d (Table 
12, entries 14 and 15). A mixture of 380c and (381c) was obtained from azetidine 373c, and 3-
fluoroazetidine 380c was isolated in 30% yield. When azetidine 373d was used as starting substrate, 
the desired 3-fluoroazetidine 380d was isolated in 35% yield. Formation of side product (381d) was 
not observed in the crude reaction mixture. The unknown compounds (381c) and (381b) have a 
similar structure based on 1H NMR analysis of the crude reaction mixture. For both compounds, two 
triplets at 3.04 ppm and 3.18 ppm (J = 6 Hz) were observed as well as LC-MS data supported the 
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tentative structures of 381b,c. Additionally, it was established by 19F NMR analysis that these side 
products do not contain fluorine in their structure. A possible structure for these unknown compounds 
is that of β-aminoketone 381. The problems with the isolation of putative compound 381 are believed 
to be caused by the lack of their stability. Remarkably, the reaction of halogen-lithium excenge 
proceeds stereoselectively and is assumed to furnish the trans-3-fluoroazetidines 380, based on 
analysis of coupling constants between the proton at C-2 and fluorine at C-3 atom (J3H,F = 22 Hz).[188] 
Further attempts to extend this reaction to the use of other electrophiles, unfortunately, failed. 
Introduction of ethoxycarbonyl or alkyl groups was problematic and led to formation of very 
complex mixtures (Table 12, entries 16-20). 19F NMR data clearly indicated that the crude reaction 
mixtures did not contain fluorinated compounds. 
 
Table 12. Optimization of halogen-lithium exchange reaction of 3-bromo-3-fluoroazetidines 373. 
 
Entry X Base/ equiv Electrophile/equiv T/t  Results a 
1 OMe nBuLi/ 1.5 H2O/5 1) -78 oC/ 45 min 
2) -78 oC to rt, 2h 
380b b 
2 OMe nBuLi/ 3.0 H2O/5 1) -90 oC/ 30 min 
2) -90 oC to rt, 2h 
380b/381b = 40/60 
3 OMe secBuLi/ 1.0 H2O/5 1) -78 oC/ 10 min 
2) -78 oC to rt, 2h 
381b/373b = 66/34 
4 OMe secBuLi/ 1.5 H2O/5 1) -78 oC/ 15 min 
2) -78 oC to rt, 2h 
380b/373b = 40/60 
5 OMe secBuLi/ 1.7 H2O/5 1) -78 oC/ 15 min 
2) -78 oC to rt, 2h 
380b/381b = 66/34 
380b (12%) c 
6 OMe secBuLi/ 2.0 H2O/5 1) -78 oC/ 20 min 380b/381b e 
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2) -78 oC to rt, 2h  
7 OMe secBuLi/ 4.0 H2O/5 1) -90 oC/ 30 min 
2) -90 oC to rt, 2h 
(-) f 
8 OMe secBuLi/ 2.0 H2O/5 1) -95 oC/ 60 min 
2) -95 oC to rt, 2h 
373b/380b/381b = 
20/29/51 
9 OMe secBuLi/ 3.0 H2O/5 1) -90 oC/ 45 min 
2) -90 oC to rt, 2h 
380b/381b = 20/80 
10 OMe secBuLi/ 2.0 H2O/5 1) -90 oC/ 80 min 
2) -90 oC to rt, 2h 
380b/381b = 30/70 
11 OMe secBuLi/ 1.0 H2O/5 1) -90 oC/ 30 min 
2) -90 oC to rt, 2h 
380b/381b = 35/65 
12 OMe secBuLi/ 1.4 H2O/5 1) -90 oC/ 30 min 
2) -90 oC to rt, 2h 
380b/381b = 40/60 
380b (27%) c 
13 OMe secBuLi/ 1.5 g H2O/5 1) -90 oC/ 30 min 
2) -90 oC to rt, 2h 
380b/373b = 65/35 
14 Cl secBuLi/ 1.4 H2O/5 1) -90 oC/ 30 min 
2) -90 oC to rt, 2h 
380c/381c = 50/50 
380c (30%) c 
15 CF3 secBuLi/ 1.4 H2O/5 1) -90 oC/ 30 min 
2) -90 oC to rt, 2h 
380d (35%) c,d 
16 OMe secBuLi/ 1.4 ClCOOEt/1 1) -90 oC/ 30 min 
2) -90 oC/ 20 min 
(-) f,h 
17 OMe secBuLi/ 1.0 ClCOOEt/1 1) -78 oC/ 40 min 
2) -78 oC/ 20 min 
(-) f,h 
18 OMe secBuLi/ 1.5 ClCOOEt/1 1) -90 oC/ 5 min 
2) -90 oC/ 20 min 
(-) f,h 
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19 OMe secBuLi/ 1.5 CH3I/2 eq 1) -90 oC/ 5 min 
2) -90 oC/ 20 min 
(-) f,h 
20 OMe nBuLi/ 1.0 CO2 (dry) 1) -78 oC/ 15 min 
2) -78 oC/ 60 min 
(-) f,h 
a Based on 1H and 19F NMR analysis of the crude reaction mixture. b Several unidentified side products were 
observed in the crude reaction mixture. c Yield after column chromatography. d Formation of 381d was not 
observed. e Ratio was not determined due to the complexity of the crude reaction mixture. f Complex reaction 
reaction mixture. g Dioxane was used as solvent. h No fluorinated products were detected via 19F NMR 
analysis. 
 
Additionally, reaction of 1,2,3,3-tetrasubstituted azetidine 373b with sodium hydride in dimethyl 
sulfoxide for two hours at 75 oC afforded ring opened product 382 in a poor yield of 21% (Scheme 
86). The reaction outcome could be rationalized via formation of the strained 2-azetine 379b by 
means of elimination of hydrogen bromide, followed by hydrolysis of the reactive intermediate 
during the aqueous work-up procedure.[45b] An attempt to characterize the intermediate 379b by direct 
NMR-monitoring of the reaction, which was carried out in an NMR tube in DMSO-D6, was not 
successful due to the complexity of the reaction mixture. 
 
Scheme 86 
3.3.4 Synthesis of trans-N-benzyl-3-fluoro-3-iodo-2-phenylazetidine 383 
In this part, the influence of substrate structure on the reactivity 3-fluorinated azetidines was 
investigated. It has been reported that the preferred conformation for both cis- and trans-2,3-
disubstituted azetidines is that conformer in which the N-alkyl and 2-aryl substituents occupy 
pseudoequatorial positions in order to decrease steric interactions.[188-189] Analogously, N-benzyl cis-
2-aryl-3-bromo-3-fluoroazetidine cis-373 occurs as conformer A rather than as conformer B (Figure 
19). However, in conformer A bromide occupies a pseudoaxial position, which might encumber the 
nucleophilic substitution assisted by the azetidine nitrogen. It was envisioned that the use of trans-
2-aryl-3-fluoro-3-iodoazetidine 383 (occurs as conformer C, Figure 19) as starting substrate could 
solve that problem. In order to have a better leaving group to promote the nucleophilic substitution, 
trans-3-iodinated azetidine 383 was synthesized instead of the 3-brominated substrate. 





First, the synthesis of cis-4-aryl-3-fluoroazetidinone 386 was conducted via a modified literature 
procedure.[190] Sodium 2-fluoroacetate 384 reacted with phosphorus(VI) chloride at 100 oC for one 
hour, affording fluoroacetyl chloride 385 in excellent yield of 95% (Scheme 87).[191] Subsequently, 
2-fluoroacetyl chloride 385 was subjected to condensation across imine 362a in dichloromethane at 
room temperature for two hours, resulting in the selective formation of cis-3-fluoro-4-
phenylazetidinone 386 in good yield of 64%. The selectivity of this condensation was previously 
described as the selective reaction of imine 362a with fluoroketene, which is formed after treatment 
of acid chloride 385 with triethylamine.[190, 192] 
 
Scheme 87 
Next, the synthesis of 3-fluoro-3-iodo-2-azetidinone 387 was attempted via iodination of the enolate 
of 3-fluoro-β-lactam 386. In a first attempt, β-lactam 386 was treated with n-butyllithium in THF at 
-78 oC for 45 minutes and the resulting enolate was subsequently added to a solution of iodine in 
THF at -78 °C following a literature procedure (Table 13, entry 1).[193] The reaction was stirred for 
one hour affording aminoketone 389, which was a result of the nucleophilic attack of the n-
butyllithium across carbonyl group of β-lactam 386. Remarkably, only the difluorinated analogue of 
the obtained β-amino-α-fluoroketone 389 was reported in literature.[194] When one equivalent of 
LiHMDS was used as a base, the desired 3-fluoro-3-iodo-2-azetidinone 387 was obtained. However, 
this compound occurred as a mixture of trans/cis isomers in a ratio of 85/15 (Table 13, entry 2). 
Moreover, conversion of starting material cis-386 was limited to 33% and formation of the trans-
isomer trans-388 of starting material 386 was observed in the crude reaction mixture. Interestingly, 
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stirring the reaction mixture for an additional 18 hours at room temperature gave no changes in the 
ratio of the formed products. In order to obtain a better conversion of starting azetidinone 386, the 
amount of base was increased to 1.5 and 2.0 equivalents (Table 13, entries 3 and 4). Both attempts 
gave very similar results, namely, conversion of starting material was around 80% and formation of 
trans-isomer 388 of starting material increased up to 20% versus 5% in case of using of one 
equivalent of LiHMDS. The desired 3-iodo-2-azetidinone 387 was isolated as a mixture of its 
trans/cis isomers in a ratio of 85/15 in low yields (20-31%). The distinction between both 
stereoisomeric compounds was easily made by means of the coupling constants between C-4 proton 
and C-3 fluorine (trans: J3H,F = 2.8 Hz; cis: J
3
H,F = 11.3 Hz). Finally, lithium diisopropylamide was 
applied as a base. Using one equivalent of LDA in THF at -78 oC for 45 minutes, followed by the 
addition of a solution of 1.1 equivalents of iodine in THF at -78 oC and stirring the reaction mixture 
for one hour, led to formation of a mixture of azetidinones 387, starting material cis-386 and 
unidentified side product (390), which could not be separated from the azetidinone 387 (Table 13, 
entry 5). Continuation of the reaction at room temperature for 18 hours did not shift the ratio of the 
constituents of the crude reaction mixture. Applying 2.5 equivalents of LDA and performing the 
reaction at -78 oC for 1.5 hours gave a mixture of desired iodo compound 387 and unidentified side 
product (390) in a ratio of 50/50 (Table 13, entry 6). Noteworthy, the stereoselectivity of the 
iodination reaction under the described conditions dropped, giving a mixture of trans- and cis-
isomers 373 in a ratio of 72/28. 
Table 13. Optimization of the reaction conditions towards synthesis of the 3-iodo-3-fluoroazetidinone 387. 
 
Entry Base/ equiv T, oC/ t, h Results Ratio of trans/cis 387 a 
(yield, %) b 
1 nBuLi/ 2.0 -78/ 1 c syn-389 (85%)  
2 LiHMDS/ 1.0 -78/ 1 
+rt/ 18 
387/386/388 = 28/67/5 
387/386/388 = 28/67/5 
85/15 
85/15 
3 LiHMDS/ 1.5 -78/ 1 c 387/386/388 = 60/20/20 85/15 (20%) 
4 LiHMDS/ 2.0 -78/ 1 387/386/388 = 62/23/15 85/15 (31%) 
5 LDA/ 1.0 -78/ 1 387/386/(390) d = 50/25/25 - e 
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+rt/ 18 387/386/(390) d = 50/25/25 - e 
6 LDA/ 2.5 -78/ 1.5 387/(390) d = 50/50 72/28 f 
a Determined based on 1H NMR analysis of crude reaction mixture. b Yield after purification via column 
chromatography. c Iodination of enolate using inverse addition technique. d 390 is unidentified product e 
Determination is complicated due to overlap of signals in crude reaction mixture. f Unidentified product 390 
could not be separated from product 387 and a mixture of 387/390 (1/1) was obtained after purification via 
column chromatography. 
 
The isolated mixture of trans/cis-β-lactams 387 was further subjected to reduction with chloroalane 
in diethyl ether at reflux for two hours, affording the desired azetidine 383 in good yield of 78% and 
ratio trans/cis isomers of 96/4. This mixture was treated with sodium azide in DMSO or acetone. 
However, the substitution failed, giving no reaction or a complex reaction mixture when harsh 
conditions were applied (Table 14, entries 1-3). 
Table 14. Attempted transformation of β-lactam 387 towards azetidine 391. 
 
Entry Reaction conditions Result 
1 3 equiv NaN3, DMSO, 70 oC, 10 min 
+ 80 oC, 30 min 




2 4 equiv NaN3, DMSO, 100 oC, 5 h (-) d 
3 3 equiv NaN3, acetone, ∆, 24 h (-) b,c 
a Microwave assisted synthesis. b No reaction.c Starting material was recuperated. d Partial or full degradation 
of starting material.  
 
Based on the performed experiments with the different 3-halo-3-fluoroazetidines, it can be concluded 
that the presence of fluorine dramatically decreases the reactivity of the attached halocarbon towards 
nucleophiles. 
In conclusion, the synthesis of new N-benzyl 3-bromo-3-fluoroazetidines cis-373 was performed via 
direct reduction of the corresponding β-lactams cis-363 without loss of stereochemistry. The 
reactivity of 3-bromo-3-fluoroazetidines 373 with nucleophiles and electrophiles was studied. The 
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obtained N-benzyl-3-fluoro-2-phenylazetidine-2-carbonitriles 377 and N-benzyl-2-aryl-3-
fluoroazetidines 380 can serve as versatile building blocks for further elaboration (e.g. synthesis of 
azetidine-2-carboxylic acids, ring opening, …). Additionally, the synthesis of new N-benzyl 4-aryl-
3-fluoro-3-iodo-2-azetidinones 387 and 3-fluoro-3-iodoazetidines 383 was achieved. Moreover, the 
diethylzinc-mediated Reformatsky-type reaction of ethyl dibromofluoroacetate 34 across aldimines 
was extended to diverse substrates, including aliphatic aldimines and aldimines bearing an electron-
withdrawing group at nitrogen, giving new ethyl 2-fluoroaziridine-2-carboxylates 366, 368 and ethyl 
3-amino-2-bromo-2-fluoro-3-phenylpropanoates 367 and 370. The importance of aziridine-2-
carboxylate units is worth to note, as they present one of the classes of natural aziridine-containing 
alkaloids which are an important source of drug prototypes.[195] 
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3.4 Synthesis of 3-amino-1,2-diols and their elaboration towards small 
membered amino acid derivatives bearing an aziridine, azetidine or epoxide 
scaffold 
In the following chapter, results are disclosed on the elaboration of N-substituted alkyl 2-
(aminomethyl)acrylates 42 towards the synthesis of the corresponding 2-(aminomethyl)oxirane-2-
carboxylates 44, aziridine-2-carboxylates 45 or azetidine-3-carboxylates 46 (Figure 20). The present 
research is an extension of results preliminary reported by our research group.[50] 
 
Figure 20. Overview of the targeted amino acids derivatives. 
3.4.1 Introduction 
N-Substituted allylamines 392 (Figure 21) are attractive substrates for diverse organic syntheses due 
to the reactivity of the double bond towards diverse transformations such as dihalogenation,[127, 196] 
epoxidation,[197] direct aziridination,[198] halohydroxylation,[199] aminohalogenation,[200] 
haloazidation,[201] aminohydroxylation,[202] and asymmetric dihydroxylation[203]. Moreover, N-
substituted allylamines 392 and 393 are valuable building blocks for numerous elaborations towards 
the synthesis of bioactive compounds.[45a, 204] 
 
Figure 21 
Cα-Tetrasubstituted α-amino acids, for example, α-aminoisobutyric acid 394 and 3-
aminocyclobutane-1-carboxylic acid 395 (Figure 21), play an important role in the design of peptides 
and peptidomimetics with enhanced properties, as they possess a stereochemically stable quaternary 
carbon center which results, after incorporation into peptides, in a significant conformational bias.[51b, 
51c, 205] 
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Recently, our research group reported on the synthesis of heterocyclic analogues 296 of amino acid 
395 bearing an electron donating group at nitrogen (Scheme 88).[127b] Subsequently, investigation of 
the conformational features of these amino acids in model peptides 396 and 397 allowed to conclude 
that such a 3-aminoazetidine-3-carboxylic acid moiety 296 is a β-turn inducer.[51a] Moreover, the 3-




Aziridine-2-carboxylic acid derivatives are known building blocks for the synthesis of proteinogenic 
and non-proteinogenic amino acids and biologically active compounds.[207] 
On the other hand, the use of β-amino acids in the development of β-peptide foldamers, pioneered 
by Seebach,[31b] has received much interest due to the stability of β-peptides compared to peptides 
constituted from α-amino acids. Alicyclic β-amino acids are a well known class of non-proteinogenic 
amino acids which are found in nature both in free form and in peptides.[208] Their synthetic analogues 
are useful units for the synthesis of peptides with modified and improved pharmacological 
properties.[32c, 32d, 167a, 207c, 209] The synthesis and study of α-epoxy-β-amino acids is rarely described in 
the literature.[210] However, the oxirane ring has proven to be a versatile building block and synthetic 
intermediate.[211] 
3.4.2 Synthesis of 3-amino-1,2-diols 43 and study of their transformations 
N-substituted alkyl 2-(aminomethyl)acrylates 42a and 42b were prepared via literature procedures 
starting from the corresponding ethyl 398a and methyl 2-(hydroxymethyl)acrylate 398b, 
respectively.[196b, 204g, 212] Next, Upjohn dihydroxylation was performed under the conditions 
previously optimized by our research group.[50] Using a catalytic amount of OsO4 and 2.5 equivalents 
of N-methylmorpholine-N-oxide (NMO) as co-oxidant, full dihydroxylation of acrylates 42a,b was 
achieved at room temperature. After flash chromatography, aminodiols 43a,b were isolated in 82% 
and 89% yield, respectively (Scheme 89). Noteworthy, for the formation of methyl 2,3-
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Subsequently, the reactivity of versatile building blocks 43a,b and their cyclization towards 
aziridines, azetidines and epoxides was studied. 
First, cyclization of 3-amino-1,2-diol 43b under Mitsunobu conditions was carried out in analogy 
with the reported cyclization of 43a (Scheme 3).[50] The use of 1.5 equivalents of PPh3 and 1.5 
equivalents of diisopropyl azodicarboxylate (DIAD) in dry THF at reflux for 27 hours afforded 
oxirane 44b in 34% yield. Furthermore, a more efficient method for cyclization towards epoxides 
44, which involves the activation of the primary alcohol into a good leaving group by means of 
mesylation, was applied (Scheme 90).[50] 
Treatment of 3-amino-1,2-diol 43a with 1.05 equivalents of triethylamine and 1.05 equivalents of 
methanesulfonyl chloride in dry THF at 0 oC followed by warming up to room temperature for two 
hours afforded monomesylated aminoalchohol 400a (Scheme 90). For the synthesis of N-Boc-
protected derivative 400b similar reaction conditions were applied, though the reaction time could 
be shortened to 40 minutes. 





Next, monomesylated aminodiols 400a and 400b were treated with 1.5 equivalents of K2CO3 in 
acetonitrile at 60 oC for three hours, exclusively affording epoxides 44a and 44b in 78% and 80% 
yield, respectively (Scheme 90). In order to demonstrate the potential applicability of the synthesized 
β-amino acid derivatives, N-deprotection of epoxide 44b was attempted by treatment with TFA in 
CH2Cl2, unfortunately with no success and only complex mixture of unidentified products was 
formed (Scheme 90). When initial N-Boc deprotection of mesylate 400b was performed with TFA 
followed by base mediated cyclization, the desired oxirane 402 was not observed and only plausible 
side product 401 could be detected as tentatively assigned via 1H and 13C NMR. However, further 
efforts to isolate an analytically pure product 401 via column chromatography or preparative thin 
layer chromatography failed. The formation of O-protected amino-1,2-diol 401 might be explained 
by instability of epoxides in acidic conditions.[213] 
Based on a preliminary study by our research group, the selective synthesis of aziridines and 
azetidines from aminodiols 400, avoiding ring closure towards epoxides, could be achieved by simple 
manipulations.[50] 
Thus, monomesylated aminodiols 400 were subjected to further mesylation, since bismesylated 
aminodiol 400a proved to be a good substrate for the synthesis of the corresponding aziridine 45a 
(Scheme 91). The use of two equivalents of triethylamine and two equivalents of methanesulfonyl 
chloride in CH2Cl2 (for 400a) or THF (for 400b) at room temperature for two hours afforded 
derivatives 403a and 403b in 27% and 59% yield, respectively (Scheme 91). Noteworthy, when THF 
was used as solvent for mesylation of substrate 400a, the yield of product 403a dropped to less than 
10%.  
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Next, 2-(methanesulfonyloxymethyl)-1-(toluene-4-sulfonyl)aziridine-2-carboxylate 45a, resulting 
from 3-exo-tet ring closure, was prepared in 58% yield upon treatment of mesylate 403a with three 
equivalents of K2CO3 in CH3CN at 60 °C for 1.5 hours (Table 15, entry 1).[50] Noteworthy, formation 
of the alternative azetidine, the 4-endo-tet product, did not occur. Treatment of N-Boc derivative 
403b under similar reaction conditions gave no reaction, while subsequent prolongation of the 
reaction time and increase of the temperature gave only complex reaction mixtures (Table 15, entry 
2). This might be explained by the strong deactivating character of the tert-butoxycarbonyl group on 
nitrogen, which can prevent cyclization. It was foreseen that the aforementioned problem could be 
eliminated by N-deprotection of substrate 403b followed by intramolecular cyclization (Scheme 91). 
Thus, bismesylate 403b was treated with TFA in CH2Cl2 and intermediate 404 was subjected to the 
cyclisation reaction with potassium carbonate in CH3CN affording methyl 2-
[(methanesulfonyloxy)methyl]aziridine-2-carboxylate 405 although the full conversion of mesylate 
404 was not achieved. The purification of the resulting crude mixture via preparative HPLC did not 
lead to separation of the individual compounds 404 and 405 which were obtained as a mixture of 
404/405 in a ratio of 20/80 (Scheme 91).  
 
Scheme 91 
Table 15. Investigation of the ring closure of bismesylates 403. 
Entry R1 R2 Reaction conditions Resulta 
1 Tos Et 3 equiv K2CO3, CH3CN, 60 °C, 1.5 h 45a (58%) 
2 Boc Me 1.5-3 equiv K2CO3, CH3CN, 60-90°C, 2-24 h -b 
a Yield after purification by flash chromatography. b Degradation of starting material. 
 
In order to prepare substrates for the direct cyclization of monomesylated aminodiols 400 towards 
azetidines, protection of the tertiary hydroxyl group was performed by using preliminary optimized 
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reaction conditions.[50] Substrates 400a and 400b were treated with two equivalents of TMSCl and 
five equivalents of imidazole in CH2Cl2 at room temperature for 30 minutes, affording disubstituted 
aminoalcohols 406a and 406b in 90% and 94% yield, respectively (Scheme 92). Noteworthy, when 
THF was used instead of CH2Cl2, no conversion of starting material 400a was observed even when 
the reaction time was extended to 28 hours.  
 
Scheme 92 
In the next step, mesylate 406a was easily cyclized to azetidine 407a (95% yield) via addition of 
three equivalents of K2CO3 in acetonitrile (Scheme 92).[50] Contrary, cyclization of N-Boc substituted 
derivative 406b did not proceed towards the desired compound 407b, while increasing the 
temperature and the reaction time up to 18 hours led to the formation of epoxide 44b. The latter could 
be explained via the degradation of starting material 407b to its precursor 406b, and subsequent 
cyclization. Due to the problematic synthesis of N-Boc protected azetidine 407b, further 
transformations were performed on N-Tos protected azetidine 407a exclusively. 3-Hydroxyazetidine 
46a was easily accessed (90% yield) after deprotection of the TMS-group with an excess of gaseous 
HCl in diethyl ether (Scheme 93).[50] 
 
Scheme 93 
Azetidine 46a was envisioned as a suitable substrate for the preparation of derivatives of 
Cα-tetrasubstituted amino acids via nucleophilic substitution of the hydroxyl group and further 
transformations. In a first attempt, substitution of the tertiary hydroxyl group of 46a with iodide was 
tested. Following a literature procedure,[214] substitution of the hydroxyl group with iodide was 
performed by treatment of azetidine 46a with 1.2 equivalents of triphenylphosphine, 1.2 equivalents 
of imidazole and 1.2 equivalents of iodine in CH2Cl2 at room temperature. After full consumption of 
starting material (LC-MS and TLC control), no formation of 3-iodoazetidine 408 was detected by 
LC-MS and 1H NMR analysis of the crude reaction mixture. Instead, a non-separable mixture of two 
ring-opened products was isolated after column chromatography. The composition of the mixture 
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was determined as ethyl 2-hydroxy-3-iodo-2-[(tosylamino)methyl]propanoate 409 and ethyl 2-
[(tosylamino)methyl]acrylate 42a in a ratio of 75/25 (Scheme 94).  
Recently, the use of PPh3/halogenating agents was reported as a highly efficient approach for the ring 
opening of activated and non-activated aziridines with halides.[215] However, this methodology was 
not applied for azetidine ring opening. Due to the poor reactivity of (non)activated azetidines, an 
additional activation step, leading to the formation of an azetidinium ion, is needed to promote the 
ring opening reaction.[216] Moreover, the ring opening of 3-substituted azetidines has only been 
reported in one recent publication, where the reaction proceeds via nitrogen activation as well.[217] 
 
Scheme 94 
The obtained results could be explained by the high reactivity of the azetidine ring 46a towards 
nucleophilic ring opening. Presumably, triphenylphosphine acts as a Lewis base and attacks iodine, 
giving iodotriphenylphosphonium iodide (Scheme 95).[218] Subsequently, the activated azetidine 46a 
undergoes nucleophilic attack by iodide at C-2, leading to the ring opened product 409 after 
protonation (route a). Formation of acrylate 42a could be rationalized by halophilic reaction of the 
intermediate 410 and in situ generated iodide (Scheme 95, route b), which, likely, was formed via 
reaction of the iodotriphenylphosphonium cation and imidazole.[219] 
 
Scheme 95 
In subsequent attempts, the reaction of 3-hydroxyazetidine 46a and thionyl chloride was tested. 
When azetidine 46a was treated with 1.2 equivalents of thionyl chloride at room temperature for up 
to four days, only starting material was detected. Addition of one equivalent of triethylamine to the 
reaction resulted in full consumption of starting material 46a at room temperature within 30 minutes 
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(Scheme 96). Analysis of the crude reaction mixture by LC-MS and 1H NMR led to conclude, that 
the expected 3-chloroazetidine 411 was not formed. The crude mixture was purified by column 
chromatography and the isolated product was identified as ethyl 3-chloro-2-hydroxy-2-
[(tosylamino)methyl]propanoate 412 (78%), which is an analogue of the aforementioned 3-
iodopropanoate 409 (Scheme 96). The proposed pathway of this reaction includes similar steps as 
described above: formation of the nucleophile by reaction of triethylamine with thionyl chloride and 
nucleophilic attack of chloride at the azetidine carbon C-2 of 46a, followed by protonation of the 





The similar outcome points to the high propensity of this type of azetidine 46a towards nucleophilic 
ring opening. The proposed reaction routes could be elaborated by a more detailed mechanistic study, 
which was not conducted in the context of the present PhD. 
Furthermore, mesylation of the tertiary hydroxyl group of azetidine 46a by treatment with three 
equivalents of Et3N and three equivalents of MsCl in THF afforded mesylate 413 in 95% yield 
(Scheme 98).[50] Next, the activity of the latter compound towards nucleophilic substitution was 
examined. Treatment of azetidine 413 with NaN3 in DMSO, DMF or acetone gave no conversion of 
starting material and only some decomposition was observed after prolonged heating (Table 16, 
entries 1-3). Subsequently, substitution was attempted by using four equivalents of NaI and four 
equivalents of NaN3 in DMSO at 110  oC for 24 hours, which afforded the desired 3-azidoazetidine 
414 in 25% isolated yield (Table 16, entry 4). Full conversion, however, was not achieved and the 
remaining starting material could be isolated in 8% yield. Besides, side product 415 was formed and 
isolated in 5% yield. Based on this analysis of the reaction mixture, it is clear that applying more 
harsh conditions (a larger excess of nucleophile, high temperatures and prolonged reaction times) 
would promote the formation of side product 415 and decomposition of the starting material 413. 
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Reaction with three equivalents of NaI and three equivalents of NaN3 in DMSO at 85 ºC for 20 hours 
resulted in a mixture of starting 413 and product 414 in a ratio of 3/1. After work-up and purification 
via column chromatography, 3-azidoazetidine 414 was isolated in 21% yield and the recovered 
starting material was subsequently subjected to further substitution under the same reaction 
conditions. After repeating the sequence one more time, full conversion of starting material 413 was 
achieved, affording 3-azidoazetidine 414 in a combined yield of 56% (Table 16, entry 5). Changing 
the solvent to ethanol resulted in a low conversion of starting material 413 (Table 16, entry 6). 
Further, the enhancement using microwave heating was tested. In a first attempt, azetidine 413 was 
treated with two equivalents of NaI and two equivalents of NaN3 in DMSO at 80  oC for 30 minutes. 
This gave no satisfying result, while subsequent increase of the temperature up to 120  oC afforded a 
reaction mixture of 414/415/413 in a ratio 69/12/19 based on 1H NMR analysis of the crude reaction 
mixture (Table 16, entry 7). Finally, DMF was used as a solvent, resulting in a lower conversion of 
starting mesylate 413 (Table 16, entry 8). Despite the advantage of microwave assisted synthesis, i.e. 
a better conversion of the starting compound, it seems to be more difficult to control the ring opening 
as a side reaction. Importantly, the formation of α,β-diazido ester 415 makes the reaction potentially 
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Table 16. Optimization of the substitution reaction with NaN3. 
Entry Reaction conditions Result a 
1 4 equiv NaN3, DMSO, 65 °C, 20 h -b 
2 4 equiv NaN3, acetone, ∆, 20 min -b 
3 2 equiv NaN3, DMF, 70°C, 4 h -b 
4 4 equiv NaI, 4 equiv NaN3, DMSO, 110 °C, 24 h 414 (25%), 415 (5%), 413 (8%) 
5 3 equiv NaI, 3.0 equiv NaN3, DMSO, 85 °C, 20 h 414 (56%)c 
6 3 equiv NaI, 3.0 equiv NaN3, EtOH, ∆, 1-48 h 414/413 = 5/95d  
7 2 equiv NaI, 2 equiv NaN3, DMSO, 120 °C, 20 mine 414/415/413 = 69/12/19d 
8 2 equiv NaI, 2 equiv NaN3, DMF, 80-120 °C/30-60 mine 414/415/413 = 53/4/43d 
a Yield after purification by flash chromatography. b No reaction. c Yield after 3 sequences of recuperation of 
unreacted starting material 413 followed by repeating the reaction conditions. d Determined via 1H NMR of 
crude reaction mixture. e Microwave assisted reaction.  
 
In order to demonstrate the usefulness of the synthesized constrained amino acid precursor 414 as 
possible building block for the synthesis of foldamers, it was subjected to hydrogenolysis and 
hydrolysis reaction conditions.[51a, 127b] Simple hydrogenolysis of 3-azidoazetidine 414 using 10 wt.% 
palladium on carbon in ethanol at room temperature for 30 minutes afforded 3-aminoazetidine 47 in 
83% yield. Additionally, hydrolysis of ester 414 to the corresponding 3-azidoazetidine-3-carboxylic 
acid 48 was achieved in 80% yield upon reaction with 2M aqueous NaOH in methanol (1/1) at room 
temperature for two hours (Scheme 99). 
 
Scheme 99 
In a last part, the detosylation of azetidine 46a was attempted in order to obtain a valuable building 
block 416 for potentially active pharmaceutical compounds as well as for the synthesis of β-peptides 
(Scheme 100).[190, 220] When the reaction of azetidine 46a was performed with 10-20 equivalents of 
Mg turnings in dry methanol using sonication at 40 ºC for 1-24 hours, only complex reaction mixtures 
were obtained (Table 17, entry 1). Performing the reaction with Mg turnings upon sonication 
followed by treatment with Boc2O and DMAP in acetonitrile gave a mixture of azetidines 417 and 
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418 in 8% and 5% yield, respectively (Table 17, entry 2). In the next attempt, 10 equivalents of Mg 
powder were used in dry methanol at room temperature for two hours and consequently 1.1 
equivalents of Et3N and 1.1 equivalents of Boc2O were added to the reaction mixture and the reaction 
was stirred at room temperature for 3 hours, resulting in a mixture of 46b and 46c in a 68/32 ratio 
based on the 1H NMR analysis of the crude reaction mixture (Table 17, entry 3). Noteworthy, under 
such reaction conditions the starting carboxylate 46a underwent full transesterification to the 
corresponding methyl azetidine-3-carboxylate. Using 15 equivalents of Mg for three hours caused a 
slight increase in the conversion of the starting material (Table 17, entry 4). Finally, extension of the 
reaction time to 18 hours led to a full consumption of N-Tos protected azetidine 46a and treatment 




Table 17. Optimization of Tos-deprotection of 3-hydroxyazetidine-3-carboxylate 46a and subsequent protection with a 
Boc-group. 
Entry Reaction conditions Result a 
1 10-20 equiv Mg (turnings), MeOH, 40 oC, sonication 1-24 h - 
2 1) 20 quiv Mg (turnings), MeOH, 40 oC, sonication, 5 h 
2) 1.1 equiv Boc2O, 0.1 mol DMAP, CH3CN, r.t., 3 h 
417 (8%), 418 (5%) 
3 1) 10 equiv Mg (powder), MeOH, r.t., 2 h 
2) 1.1 equiv Boc2O, 1.1 equiv Et3N, MeOH, r.t., 3 h 
46b/46c = 68/32b 
4 1) 15 equiv Mg (powder), MeOH, r.t., 3 h 
2) 1.1 equiv Boc2O, 1.1 equiv Et3N, MeOH, r.t., 3 h 
46b/46c  = 77/23b 
5 1) 15 equiv Mg (powder), MeOH, r.t., 18 h 
2) 1.1 equiv Boc2O, 1.1 equiv Et3N, MeOH, r.t., 3 h 
46b (54%) 
a Yield after purification by flash chromatography (or preparative TLC). b Determined via 1H 
NMR analysis of the crude reaction mixture. 
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In conclusion, an efficient synthesis of alkyl 2-(aminomethyl)oxirane-2-carboxylates 44, alkyl 2-
[(methanesulfonyloxy)methyl]aziridine-2-carboxylates 45, and 3-hydroxyazetidine-3-carboxylates 
46 was developed starting from N-substituted allylamines 42. The versatility of the N-tosyl-3-
hydroxyazetidine-3-carboxylate 46a was demonstrated by its transformation to the corresponding 
Cα-tetrasubstituted α-amino acid derivatives, namely, ethyl 3-aminoazetidine-3-carboxylate 47, 3-
azidoazetidine-3-carboxylic acid 48 and N-Boc protected methyl 3-hydroxyazetidine-3-carboxylate 
46b. The obtained small ring heterocyclic α- and β-amino acid derivatives can be considered as 




























The development of new short efficient synthetic routes towards acyclic and cyclic biologically 
relevant α- and β-amino acid derivatives was a main issue of the present PhD research. Albeit some 
methods did not lead to the desired results, the optimization and modification of the reaction 
conditions and substrates seems an interesting and challenging field for further research. 
A first proposal relates to the addition reaction of α-anions of α,α-dichloroketimines (1-azaenolates) 
across imines (Section 3.1.3).  
The adducts 303 might be subjected to transformations leading to the possible formation of 
dichlorinated diamino acid derivatives 419 or 2-aziridinyl amino ester 420 (Scheme 101). These 
transformations might include the selective reduction of the C=N bond and N-sulfinyl deprotection. 
From the other hand, reductive amination of the hydrolyzed product 319 could give compound 421 
and subsequent NH-deprotection could provide free α,γ-diaminocarboxylic acid 422. Important 
considerations to be taken into account concerns the necessity to carefully control the reaction 
conditions such as temperature and solvent as well as the work-up conditions to minimize side 




In the second part of this thesis (Section 3.2.2), it was demonstrated that the δ-chloro-β-amino-N-
sulfinyl imidates 339/340 are efficient building blocks for the synthesis of various chiral 2,3-
disubstituted piperidines such as 3-amino-2-arylpiperidines 350/351 and 2-arylpiperidine-3-
carboxylic acid derivatives 354-357. In order to extend the application of the imidates 339/340, the 
N-sulfinyl deprotection leading to the formation of ester 423 can serve as a method for the synthesis 
of a new scaffold of β-amino acid derivatives (Scheme 102). Moreover, the functionalized β-amino 
esters 423 could be envisioned as synthons for further elaborations towards biologically relevant 




Organic Chemistry and Technology (UGent) towards chiral 3-chloroazetidines,[47] substrates 423 
could be transformed to 2,3-disubstituted azetidines 424 via reduction of the ester group of 423 
towards primary alcohols and subsequent cyclization under Mitsunobu conditions. In previous 
research, it was shown that azetidine derivatives 426 are as potent as their β-lactam counterparts 425 
(e. g. ezetimibe) in inhibiting cholesterol absorption in vitro.[221] Thus, the proposed azetidines 424 
could be seen as precursors for the design of small-molecule cholesterol absorption inhibitors that 
can be useful in preventing cardiovascular disease by lowering blood cholesterol level. Moreover, 
the 2,3-substituted azetidines 424 might act as valuable building blocks for the synthesis of analogues 
of clindamycin 427, such as azetidine lincosamides 428 with promising antimicrobial activities.[222] 
As it was reported in Section 3.2.1, a successful oxidation of the aryl substituent at C-2 of azetidines 
424 might be a challenging step of the aforementioned transformation. Additionally, the δ-chloro-β-
amino esters 423 could be elaborated towards substituted δ-lactones 429 [223] which can be found in 
the structure of some bioactive compounds. For example, the δ-lactone unit is present in the structure 
of the Lovastatin 430 (Mevacor®, Merck), the first marketed statin used as cholesterol lowering 
drug.[224] Also, compounds with a δ-lactone core were detected in the pheromone system of the giant 
white butterfly Idea leuconoe.[225] The substitution of chloride in 423 with azide followed by 
reduction could afford the δ-amino acid derivatives 431. Along with β- and γ-amino acids which 
have proven to be valuable building blocks for peptidomimetics,[31d] less studied δ-amino acid 
derivatives have potential application in the synthesis of peptides[226] with well-defined secondary 
structure as it was suggested by Hofmann in a theoretical study of the possible helix types in 
oligomers of δ-amino acids.[227] The main interest for the δ-peptides arises from the close 
correspondence between δ-amino acid oligomers 432 and dipeptide units in α-peptides 433. 





In view of the successful Mannich-type addition of N-sulfinyl imidates 26a across aromatic 
aldimines, the addition of N-sulfinyl imidates 26a across ethyl (tosylimino)acetate 434 could lead to 
the synthesis of piperidine-2,3-dicarboxylic acid 334/335 via the established synthetic approach 
(Scheme 103). The latter piperidine 434/435 is a cyclic analogue of NMDA and could be used for 
the study of its interactions with amino acid neuromediated receptors. The adduct 435 could be also 







Since the presence of fluorine atoms in molecular structures has a great impact on their physical, 
biological and chemical properties, it would be interesting to expand the described results in Section 
3.3 with additional experiments. The asymmetric version of the Reformatsky-type reaction between 
ethyl dibromofluoroacetate 34 and aldimines 297, 439 bearing an electron-withdrawing group at 
nitrogen could be performed in order to synthesize fluorinated β-amino acid derivatives 440 (Scheme 
104).[228] Moreover, investigation of the nucleophilic substitution of the bromide in the acyclic 
adducts 440 could give additional information about the reactivity of the carbon atom attached to the 
fluorine. The suggested cyclization of adducts 440 to aziridines 442 constitutes a valuable 
transformation (Scheme 104). However, as it follows from the described results (Section 3.3), the 
isolation of cyclized products 442 could be difficult due to the instability of aziridines 442. 
 
Scheme 104 
Also, the 2-cyanoazetidine derivatives 377 (Section 3.3.3.1) form a direct precursor for the synthesis 
of fluorinated azetidine-2-carboxylic acid derivatives 443 (Scheme 105). 





Based on previous research, azetidine-3-carboxylic acid derivatives 294 with an electron-donating 
group on nitrogen act as β-turn inducers in model peptides 396 and 397.[51a] Noteworthy, an 
interesting main-chain-to-side-chain hydrogen bond has been detected between the trisubstituted 
nitrogen of the azetidine ring and amide NH of the immediately following residue, forming a six-
membered pseudo-cycle. Therefore, the incorporation of the azetidine-3-carboxylic acid derivatives 
47a and 48a (Scheme 106) into peptides (e. g. 444 and 445) followed by study of their structures 
might be helpful in order to establish the influence of the electron-withdrawing N-substituents on the 
azetidine nitrogen on the peptide structure. 
 
Scheme 106 
In the same manner, substrate 46b could be elaborated to Cα-tetrasubstituted amino acid derivatives 
47b and 48b (Scheme 107) which are of interest in peptide modeling (e. g. 446 and 447). Noteworthy, 
the N-Boc protected derivatives have an advantage in being more synthetically friendly towards N-






Additional attempts could be performed towards the preparation of cyclic β-amino acid derivative 
416 (Section 3.4.2) (Scheme 108) via N-Boc deprotection of mesylate 400b as key step. Further O-




Moreover, the structural moiety of the aminodiols 42 (Section 3.4.2) is present in the structure of α-
oxoamides, salaramide A (452) and its homologue salaramide B (453), isolated from the Madagascar 
marine sponge Hippospongia sp.[229] Having a good dihydroxylation method for the allylamines 42 
in hand, the latter could be foreseen as promising precursors for the synthesis of natural compounds 
452 and 453 in order to investigate their potential biological activity (Scheme 109). It might be more 
practical to start the synthesis with the deprotection and subsequent derivatization (i.e. acylation with 
2-oxotetradecanoyl chloride or 2-oxopentadecanoyl chloride) of the allylamines 42 [230] followed by 
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5 Experimental part 
5.1 General methods 
Flame-dried glassware was used for all non-aqueous reactions. Commercially available solvents and 
reagents were purchased from common chemical suppliers and used without further purification , 
unless stated otherwise. 
Solvents 
Diethyl ether (Et2O), tetrahydrofuran (THF) and toluene were dried by distillation over 
sodium/benzophenone ketyl, whereas hexane was distilled from calcium hydride. Methanol (MeOH) 
was reacted in the presence of magnesium and iodine, distilled and kept over molecular sieves. 
Dichloromethane (CH2Cl2) was distilled from calcium hydride prior to use. Petroleum ether refers to 
the 40-60 oC boiling fraction. Acetonitrile (CH3CN) was kept over molecular sieves at least 24 hours 
prior to use. 
Column chromatography 
The purification of the reaction mixtures was performed by column chromatography with silica gel 
(Acros, particle size 0.035-0.070 mm, pore diameter ca. 6 nm). Solvent systems were determined via 
thin layer chromatography (TLC) on glass plates coated with silica gel (Merck, Kieselgel 60 F254, 
precoated 0.25 mm) using standard visualization techniques or agents: UV fluorescence (254 nm and 
366 nm) and coloring with iodine vapors or with potassium permanganate solution. 
Liquid chromatography 
Liquid chromatography analysis was performed by a reverse phase LC-column (Eclipse plus C18 
column). The LC column has dimensions of 50 x 4.6 mm and has a particle size of 3.5 µm. Gradient 
elution was used (30% acetonitrile in water to 100% acetonitrile over 6 minutes). 
Chiral HPLC analysis was performed using a Daicel Chiralcel IA column [amylose tris (3,5-
dimethylphenylcarbamate) immobilised on 5 μm silica gel] or IB column [cellulose tris (3,5-
dimethylphenylcarbamate) immobilised on 5 μm silica gel] and with a solvent mixture of 
hexane/ethanol as the mobile phase. 
Mass spectrometry 
Low-resolution mass spectra were recorded using a direct inlet system with an Agilent 1100 series 
LC/MSD type SL with a UV detector and mass spectrometer with electrospray ionisation geometry 




High-resolution mass spectra were obtained using an Agilent 1100 series HPLC coupled to an 
Agilent 6210 TOF-Mass Spectrometer, equipped with ESI/APCI-multimode source.  
NMR spectroscopy 
1H (300 or 400 MHz), 13C (75 or 100.6 MHz) and 19F-NMR (376.5 or 282 MHz) NMR spectra were 
recorded on a Jeol Eclipse FT 300 NMR spectrometer or a Bruker Avance III Nanobay 400 MHz 
spectrometer at room temperature. Peak assignments were obtained with the aid of DEPT, COSY, 
HSQC and/or HMBC spectra. The compounds were diluted in deuterated solvents, quoted in parts 
per million (ppm) with tetramethylsilane (TMS) and trichlorofluoromethane (CFCl3) as internal 
standards. 
Infrared spectroscopy 
IR spectra were recorded with a Perkin–Elmer Spectrum One FTIR spectrometer with an ATR 
(Attenuated Total Reflectance) accessory in neat form. 
Melting point 
Melting points were measured using a Kofler bench, type WME Heizbank of Wagner & Munz. 
Optical rotation 
Optical rotations were measured with a Jasco P-2000 polarimeter.  
Microwave irradiation 
All microwave reactions were performed in a CEM Focused MicrowaveTM Synthesis System, Model 
Discover, with a continuous output from 0 to 300 watt and a self-adjusting, single mode MW cavity. 
The reactions were performed in 10 mL thick-walled pyrex reaction vessels, closed with a ‘snap-on’ 
septa cap and equipped with a small stirring bar. A ramp time of maximum five minutes was used 
whereby the temperature was increased from room temperature to the desired one. This temperature 
was maintained during the course of the reaction for the indicated time. The temperature control 
system used a non-contact infrared sensor to measure the temperature on the bottom of the vessel 
and was used in a feedback loop with the on-board computer to regulate the temperature from 25 to 
250 oC by adjusting the power output (1 Watt increments). The pressure control IntelliVentTM 
Pressure control system, used an direct measurement of the pressure by sensing changes in the 
external deflection of the septa on the top of the sealed pressure vessel. Stirring was performed by a 
rotating magnetic plate, located below the floor of the microwave cavity. When the reaction was 
done, cooling of the vial was performed by a stream of clean air onto the vial, which decreased the 
temperature of a 2 mL solution from approximately 150 oC to 40 oC in less than 120 seconds. 





X-ray intensity data were collected on a Agilent Supernova Dual Source (Cu at zero) diffractometer 
equipped with an Atlas CCD detector using CuK radiation ( = 1.54178 Å) and  scans. The images 
were interpreted and integrated with the program CrysAlisPro (Agilent Technologies).[231] Using 
Olex2,[232] the structure was solved by direct methods using the ShelXS structure solution program 
and refined by full-matrix least-squares on F2 using the ShelXL program package.[233] Non-hydrogen 
atoms were anisotropically refined and the hydrogen atoms in the riding mode and isotropic 
temperature factors fixed at 1.2 times U(eq) of the parent atoms (1.5 times for methyl groups and the 
hydroxyl group). 
CCDC-1046634-1046639 and 1400317 contains the supplementary crystallographic data for the 
Section 3.2.3 and can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or 
from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; 
fax: +44-1223-336033; or deposit@ccdc.cam.ac.uk). 
All X-ray diffraction analyzes were performed in collaboration with Prof. Dr. K. Van Hecke, 
XStruct, Department of inorganic and Physical Chemistry, Ghent University, Belgium. 
5.2 Synthetic procedures 
5.2.1 Synthesis of ethyl 2-((1,1-dimethylethyl)sulfonamido)-3-(pyrrolidin-1-
ylimino)propanoate 300 and ethyl 2-((1,1-dimethylethyl)sulfonamido)-3-(pyrrolidin-1-
ylamino)acrylate 313 
To a solution of ethyl 2-((tert-butylsulfonyl)imino)acetate 298 (1.0 equiv, 4.52 mmol, 1.00 g) in 
CHCl3 (15 mL) was slowly added N-(pyrrolidin-1-yl)methanimine 12 (1.0 equiv, 4.52 mmol, 0.44 
g) at room temperature. The reaction mixture was stirred at ambient temperature for 1 hour. 
Subsequently, the solvent was removed in vacuo and the crude mixture was purified by column 
chromatography, affording an equilibrium mixture of 2-((1,1-dimethylethyl)sulfonamido)-3-
(pyrrolidin-1-ylimino)propanoate 300 (major) and ethyl 2-((1,1-dimethylethyl)sulfonamido)-3-




Rf = 0.60 (PE/EtOAc 1/3). Brown oil, yield 87%. IR (cm-1): νmax 1152, 1292, 
1493, 1740, 3256. 1H NMR (300 MHz, CDCl3): δ 1.18-1.33 (6H, m, 2 x 
OCH2CH3), 1.45 (9H, s, tBumajor), 1.46 (9H, s, tBuminor), 1.78-1.85 (4H, m, 
CH2CH2CH2CH2,minor), 1.86-1.94 (4H, m, CH2CH2CH2CH2,major), 2.82-2.93 
(4H, m, CH2CH2CH2CH2,minor), 3.12-3.22 (4H, m, CH2CH2CH2CH2,major), 4.09-
4.29 (4H, m, 2 x OCH2CH3,major and minor), 4.79 (1H, d, J = 3.9 Hz, CHNHmajor), 
6.38 (1H, d, J = 3.9 Hz, CH=Nmajor), 6.77 (1H, d, J = 11.0 Hz, CHNHminor), 7.68 (1H, d, J = 11.0 Hz, 
CHNHminor). 13C NMR (75 MHz, CDCl3): δ 14.2 (OCH2CH3,major), 14.6 (OCH2CH3,minor), 21.9 (2C, 
CH2CH2CH2CH2,minor), 23.5 (2C, CH2CH2CH2CH2,major), 24.2 (3C, tBumajor), 24.5 (3C, tBuminor), 50.9 
(2C, CH2CH2CH2CH2,major), 56.9 (2C, CH2CH2CH2CH2,minor), 57.1 (2 x Cquat, tBumajor and minor), 58.5 
(CHNHmajor), 61.9 (OCH2CH3,minor), 62.3 (OCH2CH3,major), 124.9 (CH=Nmajor), 129.5 (C=CHminor), 
146.1 (C=CHminor), 170.4 (C=Omajor and minor). MS (ES, pos mode) m/z (%): 320 (100) [M + H]+. 
5.2.2 Synthesis of ethyl 2-(sulfinylamino)-4-(sulfinylimino)-4-methoxybutanoates 301 
The synthesis of 301a is representative. A solution of imidate 13a (1.0 equiv, 1.57 mmol, 0.30 g) in 
THF (6 mL) was cooled to -78 oC under nitrogen atmosphere. A 1M solution of LiHMDS (1.2 equiv, 
1.88 mL, 1.88 mmol) in THF was slowly added and the resulting solution was stirred at the same 
temperature for 45 minutes. After deprotonation, a solution of (RS)-iminoacetate 297 (1.2 equiv, 1.88 
mmol, 0.39 g) in THF (6 mL) was added dropwise and the reaction mixture was stirred additionally 
for 1 hour. Subsequently, the reaction was quenched with a saturated solution of NH4Cl (2 mL) and 
was brought to room temperature. To the reaction mixture 10 mL of saturated NaHCO3 was added 
followed by extraction with EtOAc (3 x 8 mL). The combined organic phases were dried (MgSO4), 
filtered and evaporated in vacuo. Purification by column chromatography afforded two diastereomers 
of 301a in 18% and 9% yield. The stereochemistry was not established. 
(RS, RS)-Ethyl 2-(tert-butylsulfinylamino)-4-(tert-butylsulfinylimino)-4-methoxy-3-
methylbutanoate 301a 
Major isomer 301a: Rf = 0.19 (PE/Et2O 1/1). White amorphous solid, yield 
18%. [α]D -137.3 (c 0.6, CHCl3). IR (cm-1): νmax 1057, 1257, 1603, 1734, 3228. 
1H NMR (400 MHz, CDCl3): δ 1.19 (9H, s, tBu), 1.22 (9H, s, tBu), 1.23 (3H, 
d, J = 6.1 Hz, CHCH3), 1.31 (3H, t, J = 7.2 Hz, OCH2CH3), 3.74 (3H, s, OCH3), 
3.71-3.83 (1H, m, CHCH3), 4.01 (1H, dd, J = 9.9, 10.5 Hz, CHNH), 4.09 (1H, d, J = 10.5 Hz, CHNH), 
4.25 (2H, q, J = 7.2 Hz, OCH2CH3). 13C NMR (100.6 MHz, CDCl3): δ 14.2 (OCH2CH3), 15.1 
(CHCH3), 22.0 (3C, tBu), 22.6 (3C, tBu), 41.6 (CHCH3), 54.3 (OCH3), 56.1 (Cquat, tBu), 56.2 (Cquat, 
tBu), 61.5 (CHNH), 62.0 (OCH2CH3), 171.8 (C=N), 175.0 (C=O). MS (ES, pos mode) m/z (%): 397 
(100) [M + H]+. 
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Minor isomer 301a: Rf = 0.07 (PE/Et2O 1/1). White amorphous solid, yield 9%. [α]D -111.6 (c 0.7, 
CHCl3). IR (cm-1): νmax 1041, 1090, 1181, 1292, 1607, 1736, 3164. 1H NMR (400 MHz, CDCl3): δ 
1.21 (9H, s, tBu), 1.24 (6H, m, OCH2CH3 and CHCH3), 1.26 (9H, s, tBu), 3.68 (1H, m, CHCH3), 
3.75 (3H, s, OCH3), 4.18-4.29 (3H, m, OCH2CH3 and CHNH), 4.37 (1H, d, J = 7.7 Hz, CHNH). 13C 
NMR (100.6 MHz, CDCl3): δ 14.1 and 15.1 (OCH2CH3 and CHCH3), 22.0 (3C, tBu), 22.8 (3C, tBu), 
41.6 (CHCH3), 54.2 (OCH3), 56.2 (Cquat, tBu), 56.5 (Cquat, tBu), 59.9 (CHNH), 62.3 (OCH2CH3), 
171.3 (C=N), 174.4 (C=O). MS (ES, pos mode) m/z (%): 397 (100) [M + H]+. 
(RS, RS)-Ethyl 2-(tert-butylsulfinylamino)-4-(tert-butylsulfinylimino)-4-methoxy-3-
phenylbutano-ate 301b 
Major isomer 301b: Rf = 0.26 (PE/Et2O 1/9). Pale yellow oil, yield 8%. [α]D -
247.2 (c 0.2, CHCl3). IR (cm-1): νmax 1074, 1247, 1613, 1742, 3304. 1H NMR 
(400 MHz, CDCl3): δ 0.94 (3H, t, J = 7.1 Hz, OCH2CH3), 1.20 (9H, s, tBu), 
1.25 (9H, s, tBu), 3.85 (3H, s, OCH3), 3.88-3.94 (2H, m, OCH2CH3), 4.61 (1H, 
dxd, J = 11.2, 8.4 Hz, CHNH), 5.11 (1H, d, J = 11.2 Hz, CHPh), 5.26 (1H, d, J = 8.4 Hz, CHNH), 
7.28-7.35 (3H, m, 3 x CHarom), 7.41-7.45 (2H, m, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 13.8 
(OCH2CH3), 22.0 (3C, tBu), 22.6 (3C, tBu), 52.0 (CHPh), 55.3 (OCH3), 56.5 (Cquat, tBu), 56.7 (Cquat, 
tBu), 61.0 (OCH2CH3), 61.5 (CHNH), 128.4 (CHarom), 128.7 (2 x CHarom), 128.8 (2 x CHarom), 134.0 
(Carom,quat), 170.2 (C=N), 171.5 (C=O). MS (ES, pos mode) m/z (%): 459 (100) [M + H]+. 
Minor isomer 301b: Rf = 0.11 (PE/Et2O 1/9). Pale yellow oil, yield 6%. [α]D -129.6 (c 0.2, CHCl3). 
IR (cm-1): νmax 1077, 1245, 1614, 1739, 3195. 1H NMR (400 MHz, CDCl3): δ 0.87 (9H, s, tBu), 1.12 
(9H, s, tBu), 1.30 (3H, t, J = 7.1 Hz, OCH2CH3), 3.80 (3H, s, OCH3), 3.98 (1H, d, J = 8.8 Hz, CHNH), 
4.25 (2H, q, J = 7.1 Hz, OCH2CH3), 4.63 (1H, dxd, J = 10.2, 8.8 Hz, CHNH), 4.93 (1H, d, J = 10.2 
Hz, CHPh), 7.23-7.39 (5H, m, 5 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 14.1 (OCH2CH3), 21.9 
(3C, tBu), 22.1 (3C, tBu), 52.0 (CHPh), 55.4 (OCH3), 56.1 (Cquat, tBu), 56.4 (Cquat, tBu), 60.2 
(CHNH), 62.3 (OCH2CH3), 128.0 (CHarom), 128.7 (2 x CHarom), 129.7 (2 x CHarom), 134.9 (CHarom,quat), 
170.6 (C=N), 171.1 (C=O). MS (ES, pos mode) m/z (%): 459 (100) [M + H]+ 
5.2.3 Synthesis of (RS)-ethyl 2-(tert-butylsulfinylamino)-3,3-dichloro-4-(isopropyl-
imino)-4-phenylbutanoate 303a 
To a flame dried round-bottomed flask with freshly distilled diisopropylamine (1.1 equiv, 14.4 mmol, 
14 mL) in dry THF (5 mL) was added nBuLi (2.3M solution in hexane) (1.1 equiv, 14.4 mmol, 6.3 
mL) under nitrogen atmosphere. The reaction mixture was stirred for 30 minutes at 0 oC. 
Subsequently, a solution of α,α-dichloroketimine 14a (1.0 equiv, 13.10 mmol, 3.00 g) in dry THF 
(30 mL) was slowly added and the resulting solution was stirred at 0 oC for 40 minutes and was 




mmol, 3.21 g) in dry THF (10 mL) was slowly added and the resulting solution was stirred at the 
same temperature for 1 hour. The reaction mixture was quenched with a saturated solution of NH4Cl 
(6 mL) and was slowly warmed to room temperature followed by an extraction with EtOAc (3 x 30 
mL). The combined organic phases were dried (MgSO4), filtered and evaporated in vacuo. The crude 
product was purified by column chromatography to yield 303a in 80% yield. 
Rf = 0.19 (PE/Et2O 1/1). Red oil, yield 80%. [α]D -24.6 (c 0.9, CHCl3). IR (cm-
1): νmax 1085, 1186, 1740, 3240. 1H NMR (400 MHz, CDCl3): δ 1.04 (6H, 2 x 
d, J = 6.1 Hz, 2 x CH(CH3)2), 1.31 (9H, s, tBu), 1.36 (3H, t, J = 7.2 Hz, 
OCH2CH3), 3.27 (1H, sep, J = 6.1 Hz, CH(CH3)2), 4.20-4.36 (2H, m, 
OCH2CH3), 4.88 (1H, d, J = 9.4 Hz, HNH), 5.19 (1H, d, J = 9.4 Hz, CHNH), 7.24-7.30 (2H, m, 2 x 
CHarom), 7.39-7.46 (3H, m, 3 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 14.1 (2C, CH(CH3)2), 15.4 
(OCH2CH3), 23.0 (3C, tBu), 53.5 (CH(CH3)2), 57.3 (Cquat, tBu), 62.2 (OCH2CH3), 66.7 (CHNH), 
89.8 (CCl2), 128.1 (2 x CHarom), 128.4 (2 x CHarom), 129.1 (CHarom), 133.2 (Carom,quat), 163.8 (C=N), 
169.1 (C=O). MS (ES, pos mode) m/z (%): 435/437/439 (100) [M + H]+. 
5.2.4 Synthesis of (RS)-ethyl 2-(tert-butylsulfinylamino)-3,3-dichloro-4-oxo-4-
phenylbutanoate 319 and (RS)-ethyl 2-(tert-butylsulfinylamino)-3-chloro-4-oxo-4-
phenylbut-2-enoate 320 
To a solution of (RS)-ethyl 2-(tert-butylsulfinylamino)-3,3-dichloro-4-(isopropylimino)-4-
phenylbutanoate 303a (2.17 mmol, 0.94 g) in THF (25 mL) was added 2M HCl (25 mL) at room 
temperature. The reaction mixture was stirred at room temperature for 30 minutes and subsequently 
was cooled to 0 oC. After 5 minutes, 2M NaOH was added until pH=8. The aqueous phase was 
extracted with CH2Cl2 (3 x 20 mL). The combined organic phases were dried (MgSO4), filtered and 
evaporated in vacuo, affording the α,α-dichloroketone 319. The purification of the crude product by 
column chromatography (PE/Et2O 1/1, Rf = 0.20, silica gel) triggered the dehydrochlorination 
reaction to give product 320 in yield of 51%. 
(RS)-Ethyl 2-(tert-butylsulfinylamino)-3,3-dichloro-4-oxo-4-phenylbutanoate 319 
Rf = 0.49 (PE/EtOAc 1/2). Brown oil, yield 91% (crude). [α]D -28.1 (c 0.7, 
CHCl3). IR (cm-1): νmax 690, 1079, 1185, 1241, 1695, 1741, 3145. 1H NMR 
(400 MHz, CDCl3): δ 1.28 (9H, s, tBu), 1.29 (3H, t, J = 7.2 Hz, OCH2CH3), 
4.18-4.36 (2H, m, OCH2CH3), 4.58 (1H, d, J = 8.3 Hz, CHNH), 5.13 (1H, d, J 
= 8.3 Hz, CHNH), 7.45-7.66 (5H, m, 5 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 13.9 
(OCH2CH3), 22.7 (3C, tBu), 57.2 (Cquat, tBu), 63.0 (OCH2CH3), 65.6 (CHNH), 86.6 (CCl2), 128.3 (2 
x CHarom), 130.3 (2 x CHarom), 132.3 (Carom,quat), 133.6 (CHarom), 167.7 (C=O), 187.5 (C=O). MS (ES, 
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pos mode) m/z (%): 394/396/398 (100) [M + H]+. HRMS: calcd. for C16H22Cl2NO4S+ [MH]+ 
394.0641; found: 394.0657. 
(RS)-Ethyl 2-(tert-butylsulfinylamino)-3-chloro-4-oxo-4-phenylbut-2-enoate 320 
Rf = 0.14 (PE/Et2O 6/4). Yellow oil, yield 51%. IR (cm-1): νmax 696, 1089, 
1259, 1545, 1735, 3061. Isomer 1 (major): 1H NMR (400 MHz, CDCl3): δ 
1.06 (3H, t, J = 7.2 Hz. OCH2CH3), 1.38 (9H, s, tBu), 4.04-4.14 (2H, m, 
OCH2CH3), 6.10 (1H, s, NH), 7.34-7.52 (3H, m, 3 x CHarom), 7.85-7.89 (2H, 
m, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 13.4 (OCH2CH3), 22.3 (3C, tBu), 58.2 (Cquat, tBu), 
63.1 (OCH2CH3), 118.7 (ClC=C), 128.7 (2 x CHarom), 129.5 (2 x CHarom), 133.6 (CHarom), 135.6 
(Carom,quat), 143.3 (ClC=C), 161.5 (C=O), 188.3 (C=O). MS (ES, pos mode) m/z (%): 358/360 (100) 
[M + H]+. HRMS: calcd. for C16H21ClNO4S+ [M + H] + 358.0874; found: 358.0884. Isomer 2 (minor): 
1H NMR (400 MHz, CDCl3): δ 1.36 (9H, s, tBu), 1.44 (3H, t, J = 7.2 Hz. OCH2CH3), 4.42-4.53 (2H, 
m, OCH2CH3), 7.56-7.62 (3H, m, 3 x CHarom), 7.65-7.74 (2H, m, 2 x CHarom), 11.31 (1H, s, NH). 13C 
NMR (100.6 MHz, CDCl3): δ 14.1 (OCH2CH3), 22.3 (3C, tBu), 58.5 (Cquat, tBu), 63.3 (OCH2CH3), 
126.9 (ClC=C), 128.0 (2 x CHarom), 128.5 (2 x CHarom), 132.0 (CHarom), 135.3 (Carom,quat), 149.2 
(ClC=C), 161.0 (C=O), 194.9 (C=O). MS (ES, pos mode) m/z (%): 358/360 (100) [M + H]+. HRMS: 
calcd. for C16H21ClNO4S+ [MH]+ 358.0874; found: 358.0884. 
5.2.5 Synthesis of N-(2-chloro-3-(4-methoxyphenyl)-3-oxopropyl)-4-methylbenzene-
sulfonamide 328b 
To a solution of (2R,3S)-3-chloro-2-(4-methoxyphenyl)-1-tosylazetidine 22b (92.6 mg, 0.26 mmol) 
in CCl4 (1 mL), CH3CN (1 mL) and deionized water (1 mL), periodic acid (H5IO6) (10 equiv, 593 
mg, 2.6 mmol) was added and the flask contents were stirred until both phases became clear. To the 
mixture was slowly added ruthenium(III) chloride (0.05 equiv, 2.7 mg, 0.01 mmol) at 0 oC, and the 
reaction mixture was vigorously stirred for 2.5 hours at room temperature. After, the reaction mixture 
was cooled to 0 oC and diethyl ether was added with vigorous stirring for 20 minutes. The organic 
phase was separated and the aqueous phase extracted with EtOAc (2 x 3 mL). The combined organic 
phases were washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The crude 
mixture was purified by thin layer chromatography to yield the N-(2-chloro-3-(4-methoxyphenyl)-3-
oxopropyl)-4-methylbenzenesulfonamide 328b. 
Rf = 0.19 (PE/Et2O 8/2). Yellow oil, yield 10%. IR (cm-1): νmax 1115, 1239, 
1724, 3318. 1H NMR (400 MHz, CDCl3): δ 2.32 (3H, s, CH3), 3.42-3.68 
(2H, m, CH2CHCl),4.01 (3H, s, OCH3), 5.10 (1H, d, J = 7.71 Hz, CHCl), 
5.12 (1H, d, J = 8.26, NH), 7.00 (2H, d, J = 8.81 Hz, 2 x CHarom), 7.31 (2H, d, J = 8.26 Hz, 2 x 




MHz, CDCl3): δ 21.6 (CH3), 45.0 (CH2NH), 53.4 (OCH3), 55.7 (CHCl), 114.2 (2 x CHarom), 126.7 
(Carom,quat), 127.1 (2 x CHarom), 130.0 (2 x CHarom), 131.8 (2 x CHarom), 137.0 (Carom,quat), 143.9 
(Carom,quat), 164.6 (Carom,quat), 191.2 (C=O). MS (ES, pos mode) m/z (%): 368 (100) [M + H]+. 
5.2.6 Synthesis of (RS,R,R,)-methyl N-(tert-butylsulfinyl)-2-chloro-3-[(3,5-
dimethoxyphenyl)(p-toluenesulfonylamino)methyl]propanimidate (RS,R,R)-anti-325c 
A solution of (RS)-methyl N-tert-butanesulfinyl-2-chloroethanimidate (RS)-324 (1.5 equiv, 0.40 g, 
1.9 mmol) in THF (5 mL) was cooled to -78 °C. A 1M solution of LiHMDS (1.5 equiv, 1.9 mL, 1.90 
mmol) in THF was slowly added, and the resulting solution was stirred for 45 minutes at -78 °C. 
After deprotonation, a solution of N-(3,5-dimethoxybenzylidene)-4-methylbenzenesulfonamide 330 
(1.0 equiv, 0.40 g, 1.26 mmol) in THF (5 mL) was added dropwise, and the reaction mixture was 
stirred at -78 ºC for 1 hour. To the reaction mixture was added a saturated solution NH4Cl (2 mL), 
followed by a saturated solution of NaHCO3 (10 mL). The aqueous phase was extracted with Et2O 
(3 x 10 mL). The combined organic phases were dried (MgSO4), filtered, and evaporated in vacuo. 




Rf = 0.13 (PE/Et2O 7/3). Colorless oil, yield 33%. [α]D -131.5 (c 0.3, 
CHCl3). IR (cm-1): νmax 1058, 1154, 1157, 1295, 1456, 1598, 3105. 1H 
NMR (400 MHz, CDCl3): δ 1.40 (9H, s, tBu), 2.29 (3H, s, CH3), 3.67 (6H, 
s, 2 x OCH3), 3.86 (3H, s, OCH3), 4.54 (1H, t, J = 9.9 Hz, CHNH), 5.39 
(1H, d, J = 9.9 Hz, CHCl), 6.21 (1H, s, CHarom), 6.24 (2H, s, CHarom), 6.73 (1H, d, J = 9.9 Hz, CHNH), 
7.00 (2H, d, J = 8.0 Hz, 2 x CHarom), 7.38 (2H, d, J = 8.0 Hz, 2 x CHarom). 13C NMR (100.6 MHz, 
CDCl3): δ 21.4 (CH3), 22.2 (3C, tBu), 55.3 (2 x OCH3), 55.6 (OCH3), 56.7 (Cquat, tBu), 58.2 (CHCl), 
60.6 (CHNH), 100.2 (CHarom), 105.8 (2 x CHarom), 127.0 (2 x CHarom), 128.9 (2 x CHarom), 137.9 
(Carom,quat), 139.0 (Carom,quat), 142.7 (Carom,quat), 160.7 (2 x Carom,quat), 167.1 (C=N). MS (ES, pos mode) 
m/z (%): 531/533 (100) [M + H]+. 
5.2.7 Synthesis of (R,R)-methyl-2-chloro-3-(3,5-dimethoxyphenyl)-3-[(4-
methylphenyl)sulfonamido]propanoate 326c and (R,R)-2-chloro-3-(3,5-
dimethoxyphenyl)-3-[(4-methylphenyl)sulfonamido]propanamide 331 
Method A. To a solution of (RS,R,R)-325c (0.38 g, 0.73 mmol) in MeOH (5 mL) was added a 3M 
solution of HCl in dioxane (30.0 equiv, 7.3 mL, 21.90 mmol) at room temperature. The mixture was 
allowed to stir for 18 hours at room temperature. Subsequently, the reaction mixture was poured into 
a saturated aqueous solution of NaHCO3 (10 mL) and extracted with EtOAc (3 x 10 mL). The 
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combined organic phases were dried (MgSO4), filtered and evaporated in vacuo. The crude mixture 
was purified by flash cromatography to yield pure ester (R,R)-anti-326c (23%) and amide (R,R)-anti-
331 (67%). 
Method B (only for (R,R)-331). To a solution of (RS,R,R)-325c (0.11 g, 0.21 mmol) in dioxane (3 
mL) was added a 3M solution of HCl in dioxane (15.0 equiv, 1.03 mL, 3.11 mmol) at room 
temperature. The mixture was allowed to stir for 1 h at room temperature. Subsequently, the reaction 




Rf = 0.34 (PE/Et2O 1/1). Pale yellow oil, yield 23% (method A). [α]D -18.3 
(c 0.3, CHCl3). IR (cm-1): νmax 1154, 1332, 1598, 1747, 3264. 1H NMR (400 
MHz, CDCl3): δ 2.34 (3H, s, CH3), 3.66 (6H, s, 2 x CH3), 3.70 (3H, s, 
OCH3), 4.54 (1H, d, J = 6.6 Hz, CHCl), 4.79 (1H, 2 x d, J = 7.15, 6.6 Hz, 
CHNH), 5.15 (1H, d, J = 7.15 Hz, CHNH), 6.20 (2H, s, 2 x CHarom), 6.26 (1H, s, CHarom), 7.19 (2H, 
d, J = 8.26 Hz, 2 x CHarom), 7.58 (2H, d, J = 8.26 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 
21.5 (CH3), 53.3 (OCH3), 55.3 (2 x OCH3), 58.9 (CHCl), 60.2 (CHNH), 100.6 (CHarom), 105.2 (2 x 
CHarom), 126.5 (CHarom), 127.2 (CHarom), 129.4 (CHarom), 129.8 (CHarom), 137.3 (Carom,quat), 137.9 
(Carom,quat), 143.5 (Carom,quat), 160.8 (2 x Carom,quat), 168.2 (C=N). MS (ES, pos mode) m/z (%): 428/430 
(100) [M + H]+. 
(R,R)-2-chloro-3-(3,5-dimethoxyphenyl)-3-[(4-methylphenyl)sulfonamido]propanamide 331 
Rf = 0.05 (PE/Et2O 1/2). White crystals, yield 67% (method A), yield 83% 
(method B). Mp 154.5-155.0 ºC. [α]D -21.8 (c 0.4, DMF). IR (cm-1): νmax 
1161, 1315, 1595, 1676, 3409, 3433. 1H NMR (400 MHz, DMSOd6): δ 2.24 
(3H, s, CH3), 3.60 (6H, s, 2 x OCH3), 4.33 (1H, d, J = 9.4 Hz, CHCl), 4.67 
(1H, t, J = 9.4 Hz, CHNH), 6.18 (1H, s, CHarom), 6.24 (2H, s, 2 x CHarom), 7.06 (2H, d, J = 8.3 Hz, 2 
x CHarom), 7.36 (2H, d, J = 8.3 Hz, 2 x CHarom), 7.46 (1H, br s, NH(H)), 7.69 (1H, br s, NH(H)), 8.28 
(1H, d, J = 9.4 Hz, CHNH). 13C NMR (100.6 MHz, DMSOd6): δ 21.4 (CH3), 55.6 (2 x OCH3), 60.3 
(CHCl), 60.4 (CHNH), 99.6 (CHarom), 106.6 (2 x CHarom), 127.0 (2 x CHarom), 129.3 (2 x CHarom), 
138.7 (Carom,quat), 139.4 (Carom,quat), 142.6 (Carom,quat), 160.4 (2 x Carom,quat), 168.6 (C=N). MS (ES, pos 




5.2.8 Synthesis of (E)-methyl N-sulfinyl-5-chloropentanimidates (RS)-26a-c 
The synthesis of (RS)-methyl N-tert-butanesulfinyl-5-chloropentanimidate (RS)-26a is representative. 
To a round-bottomed flask charged with (RS)-tert-butanesulfinamide (RS)-306 (13.17 g, 108.84 
mmol) were added 5-chloro-1,1,1-trimethoxypentane 338 (1.5 equiv, 32.00 g, 163.96 mmol) and p-
toluenesulfonic acid monohydrate (0.005 equiv, 0.10 g, 0.54 mmol). The reaction mixture was stirred 
for 20 h at 100 °C, and the volatile materials were removed in vacuo. The crude oil was purified via 
flash chromatography to yield pure (RS)-methyl N-tert-butanesulfinyl-5-chloropentanimidate (RS)-
26a. 
(E)-(RS)-Methyl N-tert-butanesulfinyl-5-chloropentanimidate (RS)-26a 
Rf = 0.15 (PE/Et2O 1/1). Yellow oil, yield 87%. [α]D -104.5 (c 0.4, CHCl3). 
IR (cm-1): νmax 1074, 1282, 1607, 2948. 1H NMR (400 MHz, CDCl3): δ 1.20 
(9H, s, tBu), 1.74-1.88 (4H, m, CH2CH2CH2Cl), 2.63-2.74 (2H, m, CH2C=N), 
3.51-3.60 (2H, m, CH2Cl), 3.75 (3H, s, OCH3). 13C NMR (100.6 MHz, CDCl3): δ 21.8 (3C, tBu), 
23.5 (CH2CH2CH2Cl), 31.7 (CH2CH2CH2Cl), 31.9 (CH2C=N), 44.2 (CH2Cl), 54.1 (OCH3), 55.8 (Cq, 
tBu), 176.0 (C=N). MS (ES, pos mode) m/z (%): 254/256 (100) [M + H]+. HRMS: calcd. for 
C10H21ClNO2S+ [MH]+ 254.0976; found: 254.0974. 
(E)-(R)-Methyl 5-chloro-N-[(2,4,6-triisopropylphenyl)sulfinyl]pentanimidate 26b 
Rf = 0.28 (PE/Et2O 1/1). Yellow oil, yield 80%. [α]D +10.2 (c 0.6, CHCl3). IR 
(cm-1): νmax 1078, 1308, 1458, 1600. 1H NMR (400 MHz, CDCl3): δ 1.26 (12H, 
2 x d, J = 6.8, 5.8 Hz, 2 x CH(CH3)2), 1.31 (6H, d, J = 6.8 Hz, CH(CH3)2), 
1.79-1.86 (4H, m, CH2CH2CH2Cl), 2.66-2.86 (2H, m, CH2C=N), 2.89 (1H, 
sep, J = 6.8 Hz, CH(CH3)2), 3.51-3.58 (2H, m, CH2Cl), 3.76 (3H, s, OCH3), 
4.07-4.20 (2H, m, 2 x CH(CH3)2), 7.09 (2H, s, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 23.4 
(CH2CH2Cl), 23.8 (CH(CH3)2), 24.5 (2 x CH(CH3)2), 28.6 (2 x CH(CH3)2), 31.7 (CH2CH2CH2Cl), 
32.0 (CH2C=N), 34.5 (CH(CH3)2), 44.4 (CH2Cl), 54.5 (OCH3), 122.9 (2 x CHarom), 138.4 (Carom,quat), 
143.9 (Carom,quat) 152.4 (2 x Carom,quat), 174.1 (C=N). MS (ES, pos mode) m/z: 400/402 (100) [M + 
H]+. 
(E)-(S)-Methyl 5-chloro-N-[(2,4,6-triisopropylphenyl)sulfinyl]pentanimidate 26c 
Rf = 0.28 (PE/Et2O 1/1). Yellow oil, yield 76%. [α]D -12.4 (c 0.5, CHCl3). IR 
(cm-1): νmax 1078, 1308, 1458, 1600. 1H NMR (400 MHz, CDCl3): δ 1.26 (12H, 
2 x d, J = 6.8, 5.8 Hz, 2 x CH(CH3)2), 1.31 (6H, d, J = 6.8 Hz, CH(CH3)2), 
1.79-1.86 (4H, m, CH2CH2CH2Cl), 2.66-2.86 (2H, m, CH2C=N), 2.89 (1H, 
sep, J = 6.9 Hz, CH(CH3)2), 3.51-3.58 (2H, m, CH2Cl), 3.76 (3H, s, OCH3), 
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4.07-4.20 (2H, m, 2 x CH(CH3)2), 7.09 (2H, s, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 23.4 
(CH2CH2Cl), 23.8 (CH(CH3)2), 24.5 (2 x CH(CH3)2), 28.6 (2 x CH(CH3)2), 31.7 (CH2CH2CH2Cl), 
32.0 (CH2C=N), 34.5 (CH(CH3)2), 44.4 (CH2Cl), 54.5 (OCH3), 122.9 (2 x CHarom), 138.4 (Carom,quat), 
143.9 (Carom,quat), 152.4 (2 x Carom,quat), 174.1 (C=N). MS (ES, pos mode) m/z: 400/402 (100) [M + 
H]+. 
5.2.9 Synthesis of (E)-(SS)-methyl 5-chloro-N-(p-tolylsulfinyl)pentanimidate 26d 
To a solution of 5-chloro-1,1,1-trimethoxypentane 338 (0.50 g, 2.55 mmol) in dry CH2Cl2 (50 mL) 
was added (SS)-p-tolylsulfinamide (RS)-216 (1.0 equiv, 0.16 g, 1.03 mmol), followed by addition of 
MgSO4 (2.5 equiv, 0.31 g, 2.55 mmol). The reaction mixture was stirred for 3 h at room temperature. 
Subsequently, the reaction mixture was filtered through a Celite® pad and the filter cake was washed 
with a small amount of EtOAc. The solvent was evaporated and the crude mixture was purified by 
column chromatography, affording pure pentanimidate 26d. 
(E)-(SS)-Methyl 5-chloro-N-(p-tolylsulfinyl)pentanimidate 26d 
Rf = 0.19 (PE/Et2O 6/4). Yellow oil, yield 61%. [α]D +6.4 (c 0.6, CHCl3). IR 
(cm-1): νmax 1076, 1286, 1610. 1H NMR (400 MHz, CDCl3): δ 1.80-1.89 (4H, 
m, CH2CH2CH2Cl), 2.42 (3H, s, pCH3), 2.76-2.82 (2H, m, CH2C=N), 3.53-
3.58 (2H, m, CH2Cl), 3.78 (3H, s, OCH3), 7.31 (2H, d, J = 8.3 Hz, 2 x CHarom), 
7.65 (2H, J = 8.3 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.5 
(pCH3), 23.7 (CH2CH2Cl), 29.7 (CH2CH2CH2Cl), 31.2 (CH2C=N), 44.3 (CH2Cl), 54.6 (OCH3), 125.0 
(2 x CHarom), 129.7 (2 x CHarom), 141.8 (Cquat,arom), 144.4 (Carom,quat), 176.0 (C=N). MS (ES, pos mode) 
m/z: 288/290 (100) [M + H]+. 
5.2.10 Synthesis of δ-chloro-β-amino-N-sulfinyl imidates anti-339 and anti-340 
The synthesis of (RS,S,R)-δ-chloro-β-amino-(sulfonylamino)-N-sulfinyl imidates (RS,S,R)-339a is 
representative. A solution of (RS)-methyl N-tert-butanesulfinyl-5-chloropentanimidate (RS)-26a (1.8 
equiv, 2.00 g, 7.91 mmol) in THF (30 mL) was cooled to -78 °C. A 1M solution of LiHMDS (1.8 
equiv, 7.91 mL, 7.91 mmol) in THF was slowly added, and the resulting solution was stirred for 45 
minutes at -78 °C. After deprotonation, a solution of N-benzylidene-4-methylbenzenesulfonamide 
27a (1.0 equiv, 1.14 g, 4.39 mmol) in THF (10 mL) was added dropwise, and the reaction mixture 
was stirred at -78 ºC for 1 h. To the reaction mixture was added a saturated solution NH4Cl (4 mL), 
followed by a saturated solution of NaHCO3 (20 mL). The aqueous phase was extracted with Et2O 
(3 x 20 mL). The combined organic phases were dried (MgSO4), filtered, and evaporated in vacuo. 





butanesulfinylpentanimidate (RS,S,R)-anti-339a. In the synthesis of (RS,R,S)-methyl 5-chloro-2-[(4-
methoxyphenyl)(p-toluenesulfonylamino)methyl]-N-tert-butanesulfinylpentanimidate (RS,R,S)-anti-
340b, purification of the reaction mixture was performed via recrystallization from diethyl ether. 
(RS,S,R)-Methyl 5-chloro-2-[(phenyl)(p-toluenesulfonylamino)methyl]-N-tert-butanesulfinyl-
pentanimidate (RS,S,R)-339a 
Rf = 0.09 (PE/Et2O 1/1). White crystals, yield 58%. Mp 78.5-80.0 °C. [α]D -
89.4 (c 0.4, CHCl3). IR (cm-1): νmax 1160, 1330, 1455, 1633, 2947. 1H NMR 
(400 MHz, CDCl3): δ 1.14 (9H, s, tBu), 1.20-1.30 (1H, m, CH2CH(H)CH2Cl), 
1.54-1.77 (3H, m, CH(H)CH(H)CH2Cl), 2.30 (3H, s, pCH3), 3.31-3.47 (2H, m, 
CH2Cl), 3.74 (3H, s. OCH3), 3.94 (1H, ddd, J = 13.7, 9.3, 4.2 Hz, CHCH2), 4.48 (1H, d x d, J = 9.3, 
9.8 Hz, CHNH), 5.67 (1H, d, J = 9.8 Hz, CHNH), 6.93-6.98 (2H, m, 2 x CHarom), 7.03 (2H, d, J = 
8.3 Hz, 2 x CHarom), 7.07-7.12 (3H, m, 3 x CHarom), 7.47 (2H, d, J = 8.3 Hz, 2 x CHarom). 13C NMR 
(100.6 MHz, CDCl3): δ 21.4 (pCH3), 22.0 (3C, tBu), 27.0 (CH2CH2Cl), 30.0 (CH2CH), 44.4 (CH2Cl), 
47.7 (CH2CH), 54.4 (OCH3), 56.4 (Cq, tBu), 60.0 (CHNH), 126.4 (2 x CHarom), 127.0 (2 x CHarom), 
127.3 (CHarom), 128.6 (2 x CHarom), 129.2 (2 x CHarom), 137.5 (Carom,quat), 138.6 (Carom,quat), 143.0 
(Carom,quat), 172.5 (C=N). MS (ES, pos mode) m/z (%): 513/515 (100) [M + H]+. HRMS: calcd. for 
C24H34ClN2O4S2+ [MH]+ 513.1643; found: 513.1655. 
(RS,S,R)-Methyl 5-chloro-2-[(benzenesulfonylamino)(p-tolyl)methyl]-N-tert-butanesulfinyl-
pentanimidate (RS,S,R)-339c 
Rf = 0.07 (PE/Et2O 1/1). White crystals, yield 45%. Mp 71.0-72.0 ºC. [α]D -
74.8 (c 0.4, CHCl3). IR (cm-1): νmax 1039, 1163, 1242, 1326, 1447, 1633, 
2958. 1H NMR (400 MHz, CDCl3): δ 0.79-0.93 (1H, m, 
CH(H)CH(H)CH2Cl), 1.17 (9H, s, tBu), 1.20-1.30 (1H, m, 
CH(H)CH(H)CH2Cl), 1.63-1.76 (2H, m, CH(H)CH(H)CH2Cl), 2.23 (3H, s, pCH3), 3.30-3.45 (2H, 
m, CH2Cl), 3.74 (3H, s, OCH3), 3.89-4.01 (1H, m, CHCH2), 4.43 (1H, d x d, J = 9.6, 9.6 Hz, CHNH), 
5.66 (1H, d, J = 9.6 Hz, CHNH), 6.83 (2H, d, J = 8.0 Hz, 2 x CHarom), 6.91 (2H, d, J = 8.0 Hz, 2 x 
CHarom), 7.21-7.32 (1H, m, CHarom), 7.36-7.44 (1H, m, CHarom), 7.50-7.65 (3H, m, 3 x CHarom). 13C 
NMR (100.6 MHz, CDCl3): δ 21.1 (pCH3), 22.2 (3C, tBu), 27.0 (CH2CH2Cl), 30.1 (CH2CH), 44.5 
(CH2Cl), 47.7 (CH2CH), 54.5 (OCH3), 56.5 (Cq, tBu), 60.1 (CHNH), 126.2 (2 x CHarom), 127.0 (2 x 
CHarom), 128.6 (2 x CHarom), 129.3 (2 x CHarom), 132.1 (Carom,quat), 135.4 (Carom,quat), 137.6 (Carom,quat), 
140.5 (Carom,quat), 172.5 (C=N). MS (ES, pos mode) m/z (%): 513/515 (100) [M + H]+. HRMS: calcd. 
for C24H34ClN2O4S2+ [MH]+ 513.1643; found: 513.1638. 
 





Rf = 0.16 (PE/Et2O 1/1). White crystals, yield 10%. Mp 136.5-
138.0 ºC. [α]D +29.3 (c 0.3, CHCl3). IR (cm-1): νmax 1035, 1072, 
1157, 1266, 1510, 1628, 2961. 1H NMR (400 MHz, CDCl3): δ 
1.22-1.27 (18H, m, 3 x CH(CH3)2), 1.63-1.82 (4H, 
CH2CH2CH2Cl), 2.32 (3H, s, pCH3), 2.88 (1H, sep, CH(CH3)2), 
3.36-3.50 (3H, m, 2 x CH(CH3)2 and CHCH2), 3.63 (3H, s, OCH3), 3.74 (3H, s, OCH3), 3.97-4.07 
(2H, m, CH2Cl), 4.50 (1H, dd, J = 9.5, 8.3 Hz, CHNH), 5.42 (1H, d, J = 9.5 Hz, CHNH), 6.66 (2H, 
d, J = 8.8 Hz, 2 x CHarom), 6.93 (2H, d, J = 8.6 Hz, 2 x CHarom), 7.04-7.08 (4H, m, 4 x CHarom), 7.47 
(2H, d, J = 8.6 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.4 (pCH3), 21.5 (CH2CH2Cl), 
23.8 (2C, CH(CH3)2), 24.1 (2C, CH(CH3)2), 24.4 (2C, CH(CH3)2), 27.4 (CHCH2), 29.7 (2 x 
CH(CH3)2), 30.2 (CHCH2), 34.4 (CH(CH3)2), 44.4 (CH2Cl), 48.2 (CHNH), 54.6 (OCH3), 55.2 
(OCH3), 113.9 (2 x CHarom), 126.4 (Carom,quat), 127.0 (2 x CHarom), 127.5 (2 x CHarom), 129.2 (2 x 
CHarom), 129.7 (2 x CHarom), 130.8 (Carom,quat), 137.6 (Carom,quat), 138.3 (Carom,quat), 142.9 (Carom,quat), 




Rf = 0.39 (PE/Et2O 1/1). Viscous colorless oil, yield 24%. [α]D -124.4 (c 0.3, 
CHCl3). IR (cm-1): νmax 1038, 1159, 1332, 1455, 1608, 2956. 1H NMR (400 
MHz, CDCl3): δ 1.04-1.15 (1H, m, CH2CH(H)CH2Cl), 1.34 (9H, s, tBu), 1.46-
1.76 (3H, m, CH(H)CH(H)CH2Cl), 2.25 (3H, s, pCH3), 3.25-3.40 (2H, m, 
CH2Cl), 3.54 (1H, td, J = 10.8, 3.7 Hz, CHCH2), 3.78 (3H, s, OCH3), 4.34 (1H, d x d, J = 10.8, 8.8 
Hz, CHNH), 6.91 (2H, d, J = 8.3 Hz, 2 x CHarom), 7.07-7.11 (5H, m, 5 x CHarom), 7.15 (1H, d, J = 8.8 
Hz, CHNH), 7.30 (2H, d, J = 8.3 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.3 (pCH3), 
22.0 (3C, tBu), 26.7 (CH2CH2Cl), 30.4 (CH2CH), 43.9 (CH2Cl), 50.2 (CH2CH), 54.8 (OCH3), 57.3 
(Cq, tBu), 59.4 (CHNH), 126.7 (2 x CHarom), 127.4 (2 x CHarom), 127.6 (Cquat,arom), 128.4 (2 x CHarom), 
128.8 (2 x CHarom), 138.6 (Carom,quat), 139.0 (Carom,quat), 141.9 (Carom,quat), 174.0 (C=N). MS (ES, pos 









Rf = 0.27 (PE/Et2O 1/1). White crystals, yield 69%. Mp 153.0-154.0  C. 
[α]D -151.2 (c 0.2, CHCl3). IR (cm-1): νmax 1027, 1158, 1243, 1329, 1444, 
1599, 2945, 3087. 1H NMR (400 MHz, CDCl3): δ 1.06-1.20 (1H, m, 
CH2CH(H)CH2Cl), 1.33 (9H, s, tBu), 1.45-1.56 (2H, m, 
CH(H)CH(H)CH2Cl), 1.60-1.77 (1H, m, CH(H)CH2CH2Cl), 2.27 (3H, s, pCH3), 3.25-3.42 (2H, m, 
CH2Cl), 3.50 (1H, td, J = 10.7, 3.6 Hz, CHCH2), 3.73 (3H, s, OCH3), 3.77 (3H, s, OCH3), 4.32 (1H, 
d x d, J = 10.7, 8.8 Hz, CHNH), 6.59 (2H, d, J = 8.6 Hz, 2 x CHarom), 6.94 (2H, d, J = 8.1 Hz, 2 x 
CHarom), 6.99 (2H, d, J = 8.6 Hz, 2 x CHarom), 7.08 (1H, d, J = 8.8 Hz, CHNH), 7.30 (2H, d, J = 8.1 
Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.3 (pCH3), 22.0 (3C, tBu), 26.8 (CH2CH2Cl), 
30.4 (CH2CH), 43.9 (CH2Cl), 50.3 (CH2CH), 54.8 (OCH3), 55.2 (OCH3), 57.3 (Cq, tBu), 59.0 
(CHNH), 113.7 (2 x CHarom), 126.7 (2 x CHarom), 128.5 (2 x CHarom), 128.8 (2 x CHarom), 131.2 
(Carom,quat), 138.8 (Carom,quat), 141.8 (Carom,quat), 159.1 (Carom,quat), 174.1 (C=N). MS (ES, pos mode) m/z 




Rf = 0.40 (PE/Et2O 1/1). White crystals, yield 38%. Mp 138.0-139.0 ºC. [α]D 
-128.4 (c 0.4, CHCl3). IR (cm-1): νmax 1032, 1158, 1277, 1330, 1446, 1599, 
2865, 3079. 1H NMR (400 MHz, CDCl3): δ 1.06-1.18 (1H, m, 
CH2CH(H)CH2Cl), 1.32 (9H, s, tBu), 1.46-1.60 (2H, m, 
CH(H)CH(H)CH2Cl), 1.67-1.78 (1H, m, CH(H)CH2CH2Cl), 2.22 (3H, s, pCH3), 3.25-3.43 (2H, m, 
CH2Cl), 3.52 (1H, td, J = 10.8, 3.7 Hz, CHCH2), 3.76 (3H, s, OCH3), 4.34 (1H, d x d, J = 10.8, 8.6 
Hz, CHNH), 6.86 (2H, d, J = 8.0 Hz, 2 x CHarom), 6.96 (2H, d, J = 8.0 Hz, 2 x CHarom), 7.13 (2H, m, 
2 x CHarom), 7.20 (1H, d, J = 8.6 Hz, CHNH), 7.23-7.31 (1H, m, CHarom), 7.39-7.45 (2H, m, 2 x 
CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.1 (pCH3), 22.1 (3C, tBu), 26.9 (CH2CH2Cl), 30.5 
(CH2CH), 44.0 (CH2Cl), 50.2 (CH2CH), 54.9 (OCH3), 57.4 (Cq, tBu), 59.4 (CHNH), 126.7 (2 x 
CHarom), 127.3 (2 x CHarom), 128.2 (2 x CHarom), 129.1 (2 x CHarom), 131.3 (Carom,quat), 135.9 (CHarom), 
137.5 (Carom,quat), 141.7 (Carom,quat), 174.3 (C=N). Crystal data: C24H33ClN2O4S2, M = 513.09, 
orthorhombic, space group P212121 (No. 19), a = 8.9812(2) Å, b = 10.7105(2) Å, c = 26.6055(5) Å, 
V = 2559.30(9) Å3, Z = 4, T = 100 K, calc = 1.332 g cm-3, μ(Cu-Kα) = 3.114 mm-1, F(000) = 1088, 
21184 reflections measured, 5192 unique (Rint = 0.0553) which were used in all calculations. The 
final R1 was 0.0309 (I >2 (I)) and wR2 was 0.0790 (all data). CCDC: 1400317. MS (ES, pos mode) 
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Rf = 0.16 (PE/Et2O 1/1). Colorless viscous oil, yield 70%. [α]D 
+61.8 (c 0.2, CHCl3). IR (cm-1): νmax 752, 1030, 1160, 1587, 3106. 
1H NMR (400 MHz, CDCl3): δ 1.28 (12H, d, J = 6.9 Hz, 2 x 
CH(CH3)2), 1.37 (6H, d, J = 6.9 Hz, CH(CH3)2), 1.52-1.69 (2H, m, 
CHCH(H)CH(H)), 1.73-1.86 (2H, m, CHCH(H)CH(H)), 2.27 (3H, 
s, CH3), 2.93 (1H, sep, J = 6.9 Hz, CH(CH3)2), 3.31-3.45 (2H, m, 2 x CH(CH3)2), 3.58 (1H, td, J = 
10.7, 3.4 Hz, CHCH2), 3.74 (3H, s, OCH3), 3.82 (3H, s, OCH3), 3.95-4.17 (2H, m, CH2Cl), 4.46 (1H, 
2 x d, J = 10.7, 9.5 Hz, CHNH), 6.62 (2H, d, J = 8.7 Hz, 2 x CHarom), 6.93 (2H, d, J = 8.1 Hz, 2 x 
CHarom), 7.05 (2H, d, J = 8.7 Hz, 2 x CHarom), 7.10 (1H, d, J = 9.5 Hz, NH), 7.13 (2H, s, 2 x CHarom), 
7.28 (2H, d, J = 8.1 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.3 (CH3), 23.8 (4C, 2 x 
CH(CH3)2), 24.9 (2C, CH(CH3)2), 26.9 (CH2CH2Cl), 28.9 (CHCH2), 30.5 (CHCH2), 34.5 
(CH(CH3)2), 43.8 (2 x CH(CH3)2), 49.8 (CH2Cl), 55.2 (2 x OCH3), 59.6 (CHNH), 113.2 (2 x CHarom), 
126.6 (2 x CHarom), 128.6 (2 x CHarom), 128.8 (4 x CHarom), 131.0 (Carom,quat), 136.3 (Carom,quat), 138.9 
(Carom,quat), 141.8 (Carom,quat), 152.9 (2 x Carom,quat), 159.2 (2 x Carom,quat), 176.0 (C=N). MS (ES, pos 
mode) m/z (%): 689/691 (100) [M + H]+. 
5.2.11 Synthesis of methyl 5-chloro-2-[(phenyl)(p-toluenesulfonylamino)methyl]-N-
tert-butanesulfonylpentanimidates 342 and 343 
The synthesis of (S,R)-methyl 5-chloro-2-[(phenyl)(p-toluenesulfonylamino)methyl]-N-tert-
butanesulfonylpentanimidate (S,R)-342 is representative. To a solution of (RS,S,R)-methyl 5-chloro-
2-[(phenyl)(p-toluenesulfonylamino)methyl]-N-tert-butanesulfinylpentanimidate (RS,S,R)-339a 
(0.07 g, 0.14 mmol) in CH2Cl2 (2.5 mL) was added mCPBA (1.5 equiv, 0.04 g, 0.21 mmol) in one 
portion at room temperature and the reaction mixture was stirred for 15 minutes. Subsequently, 40% 
aqueous sodium bisulfite (1.5 mL) was added. After stirring the mixture (5 minutes), the aqueous 
layer was separated and extracted with CH2Cl2 (3 x 4 mL). The organic phase was washed with 
saturated solution NaHCO3 (2 x 5 mL), then with saturated aqueous solution NaCl (5 mL). The 
combined organic phases were dried (MgSO4), filtered and evaporated in vacuo. The crude product 








Rf = 0.29 (PE/Et2O 1/1). Colorless oil, yield 75%. [α]D -8.7 (c 0.6, CHCl3). IR 
(cm-1): νmax 694, 1114, 1159, 1276, 1612, 3274. 1H NMR (400 MHz, CDCl3): 
δ 1.12-1.25 (1H, m, CH2CH(H)CH2Cl), 1.53 (9H, s, tBu), 1.58-1.72 (2H, m, 
CH(H)CH(H)CH2Cl), 1.73-1.86 (1H, m, CH(H)CH2CH2Cl), 2.27 (3H, s, 
pCH3), 3.27-3.38 (1H, m, CH(H)Cl), 3.39-3.50 (1H, m, CH(H)Cl), 3.80 (1H, td, J = 11.0, 3.6 Hz, 
CHCH2), 3.87 (3H, s, OCH3), 4.41 (1H, t, J = 10.3 Hz, CHNH), 6.38 (1H, d, J = 9.8 Hz, CHNH), 
6.94 (2H, d, J = 8.1 Hz, 2 x CHarom), 7.00-7.17 (5H, m, 5 x CHarom), 7.31 (2H, d, J = 8.1 Hz, 2 x 
CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.3 (pCH3), 24.0 (3C, tBu), 26.7 (CH2CH2Cl), 30.0 
(CH2CH), 44.1 (CH2Cl), 51.2 (CH2CH), 55.8 (OCH3), 59.3 (Cq, tBu), 60.7 (CHNH), 126.7 (2 x 
CHarom), 127.1 (2 x CHarom), 127.9 (CHarom), 128.6 (2 x CHarom), 129.0 (2 x CHarom), 138.1 (Carom,quat), 




Rf = 0.29 (PE/Et2O 1/1). Colorless oil, yield 71%. [α]D +5.7 (c 0.7, CHCl3). IR 
(cm-1): νmax 694, 1114, 1159, 1276, 1612, 3274. 1H NMR (400 MHz, CDCl3): 
δ 1.12-1.25 (1H, m, CH2CH(H)CH2Cl), 1.53 (9H, s, tBu), 1.58-1.72 (2H, m, 
CH(H)CH(H)CH2Cl), 1.73-1.86 (1H, m, CH(H)CH2CH2Cl), 2.27 (3H, s, 
pCH3), 3.27-3.38 (1H, m, CH(H)Cl), 3.39-3.50 (1H, m, CH(H)Cl), 3.80 (1H, td, J = 11.0, 3.6 Hz, 
CHCH2), 3.87 (3H, s, OCH3), 4.41 (1H, t, J = 10.3 Hz, CHNH), 6.38 (1H, d, J = 9.8 Hz, CHNH), 
6.94 (2H, d, J = 8.1 Hz, 2 x CHarom), 7.00-7.17 (5H, m, 5 x CHarom), 7.31 (2H, d, J = 8.1 Hz, 2 x 
CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.3 (pCH3), 24.0 (3C, tBu), 26.7 (CH2CH2Cl), 30.0 
(CH2CH), 44.1 (CH2Cl), 51.2 (CH2CH), 55.8 (OCH3), 59.3 (Cq, tBu), 60.7 (CHNH), 126.7 (2 x 
CHarom), 127.1 (2 x CHarom), 127.9 (CHarom), 128.6 (2 x CHarom), 129.0 (2 x CHarom), 138.1 (Carom,quat), 
138.4 (Carom,quat), 142.5 (Carom,quat), 176.8 (C=N). MS (ES, pos mode) m/z (%): 546/548 (100) [M + 
NH4]+. 
5.2.12 Synthesis of cis-methyl 2-aryl-1-sulfonylpiperidine-3-N-(tert-butylsulfinyl)-
carbimidates cis-344 and cis-345 
The synthesis of (RS,2R,3S)-methyl N-tert-butanesulfinyl-2-phenyl-1-tosylpiperidine-3-carbimidate 
(RS,2R,3S)-344a is representative. (RS,S,R)-δ-Chloro-β-amino-N-sulfinylimidates (RS,S,R)-339a 
(1.64 g, 3.20 mmol) was dissolved in acetonitrile (50 mL), and K2CO3 (3.0 equiv, 1.33 g, 9.61 mmol) 
was added in one portion. The reaction mixture was stirred for 20 hours at reflux and subsequently 
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evaporated in vacuo. The reaction mixture was dissolved in EtOAc (30 mL), washed with brine (30 
mL), dried (MgSO4), filtered, and evaporated in vacuo. Purification via flash chromatography 




Rf = 0.56 (PE/ethyl acetate 1/3). White crystals, yield 92%. Mp 132.0-134.0  C. 
[α]D -182.8 (c 0.2, CHCl3). IR (cm-1): νmax 1076, 1160, 1279, 1617, 2930. 1H NMR 
(400 MHz, CDCl3): δ 1.23 (9H, s, tBu), 1.40-1.56 (1H, m, CH(H)CH2CH2N), 1.70-
1.84 (2H, m, CH(H)CH(H)CH2N), 2.01-2.14 (1H, m, CH2CH(H)CH2N), 2.34 (3H, 
s, pCH3), 3.19-3.30 (1H, m, CH(H)N), 3.26 (3H, s, OCH3), 3.75-3.89 (2H, m, 
CH(H)N and CHC=N), 5.59 (1H, d, J = 6.0 Hz, CHPh), 7.07-7.26 (7H, m, 7 x CHarom), 7.49 (2H, d, 
J = 8.3 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 20.8 (pCH3), 21.4 (CH2CH2N), 21.9 (3H, 
tBu), 23.5 (CH2CH2CH2N), 41.8 (CH2N), 44.2 (CHC=N), 53.8 (OCH3), 56.0 (Cq, tBu), 56.9 (CHPh), 
127.1 (2 x CHarom), 127.7 (CHarom), 128.0 (2 x CHarom), 128.5 (2 x CHarom), 129.4 (2 x CHarom), 136.9 
(Carom,quat), 137.8 (Carom,quat), 142.9 (Carom,quat), 174.0 (C=N). Crystal data: C24H32N2O4S2, M = 476.64, 
tetragonal, space group P43212 (No. 96), a = b = 10.85357(10) Å, c = 42.3747(8) Å, V = 4991.74(13) 
Å3, Z = 8, T = 100 K, calc = 1.268 g cm-3, μ(Cu-Kα) = 2.193 mm-1, F(000) = 2032, 23695 reflections 
measured, 5041 unique (Rint = 0.0795) which were used in all calculations. The final R1 was 0.0425 
(I >2 (I)) and wR2 was 0.1001 (all data). CCDC: 1046634. MS (ES, pos mode) m/z (%): 477 (100) 




Rf = 0.23 (PE/Et2O 1/1). Viscous colorless oil, yield 87%. [α]D -127.9 (c 0.2, 
CHCl3). IR (cm-1): νmax 1041, 1161, 1282, 1338, 1446, 1596, 2924. 1H NMR 
(400 MHz, CDCl3): δ 1.26 (9H, s, tBu), 1.45-1.51 (1H, m, CH2CH(H)CH2N), 
1.68-1.86 (2H, m, CH(H)CH(H)CH2N), 1.98-2.18 (1H, m, CH(H)CH2CH2N), 
2.28 (3H, s, pCH3), 3.16-3.28 (1H, m, CH(H)N), 3.29 (3H, s, OCH3), 3.70-3.89 
(2H, m, CH(H)N and CHC=N), 5.56 (1H, d, J = 6.05 Hz, CHPhMe), 6.97 (2H, d, J = 8.1 Hz, 2 x 
CHarom), 7.10 (2H, d, J = 8.1 Hz, 2 x CHarom), 7.30-7.36 (2H, m, 2 x CHarom), 7.42-7.48 (1H, m, 
CHarom), 7.60-7.65 (2H, m, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 20.7 (pCH3), 21.1 
(CH2CH2N), 22.0 (3C, tBu), 23.6 (CH2CH2CH2N), 41.8 (CH2N), 44.3 (CHC=N), 53.9 (OCH3), 56.1 




132.2 (2 x CHarom), 134.7 (Carom,quat), 137.5 (Carom,quat), 139.9 (Carom,quat), 175.0 (C=N). MS (ES, pos 




Rf = 0.63 (PE/EtOAc 1/3). White crystals, yield 87%. Mp 113.0-114.0 ºC. [α]D 
+104.2 (c 0.2, CHCl3). IR (cm-1): νmax 1077, 1160, 1292, 1340, 1593, 2972. 1H NMR 
(400 MHz, CDCl3): δ 1.22 (9H, s, tBu), 1.52 (1H, ddddd, J = 13.5, 13.5, 9.1, 5.1, 4.0 
Hz, CH2CH(H)CH2N), 1.65-1.73 (1H, m, CH(H)CH2CH2N), 1.80-1.90 (1H, m, 
CH2CH(H)CH2N), 2.07 (1H, dddd, J = 13.5, 13.5, 13.5, 3.6 Hz, CH(H)CH2CH2N), 
2.33 (3H, s, pCH3), 3.20 (3H, s, OCH3), 3.34 (1H, td, J = 13.3, 3.6 Hz, CH(H)N), 3.52 (1H, ddd, J = 
12.9, 6.2, 3.6 Hz, CHC=N), 3.99 (1H, d x d, J = 13.3, 4.0 Hz, CH(H)N), 5.81 (1H, d, J = 6.2 Hz, 
CHPh), 7.06 (2H, d, J = 8.3 Hz, 2 x CHarom), 7.09-7.24 (5H, m, 5 x CHarom), 7.51 (2H, d, J = 8.3 Hz, 
2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.0 (pCH3), 21.4 (CH2CH2N), 21.9 (3C, tBu), 23.9 
(CH2CH2CH2N), 42.2 (CH2N), 45.8 (CHC=N), 53.7 (OCH3), 56.2 (Cq, tBu), 57.7 (CHPh), 127.3 (3 
x CHarom), 127.8 (2 x CHarom), 128.7 (2 x CHarom), 129.1 (2 x CHarom), 137.1 (Carom,quat), 138.2 
(Carom,quat), 142.5 (Carom,quat), 174.2 (C=N). Crystal data: C24H32N2O4S2, M = 476.64, tetragonal, space 
group P41212 (No. 92), a = b = 10.87406(11) Å, c = 41.9807(7) Å, V = 4964.02(13) Å3, Z = 8, T = 
100 K, calc = 1.276 g cm-3, μ(Cu-Kα) = 2.205 mm-1, F(000) = 2032, 96397 reflections measured, 
5145 unique (Rint = 0.1148) which were used in all calculations. The final R1 was 0.0435 (I >2 (I)) 
and wR2 was 0.0903 (all data). CCDC: 1046635. MS (ES, pos mode) m/z (%): 477 (100) [M + H]+. 
HRMS: calcd. for C24H33N2O4S2+ [MH]+ 477.1876; found: 477.1870. 
(RS,2S,3R)-cis-Methyl 2-(4-methoxyphenyl)-1-(p-toluenesulfonyl)piperidine-3-N-tert-butyl-
sulfinylcarbimidate (RS,2S,3R)-345b 
Rf = 0.16 (PE/Et2O 1/1). White crystals, yield 97%. Mp 136.5-138.0  C. [α]D 
+127.5 (c 0.4, CHCl3). IR (cm-1): νmax 1035, 1072, 1157, 1266, 1510, 1628, 
2961. 1H NMR (400 MHz, CDCl3): δ 1.21 (9H, s, tBu), 1.43-1.60 (1H, m, 
CH2CH(H)CH2N), 1.63-1.74 (1H, m, CH(H)CH2CH2N), 1.78-1.88 (1H, m, 
CH2CH(H)CH2N), 2.09 (1H, dddd, J = 13.5, 13.5, 13.5, 3.4 Hz, 
CH(H)CH2CH2N), 2.34 (3H, s, pCH3), 3.25 (3H, s, OCH3), 3.26-3.34 (1H, m, CH(H)N), 3.44-3.56 
(1H, m, CHC=N), 3.75 (3H, s, OCH3), 3.91-4.01 (1H, m, CH(H)N), 5.76 (1H, d, J = 6.1 Hz, 
CHPhOMe), 6.65 (2H, d, J = 8.6 Hz, 2 x CHarom), 7.08 (2H, d, J = 8.1 Hz, 2 x CHarom), 7.15 (2H, d, 
J = 8.6 Hz, 2 x CHarom), 7.51 (2H, d, J = 8.1 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.1 
(pCH3), 21.4 (CH2CH2N), 21.9 (3C, tBu), 23.9 (CH2CH2CH2N), 41.9 (CH2N), 45.7 (CHC=N), 53.9 
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(OCH3), 55.2 (OCH3), 56.1 (Cq, tBu), 57.2 (CHPh), 113.1 (2 x CHarom), 127.3 (2 x CHarom), 129.1 (2 
x CHarom), 130.0 (2 x CHarom), 130.4 (Carom,quat), 137.2 (Carom,quat), 142.4 (Carom,quat), 158.8 (Carom,quat), 
174.3 (C=N). Crystal data: C25H34N2O5S2, M = 506.66, orthorhombic, space group P212121 (No. 19), 
a = 10.9791(2) Å, b = 15.0941(3) Å, c = 15.4399(3) Å, V = 2558.70(9) Å3, Z = 4, T = 100 K, calc = 
1.315 g cm-3, μ(Cu-Kα) = 2.200 mm-1, F(000) = 1080, 24610 reflections measured, 5216 unique (Rint 
= 0.0584) which were used in all calculations. The final R1 was 0.0324 (I >2 (I)) and wR2 was 
0.0759 (all data). CCDC: 1046636. MS (ES, pos mode) m/z (%): 507 (100) [M + H]+. HRMS: calcd. 
for C25H35N2O5S2+ [MH]+507.1982; found: 507.1979. 
(RS,2S,3R)-cis-Methyl 1-(benzenesulfonyl)-2-p-tolylpiperidine-3-N-tert-
butylsulfinylcarbimidate (RS,2S,3R)-345c 
Rf = 0.16 (PE/Et2O 1/1). Viscous colorless oil, yield 89%. [α]D +105.1 (c 0.2, 
CHCl3). IR (cm-1): νmax 949, 1042, 1161, 1283, 1340, 1446, 1594, 2947. 1H 
NMR (400 MHz, CDCl3): δ 1.22 (9H, s, tBu), 1.45-1.60 (1H, m, 
CH2CH(H)CH2N), 1.64-1.74 (1H, m, CH(H)CH2CH2N), 1.81-1.90 (1H, m, 
CH2CH(H)CH2N), 2.01-2.14 (1H, m, CH(H)CH2CH2N), 2.25 (3H, s, pCH3), 
3.23 (3H, s, OCH3), 3.33 (1H, td, J = 13.2, 3.9 Hz, CH(H)N), 3.50 (1H, ddd, J = 12.8, 6.2, 3.4 Hz, 
CHC=N), 3.93-4.04 (1H, m, CH(H)N), 5.79 (1H, d, J = 6.2 Hz, CHPhMe), 6.91 (2H, d, J = 8.1 Hz, 
2 x CHarom), 7.09 (2H, d, J = 8.1 Hz, 2 x CHarom), 7.20-7.31 (2H, m, 2 x CHarom), 7.38-7.43 (1H, m, 
CHarom), 7.60-7.66 (2H, m, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 20.9 (pCH3), 21.0 
(CH2CH2N), 22.0 (3C, tBu), 24.0 (CH2CH2CH2N), 42.2 (CH2N), 45.8 (CHC=N), 53.8 (OCH3), 56.2 
(Cq, tBu), 57.6 (CHPh), 127.3 (2 x CHarom), 128.4 (2 x CHarom), 128.5 (2 x CHarom), 128.6 (2 x CHarom), 
131.8 (CHarom), 135.0 (Carom,quat), 137.0 (Carom,quat), 140.1 (Carom,quat), 174.2 (C=N). MS (ES, pos mode) 
m/z (%): 477 (100) [M + H]+. HRMS: calcd. for C24H33N2O4S2+ [MH]+ 477.1876; found: 477.1871. 
5.2.13 Synthesis of 2-aryl-1-sulfonylpiperidine-3-carboxamide cis-347 and cis-348 
Method A (only for (2R,3S)-347a and 348a). The synthesis of (2R,3S)-347a is representative. To a 
solution of (RS,S,R)-344a (0.24 g, 0.47 mmol) in Et2O (10 mL) was added a 3M solution of HCl in 
dioxane (15.0 equiv, 2.35 mL, 7.05 mmol) at 0 oC. The mixture was allowed to stir for 1 hour at oC. 
Subsequently, the reaction mixture was concentrated in vacuo. The resulting crude solid reaction 
mixture was heated under reflux in chlorophorm for 16 hours. After, the solvent was evaporated in 
vacuo. Precipitation in diethyl ether/hexane (1:1) afforded pure (2R,3S)-cis-2-phenyl-1-
tosylpiperidine-3-carboxamide (2R,3S)-347a. 
Method B. The synthesis of (2S,3R)-cis-2-(4-methoxyphenyl)-1-tosylpiperidine-3-carboxamide 
(2S,3R)-cis-348b is representative. To a solution of (RS,2S,3R)-345b (1.4 g, 2.77 mmol) in dioxane 




temperature. The mixture was allowed to stir for 2 hours at room temperature. Subsequently, the 
reaction mixture was concentrated in vacuo. Precipitation in diethyl ether/hexane (1:1) afforded pure 
(2S,3R)-cis-2-(4-methoxyphenyl)-1-tosylpiperidine-3-carboxamide (2S,3R)-cis-348b. 
Method C. (Only for 347a) To a solution of (RS,S,R)-344a (0.20 g, 0.40 mmol) in dioxane (8 mL) 
was added a 3M solution of HCl in dioxane (15.0 equiv, 2.00 mL, 6.00 mmol) at 0 oC. The mixture 
was allowed to stir for 2 hour at room temperature. Subsequently, the reaction mixture was 
concentrated in vacuo. The resulting crude solid reaction mixture was treated with K2CO3 (3.0 equiv, 
0.20 g, 1.20 mmol) in CH3CN (15 mL) at reflux for 15 hours. The solvent was evaporated in vacuo. 
The reactiom mixture was dissolved in EtOAc (15 mL), washed with brine (10 mL), dried MgSO4, 
filtered and evaporated in vacuo. Precipitation in diethyl ether/hexane (1:1) afforded pure (2R,3S)-
cis-2-phenyl-1-tosylpiperidine-3-carboxamide (2R,3S)-347a. 
(2R,3S)-cis-2-Phenyl-1-tosylpiperidine-3-carboxamide (2R,3S)-347a 
White crystals, yield 78% (method A), yield 99% (method B), yield 61% (method 
C). Mp 182.0-184.0 ºC. [α]D +78.4 (c 0.3, CHCl3). ee > 98%, HPLC (IB): hexane 
(80%)/ethanol (20%), 1 mL min -1, 35 ºC, tR = 9.28 min. IR (cm-1): νmax 1096, 1157, 
1331, 1599, 1664, 3343. 1H NMR (400 MHz, CDCl3): δ 1.44-1.58 (1H, m, 
CH(H)CH2N), 1.69-1.78 (1H, m, CH(H)CH2N), 1.81-2.04 (2H, m, CH2CH2CH2N), 2.38 (3H, s, 
pCH3), 2.74 (1H, ddd, J = 12.6, 5.3, 4.1 Hz, CHC=O), 2.93 (1H, td, J = 13.7, 3.1 Hz, CH(H)N), 3.76-
3.84 (1H, m, CH(H)N), 5.54 (1H, br s, NH(H)), 5.62 (1H, d, J = 5.3 Hz, CHPh), 5.85 (1H, br s, 
NH(H)), 7.14-7.32 (7H, m, 7 x CHarom), 7.55 (2H, d, J = 8.3 Hz, 2 x CHarom). 13C NMR (100.6 MHz, 
CDCl3): δ 20.9 (pCH3), 21.5 (CH2CH2N), 24.1 (CH2CH2CH2N), 41.2 (CH2N), 45.4 (CHC=O), 57.1 
(CHPh), 127.0 (2 x CHarom), 127.6 (CHarom), 128.4 (2 x CHarom), 128.7 (2 x CHarom), 129.6 (2 x 
CHarom), 136.7 (Carom,quat), 137.3 (Carom,quat), 143.2 (Carom,quat), 173.7 (C=O). Crystal data: 
C19H22N2O3S, 0.526(H2O), M = 367.92, monoclinic, space group P21 (No. 4), a = 9.5068(3) Å, b = 
10.2375(3) Å, c = 10.5226(3) Å, β = 114.558(4)°, V = 931.48(6) Å3, Z = 2, T = 100 K, calc = 1.312 
g cm-3, μ(Cu-Kα) = 1.742 mm-1, F(000) = 390.5, 9238 reflections measured, 3503 unique (Rint = 
0.0507) which were used in all calculations. The final R1 was 0.0382 (I >2 (I)) and wR2 was 0.0897 
(all data). CCDC: 1046637. MS (ES, pos mode) m/z (%): 359 (100) [M + H]+. HRMS: calcd. for 
C19H23N2O3S+ [MH]+ 359.1424; found: 359.1437. 
(2R,3S)-cis-1-(Phenylsulfonyl)-2-(p-tolyl)piperidine-3-carboxamide (2R,3S)-347c 
White crystals, yield 94% (Method B). Mp 190.0-192.0 ºC. [α]D +51.2 (c 0.3, 
CHCl3). IR (cm-1): νmax 959, 1096, 1156, 1327, 1404, 1612, 1656, 3413. 1H 
NMR (400 MHz, CDCl3): δ 1.44-1.61 (1H, m, CH(H)CH2N), 1.72-1.83 (1H, m, 
CH(H)CH2N), 1.84-1.93 (1H, m, CH(H)CH2CH2N), 1.99 (1H, dddd, J = 12.9, 
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12.9, 12.9, 4.1 Hz, CH(H)CH2CH2N), 2.27 (3H, s, pCH3), 2.76 (1H, ddd, J = 12.9, 5.3, 4.1 Hz, 
CHC=O), 2.96 (1H, td, J = 13.5, 3.0 Hz, CH(H)N), 3.76-3.87 (1H, m, CH(H)N), 5.42 (1H, br s, 
NH(H)), 5.57 (1H, d, J = 5.3 Hz, CHPhMe), 5.71 (1H, br s, NH(H)), 6.98 (2H, d, J = 8.1 Hz, 2 x 
CHarom), 7.15 (2H, d, J = 8.1 Hz, 2 x CHarom), 7.32-7.44 (2H, m, 2 x CHarom), 7.44-7.54 (1H, m, 
CHarom), 7.60-7.73 (2H, m, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 20.9 (pCH3), 21.0 
(CH2CH2N), 24.2 (CH2CH2CH2N), 41.2 (CH2N), 45.7 (CHC=O), 57.1 (CHPhMe), 127.0 (2 x 
CHarom), 128.6 (2 x CHarom), 128.9 (2 x CHarom), 129.1 (2 x CHarom), 132.3 (CHarom), 133.4 (Carom,quat), 
137.5 (Carom,quat), 140.2 (Carom,quat), 173.4 (C=O). MS (ES, pos mode) m/z (%): 359 (100) [M + H]+. 
HRMS: calcd. for C19H23N2O3S+ [MH]+ 359.1424; found: 359.1431. 
(2S,3R)-cis-2-Phenyl-1-tosylpiperidine-3-carboxamide (2S,3R)-348a 
White crystals, yield 84% (method A), yield 98% (method B). Mp 178.0-180.0 ºC. 
[α]D -80.7 (c 0.4, CHCl3). ee > 98%, HPLC (IB): hexane (80%)/ethanol (20%), 1 
mL min -1, 35 ºC, tR = 8.04 min. IR (cm-1): νmax 1151, 1316, 1410, 1597, 1660, 3418. 
1H NMR (400 MHz, CDCl3): δ 1.44-1.58 (1H, m, CH(H)CH2N), 1.69-1.78 (1H, m, 
CH(H)CH2N), 1.81-2.04 (2H, m, CH2CH2CH2N), 2.38 (3H, s, pCH3), 2.74 (1H, ddd, J = 12.6, 5.3, 
4.1 Hz, CHC=O), 2.93 (1H, td, J = 13.7, 3.1 Hz, CH(H)N), 3.76-3.84 (1H, m, CH(H)N)), 5.54 (1H, 
br s, NH(H)), 5.62 (1H, d, J = 5.3 Hz, CHPh), 5.88 (1H, br s, NH(H)), 7.14-7.32 (7H, m, 7 x CHarom), 
7.55 (2H, d, J = 8.3 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 20.9 (pCH3), 21.5 (CH2CH2N), 
24.1 (CH2CH2CH2N), 41.2 (CH2N), 45.4 (CHC=O), 57.1 (CHPh), 127.0 (2 x CHarom), 127.6 (CHarom), 
128.4 (2 x CHarom), 128.7 (2 x CHarom), 129.6 (2 x CHarom), 136.7 (Carom,quat), 137.3 (Carom,quat), 143.2 
(Carom,quat), 173.7 (C=O). Crystal data: C19H22N2O3S, 0.576(H2O), M = 368.82, monoclinic, space 
group P21 (No. 4), a = 9.5055(3) Å, b = 10.2450(2) Å, c = 10.5267(3) Å, β = 114.610(4)°, V = 
932.01(5) Å3, Z = 2, T = 100 K, calc = 1.314 g cm-3, μ(Cu-Kα) = 1.744 mm-1, F(000) = 391.5, 13909 
reflections measured, 3716 unique (Rint = 0.0330) which were used in all calculations. The final R1 
was 0.0289 (I >2 (I)) and wR2 was 0.0751 (all data). CCDC: 1046638. MS (ES, pos mode) m/z 
(%): 359 (100) [M + H]+. HRMS: calcd. for C19H23N2O3S+ [MH]+ 359.1424; found: 359.1429. 
(2S,3R)-cis-2-(4-Methoxyphenyl)-1-tosylpiperidine-3-carboxamide (2S,3R)-348b 
White crystals, yield 98% (Method B). Mp 196.0-198.0 ºC. [α]D -34.5 (c 0.3, 
CHCl3). IR (cm-1): νmax 1096, 1155, 1246, 1325, 1513, 1608, 1660, 2940, 3426. 
1H NMR (400 MHz, CDCl3): δ 1.39-1.55 (1H, m, CH(H)CH2N), 1.67-1.76 (1H, 
m, CH(H)CH2N), 1.80-1.88 (1H, m, CH(H)CH2CH2N), 1.96 (1H, dddd, J = 
13.0, 13.0, 13.0, 4.0 Hz, CH(H)CH2CH2N), 2.37 (3H, s, pCH3), 2.69 (1H, ddd, J = 13.0, 5.4, 4.0 Hz, 
CHC=O), 2.91 (1H, td, J = 13.4, 3.0 Hz, CH(H)N), 3.70-3.82 (1H, m, CH(H)N), 3.74 (3H, s, OCH3), 




= 8.8 Hz, 2 x CHarom), 7.15 (2H, d, J = 8.3 Hz, 2 x CHarom), 7.22 (2H, d, J = 8.8 Hz, 2 x CHarom), 7.54 
(2H, d, J = 8.3 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 20.8 (pCH3), 21.5 (CH2CH2N), 
24.1 (CH2CH2CH2N), 41.0 (CH2N), 45.4 (CHC=O), 55.2 (OCH3), 56.7 (CHPhOMe), 113.6 (2 x 
CHarom), 127.0 (2 x CHarom), 128.7 (CHarom), 129.6 (2 x CHarom), 130.0 (2 x CHarom), 137.3 (Carom,quat), 
143.1 (Carom,quat), 159.0 (Carom,quat), 173.9 (C=O). Crystal data: C20H24N2O4S, M = 388.47, monoclinic, 
space group P21 (No. 4), a = 9.3435(2) Å, b = 10.02409(19) Å, c = 21.4346(5) Å, β = 101.916(2) °, 
V = 1964.31(7) Å3, Z = 4, T = 100 K, calc = 1.314 g cm-3, μ(Cu-Kα) = 1.699 mm-1, F(000) = 824, 
28131 reflections measured, 7867 unique (Rint = 0.0478) which were used in all calculations. The 
final R1 was 0.0514 (I >2 (I)) and wR2 was 0.1444 (all data). CCDC: 1046639. MS (ES, pos mode) 
m/z (%): 389 (100) [M + H]+. HRMS: calcd. for C20H25N2O4S+ [MH]+ 389.1530; found: 389.1543. 
(2S,3R)-cis-1-(Phenylsulfonyl)-2-(p-tolyl)piperidine-3-carboxamide (2S,3R)-348c 
White crystals, yield 96% (Method B). Mp 186.0-188.0 ºC. [α]D -51.3 (c 0.3, 
CHCl3). IR (cm-1): νmax 959, 1096, 1155, 1326, 1446, 1611, 1656, 3413. 1H NMR 
(400 MHz, CDCl3): δ 1.44-1.61 (1H, m, CH(H)CH2N), 1.72-1.83 (1H, m, 
CH(H)CH2N), 1.84-1.93 (1H, m, CH(H)CH2CH2N), 1.99 (1H, dddd, J = 12.9, 
12.9, 12.9, 4.1 Hz, CH(H)CH2CH2N), 2.27 (3H, s, pCH3), 2.76 (1H, ddd, J = 12.9, 5.3, 4.1 Hz, 
CHC=O), 2.96 (1H, td, J = 13.5, 3.0 Hz, CH(H)N), 3.76-3.87 (1H, m, CH(H)N), 5.57 (1H, d, J = 5.3 
Hz, CHPhMe), 5.66 (2H, br s, NH2), 6.98 (2H, d, J = 8.1 Hz, 2 x CHarom), 7.15 (2H, d, J = 8.1 Hz, 2 
x CHarom), 7.32-7.44 (2H, m, 2 x CHarom), 7.44-7.54 (1H, m, CHarom), 7.60-7.73 (2H, m, 2 x CHarom). 
13C NMR (100.6 MHz, CDCl3): δ 20.9 (pCH3), 21.0 (CH2CH2N), 24.2 (CH2CH2CH2N), 41.2 
(CH2N), 45.7 (CHC=O), 57.1 (CHPhMe), 127.0 (2 x CHarom), 128.6 (2 x CHarom), 128.9 (2 x CHarom), 
129.1 (2 x CHarom), 132.3 (CHarom), 133.4 (Carom,quat), 137.5 (Carom,quat), 140.2 (Carom,quat), 173.4 (C=O). 
MS (ES, pos mode) m/z (%): 359 (100) [M + H]+. HRMS: calcd. for C19H23N2O3S+ [MH]+ 359.1424; 
found: 359.1437. 
5.2.14 Synthesis of 3-amino-2-aryl-1-sulfonylpiperidine cis-350 and cis-351 
The synthesis of (2S,3S)-3-amino-2-phenyl-1-tosylpiperidine (2S,3S)-cis-350 is representative. To a 
cooled (-5 °C) solution of NaOH (0.01 g, 0.35 mmol) in water (1.0 mL) was added bromine (1.1 
equiv, 0.02 g, 0.15 mmol). The mixture was stirred for 30 minutes and (2R,3S)-cis-2-phenyl-1-
tosylpiperidine-3-carboxamide (2R,3S)-cis-347a (1.0 equiv, 0.05 g, 0.14 mmol) in acetonitrile/water 
2:1 (5 mL) was added. The reaction mixture was stirred at 55 °C for 1 hour until completion of the 
reaction (LC-MS). Subsequently, the reaction mixture was extracted with ethyl acetate (3 x 8 mL). 
The combined organic layers were washed with 3M HCl (15 mL). The water layer was then made 
alkaline (pH = 9) with 10% NaOH and extracted with ethyl acetate. The combined organic phases 
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were dried (Na2SO4), filtered, and evaporated in vacuo and afforded 0.03 g (0.09 mmol, 60% yield) 
of (2S,3S)-3-amino-2-phenyl-1-tosylpiperidine (2S,3S)-cis-350. 
(2S,3S)-cis-3-Amino-2-phenyl-1-tosylpiperidine (2S,3S)-350 
Rf = 0.48 (EtOAc/MeOH 95/5). Viscous yellow oil, yield 60%. [α]D -17.0 (c 0.3, 
CH2Cl2). IR (cm-1): νmax 1153, 1330, 2937. 1H NMR (400 MHz, CDCl3): δ 1.07 
(2H, br s, NH2), 1.51-1.65 (1H, m, CH(H)CH2N), 1.69-1.83 (2H, m, 
CH2CH2CH2N), 1.84-1.93 (1H, m, CH(H)CH2N), 2.31 (3H, s, pCH3), 3.11 (1H, td, 
J = 13.0, 3.5 Hz, CH(H)N), 3.18 (1H, ddd, J = 12.3, 6.2, 4.0 Hz, CHNH2), 3.82 (1H, dd, J = 13.0, 
3.5 Hz, CH(H)N), 5.11 (1H, d, J = 6.2 Hz, CHPh), 7.00 (2H, d, J = 8.0 Hz, 2 x CHarom), 7.14-7.31 
(7H, m, 7 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.4 (pCH3), 24.5 (CH2CH2N), 28.4 
(CH2CH2CH2N), 41.3 (CH2N), 51.4 (CHNH2), 62.3 (CHPh), 127.0 (2 x CHarom), 127.7 (CHarom), 
128.2 (2 x CHarom), 129.0 (2 x CHarom), 130.0 (2 x CHarom), 136.5 (Carom,quat), 136.7 (Carom,quat), 142.5 
(Carom,quat). MS (ES, pos mode) m/z (%): 331 (100) [M + H]+. HRMS: calcd. for C18H23N2O2S+ [MH]+ 
331.1148; found: 331.1483. 
(2R,3R)-cis-3-Amino-2-(4-methoxyphenyl)-1-tosylpiperidine (2R,3R)-351 
Rf = 0.56 (EtOAc/MeOH 95/5). Viscous yellow oil, yield 75%. [α]D +26.7 (c 
0.3, CH2Cl2). IR (cm-1): νmax 1156, 1249, 1331, 1510, 1608, 3356. 1H NMR 
(400 MHz, CDCl3): δ 1.22 (2H, br s, NH2), 1.49-1.63 (1H, m, CH(H)CH2N), 
1.66-1.81 (2H, m, CH2CH2CH2N), 1.82-1.92 (1H, m, CH(H)CH2N), 2.32 (3H, 
s, pCH), 3.07 (1H, td, J = 12.7, 3.4 Hz, CH(H)N), 3.16 (1H, ddd, J = 12.3, 6.2, 4.0 Hz, CHNH2), 
3.73-3.81 (1H, m, CH(H)N), 3.77 (3H, s, OCH3), 5.07 (1H, d, J = 6.2 Hz, CHPhOMe), 6.71 (2H, d, 
J = 8.7 Hz, 2 x CHarom), 7.01 (2H, d, J = 8.2 Hz, 2 x CHarom), 7.17 (2H, d, J = 8.7 Hz, 2 x CHarom), 
7.30 (2H, d, J = 8.2 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.4 (pCH3), 24.5 (CH2CH2N), 
28.4 (CH2CH2CH2N), 41.2 (CH2N), 51.4 (CHNH2), 55.3 (OCH3), 61.7 (CHPh), 113.6 (2 x CHarom), 
127.1 (2 x CHarom), 128.7 (CHarom), 129.0 (2 x CHarom), 131.1 (2 x CHarom), 136.6 (Carom,quat), 142.4 
(Carom,quat), 142.3 (Carom,quat). MS (ES, pos mode) m/z (%): 361 (100) [M + H]+. HRMS: calcd. for 
C19H25N2O3S+ [MH]+ 361.1580; found: 361.1592. 
5.2.15 Synthesis of 3,3,3-trifluoro-2-methoxy-2-phenyl-N-((2S,3S)-2-phenyl-1-tosyl-
piperidin-3-yl)propanamides 352 and 353 
The synthesis of (S)-3,3,3-trifluoro-2-methoxy-2-phenyl-N-((2S,3S)-2-phenyl-1-tosylpiperidin-3-
yl)propanamide 352 is representative. In a screw-capped 4 mL glass vial, fitted with a magnetic stir 
bar, (2S,3S)-3-amino-2-phenyl-1-tosylpiperidine (2S,3S)-350 (5.1 mg, 0.016 mmol) was dissolved in 




resulting mixture was added (R)-MTPA-Cl (1.8 equiv, 7.1 mg, 0.028 mmol) and the reaction was 
stirred at room temperature for 2 hours (TLC control). After reaction completion, H2O (1 mL) was 
added and mixture was extracted with Et2O (3 x 2 mL). The organic layers were combined and dried 
(Na2SO4). The filtration, evaporation of solvent in vacuo and purification via preparative thin layer 
chromatography afforded pure (S)-3,3,3-trifluoro-2-methoxy-2-phenyl-N-((2S,3S)-2-phenyl-1-
tosylpiperidin-3-yl)propanamide 352.  
(S)-cis-3,3,3-trifluoro-2-methoxy-2-phenyl-N-((2S,3S)-2-phenyl-1-tosylpiperidin-3-
yl)propanamide 352 
Rf = 0.61 (PE/EA 1/1). Viscous colorless oil, yield 86%. [α]D -45.7 (c 0.1, 
CH3Cl). IR (cm-1): νmax 1138, 1164, 1325, 1648, 3058. 1H NMR (400 MHz, 
CDCl3): δ 1.65-1.91 (4H, m, CH(H)CH(H)CH2N), 2.33 (3H, s, CH3 in Tos), 3.06 
(3H, s, OCH3), 3.15-3.25 (1H, m, CH(H)N), 3.79-3.86 (1H, m, CH(H)N), 4.30-
4.40 (1H, m, CHN), 5.42 (1H, d, J = 6.4 Hz, CHPh), 6.23 (1H, d, J = 8.6 Hz, CHNH), 7.07 (2H, d, J 
= 8.0 Hz, 2 x CHarom), 7.20-7.44 (12H, m, 12 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.4 (CH3, 
Tos), 23.8 (CH2CH2CH2N), 25.3 (CH2CH2N), 41.3 (CH2N), 48.5 (CHNH), 54.8 (OCH3), 58.3 
(CHPh), 83.8 (CCF3, d, J = 26.3 Hz), 123.4 (CF3, q, J = 291.2 Hz), 127.1 (2 x CHarom), 127.4 (2 x 
CHarom), 128.2 (CHarom), 128.5 (2 x CHarom), 128.6 (2 x CHarom), 129.3 (2 x CHarom), 129.4 (2 x 
CHarom), 129.6 (2 x CHarom), 132.6 (Carom,quat), 136.7 (C=O, d, J = 20.9 Hz), 142.8 (Carom,quat), 165.3 
(Carom,quat). 19F NMR (282 MHz, CDCl3): δ -68.44 (3F, s, CF3). MS (ES, pos mode) m/z: 547 (100) 
[M + H]+. HRMS: calcd for C28H30F3N2O4S+ [MH]+ 547.1873; found: 547.1877. 
(R)-cis-3,3,3-trifluoro-2-methoxy-2-phenyl-N-((2S,3S)-2-phenyl-1-tosylpiperidin-3-
yl)propanamide 353 
Rf = 0.61 (PE/EA 1/1). Viscous colorless oil, yield 71%. [α]D -62.6 (c 0.1, 
CH3Cl). IR (cm-1): νmax 1134, 1158, 1330, 1654, 3042. 1H NMR (400 MHz, 
CDCl3): δ 1.66-1.91 (4H, m, CH(H)CH(H)CH2N), 2.33 (3H, s, CH3 in Tos), 3.11 
(3H, s, OCH3), 3.16-3.25 (1H, m, CH(H)N), 3.79-3.86 (1H, m, CH(H)N), 4.31-4.40 (1H, m, CHN), 
5.29 (1H, d, J = 6.4 Hz, CHPh), 6.29 (1H, d, J = 8.6 Hz, CHNH), 7.05-7.16 (6H, m, 6 x CHarom), 
7.21-7.25 (1H, m, CHarom), 7.34-7.45 (7H, m, 7 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.4 
(CH3, Tos), 23.8 (CH2CH2CH2N), 25.4 (CH2CH2N), 41.4 (CH2N), 48.2 (CHNH), 54.6 (OCH3), 58.3 
(CHPh), 83.7 (CCF3, d, J = 26.2 Hz), 123.6 (CF3, q, J = 299.4 Hz), 127.0 (2 x CHarom), 127.7 (2 x 
CHarom), 128.0 (CHarom), 128.4 (2 x CHarom), 128.6 (2 x CHarom), 129.3 (2 x CHarom), 129.4 (2 x 
CHarom), 129.5 (2 x CHarom), 131.8 (Carom,quat), 136.6 (C=O, d, J = 25.7 Hz), 142.9 (Carom,quat), 165.2 
(Carom,quat). 19F NMR (282 MHz, CDCl3): δ -69.25 (3F, s, CF3). MS (ES, pos mode) m/z: 547 (100) 
[M + H]+. HRMS: calcd for C28H30F3N2O4S+ [MH]+ 547.1873; found: 547.1875. 
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5.2.16 Synthesis of methyl 2-aryl-1-sulfonylpiperidine-3-carboxylates cis-354 and cis-
355 
The synthesis of (2S,3R)-cis-methyl 2-(4-methoxyphenyl)-1-tosylpiperidine-3-carboxylate (2S,3R)-
355b is representative. To a solution of (RS,2S,3R)-345b (0.25 g, 0.51 mmol) in methanol (15 mL) 
was added 3M HCl in methanol (80.0 equiv, 13.7 mL, 41.1 mmol) at room temperature. The mixture 
was stirred for 24 hours at room temperature and subsequently poured in saturated aqueous NaHCO3 
(20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic phases were dried (MgSO4), 
filtered, and evaporated in vacuo. The crude product was purified by flash chromatography to yield 
0.11 g (0.27 mmol, 65% yield) of pure (2S,3R)-methyl 2-(4-methoxyphenyl)-1-tosylpiperidine-3-
carboxylate (2S,3R)-cis-355b. 
(2R,3S)-cis-Methyl 2-phenyl-1-tosylpiperidine-3-carboxylate (2R,3S)-354a 
Rf = 0.32 (PE/Et2O 1/1). Colorless oil, yield 58%. [α]D +78.4 (c 0.1, CHCl3). ee > 
98%, HPLC (IA): hexane (95%)/ethanol (5%), 1 mL min -1, 35 ºC, tR = 15.65 min. 
IR (cm-1): νmax 1157, 1337, 1733, 2950. 1H NMR (400 MHz, CDCl3): δ 1.37-1.51 
(1H, m, CH(H)CH2N), 1.63-1.72 (1H, m, CH(H)CH2N), 1.92-2.02 (2H, m, 
CH2CH2CH2N), 2.40 (3H, s, pCH3), 2.74-2.82 (1H, m, CHC=O), 2.87 (1H, td, J = 13.8, 3.0 Hz, 
CH(H)N), 3.57 (3H, s, OCH3), 3.77-3.85 (1H, m, CH(H)N), 5.68 (1H, d, J = 5.4 Hz, CHPh), 7.17-
7.25 (7H, m, 7 x CHarom), 7.61 (2H, d, J = 8.3 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 
20.7 (pCH3), 21.5 (CH2CH2N), 24.0 (CH2CH2CH2N), 41.2 (CH2N), 43.9 (CHC=O), 51.9 (OCH3), 
56.4 (CHPh), 127.0 (2 x CHarom), 127.5 (CHarom), 128.3 (2 x CHarom), 128.4 (2 x CHarom), 129.6 (2 x 
CHarom), 137.1 (Carom,quat), 137.7 (Carom,quat), 143.1 (Carom,quat), 172.6 (C=O). MS (ES, pos mode) m/z 
(%): 374 (100) [M + H]+. HRMS: calcd. for C20H24NO4S+ [MH]+ 374.1426; found: 374.1415. 
 (2R,3S)-cis-Methyl 1-(phenylsulfonyl)-2-(p-tolyl)piperidine-3-carboxylate (2R,3S)-354c 
Rf = 0.24 (PE/ Et2O 7/3). Colorless oil, yield 63%. [α]D +48.3 (c 0.2, CHCl3). 
IR (cm-1): νmax 950, 1094, 1157, 1309, 1446, 1731, 2954. 1H NMR (400 MHz, 
CDCl3): δ 1.44-1.54 (1H, m, CH(H)CH2N), 1.64-1.75 (1H, m, CH(H)CH2N), 
1.91-2.02 (2H, m, CH2CH2CH2N), 2.28 (3H, s, pCH3), 2.74-2.83 (1H, m, 
CHC=O), 2.89 (1H, td, J = 13.6, 3.8 Hz, CH(H)N), 3.57 (3H, s, OCH3), 3.79-3.88 (1H, m, CH(H)N), 
5.65 (1H, d, J = 5.5 Hz, CHPhMe), 7.00 (2H, d, J = 8.2 Hz, 2 x CHarom), 7.09 (2H, d, J = 8.2 Hz, 2 x 
CHarom), 7.34-7.42 (2H, m, 2 x CHarom), 7.47-7.53 (1H, m, CHarom), 7.66-7.74 (2H, m, 2 x CHarom). 
13C NMR (100.6 MHz, CDCl3): δ 20.7 (pCH3), 20.9 (CH2CH2N), 24.1 (CH2CH2CH2N), 41.2 
(CH2N), 44.2 (CHC=O), 51.8 (OCH3), 56.3 (CHPh), 127.0 (2 x CHarom), 128.2 (2 x CHarom), 129.0 




172.5 (C=O). MS (ES, pos mode) m/z (%): 374 (100) [M + H]+. HRMS: calcd. for C20H24NO4S+ 
[MH]+ 374.1426; found: 374.1419. 
(2S,3R)-cis-Methyl 2-phenyl-1-tosylpiperidine-3-carboxylate (2S,3R)-355a 
Rf = 0.32 (PE/ Et2O 1/1). Colorless oil, yield 54 %. [α]D -76.2 (c 0.1, CHCl3). ee > 
98%, HPLC (IA): hexane (95%)/ethanol (5%), 1 mL min -1, 35 ºC, tR = 14.27 min. 
IR (cm-1): νmax 1160, 1138, 1734, 2952. 1H NMR (400 MHz, CDCl3): δ 1.37-1.51 
(1H, m, CH(H)CH2N), 1.63-1.72 (1H, m, CH(H)CH2N), 1.92-2.02 (2H, m, 
CH2CH2CH2N), 2.40 (3H, s, pCH3), 2.74-2.82 (1H, m, CHC=O), 2.87 (1H, td, J = 13.8, 3.0 Hz, 
CH(H)N), 3.57 (3H, s, OCH3), 3.77-3.85 (1H, m, CH(H)N), 5.68 (1H, d, J = 5.4 Hz, CHPh), 7.17-
7.25 (7H, m, 7 x CHarom), 7.61 (2H, d, J = 8.3 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 
20.7 (pCH3), 21.5 (CH2CH2N), 24.0 (CH2CH2CH2N), 41.2 (CH2N), 43.9 (CHC=O), 51.9 (OCH3), 
56.4 (CHPh), 127.0 (2 x CHarom), 127.5 (CHarom), 128.3 (2 x CHarom), 128.4 (2 x CHarom), 129.6 (2 x 
CHarom), 137.1 (Carom,quat), 137.7 (Carom,quat), 143.1 (Carom,quat), 172.6 (C=O). MS (ES, pos mode) m/z 
(%): 374 (100) [M + H]+. HRMS: calcd. for C20H24NO4S+ [MH]+ 374.1426; found: 374.1425. 
(2S,3R)-cis-Methyl 2-(4-methoxyphenyl)-1-tosylpiperidine-3-carboxylate (2S,3R)-355b 
Rf = 0.27 (PE/Et2O 1/1). Colorless oil, yield 65%. [α]D -50.9 (c 0.1, CHCl3). IR 
(cm-1): νmax 1157, 1459, 1513, 1734, 2923. 1H NMR (400 MHz, CDCl3): δ 1.37-
1.55 (1H, m, CH(H)CH2N), 1.64-1.73 (1H, m, CH(H)CH2N), 1.91-2.00 (2H, 
m, CH2CH2CH2N), 2.38 (3H, s, pCH3), 2.73-2.82 (1H, m, CHC=O), 2.88 (1H, 
td, J = 13.6, 3.0 Hz, CH(H)N), 3.56 (3H, s, OCH3), 3.76 (3H, s, OCH3), 3.77-3.83 (1H, m, CH(H)N), 
5.62 (1H, d, J = 5.5 Hz, CHPhOMe), 6.73 (2H, d, J = 8.8 Hz, 2 x CHarom), 7.15 (2H, d, J = 8.8 Hz, 2 
x CHarom), 7.19 (2H, d, J = 8.2 Hz, 2 x CHarom), 7.59 (2H, d, J = 8.2 Hz, 2 x CHarom). 13C NMR (100.6 
MHz, CDCl3): δ 20.7 (pCH3), 21.5 (CH2CH2N), 24.0 (CH2CH2CH2N), 41.0 (CH2N), 44.1 (CHC=O), 
51.8 (OCH3), 55.2 (OCH3), 56.0 (CHPh), 113.7 (2 x CHarom), 127.0 (2 x CHarom), 129.0 (Carom,quat), 
129.6 (4 x CHarom), 137.7 (Carom,quat), 143.0 (Carom,quat), 158.9 (Carom,quat), 172.6 (C=O). MS (ES, pos 
mode) m/z (%): 404 (97) [M + H]+, 372 (100). HRMS: calcd. for C21H26NO5S+ [MH]+ 404.1526; 
found: 404.1534. 
(2S,3R)-cis-Methyl 1-(phenylsulfonyl)-2-(p-tolyl)piperidine-3-carboxylate (2S,3R)-355c 
Rf = 0.24 (PE/Et2O 7/3). Colorless oil, yield 68%. [α]D -52.1 (c 0.2, CHCl3). IR 
(cm-1): νmax 951, 1095, 1157, 1309, 1446, 1731, 2953. 1H NMR (400 MHz, 
CDCl3): δ 1.44-1.54 (1H, m, CH(H)CH2N), 1.64-1.75 (1H, m, CH(H)CH2N), 
1.91-2.02 (2H, m, CH2CH2CH2N), 2.28 (3H, s, pCH3), 2.74-2.83 (1H, m, 
CHC=O), 2.89 (1H, td, J = 13.6, 3.8 Hz, CH(H)N), 3.57 (3H, s, OCH3), 3.79-3.88 (1H, m, CH(H)N), 
5.65 (1H, d, J = 5.5 Hz, CHPhMe), 7.00 (2H, d, J = 8.2 Hz, 2 x CHarom), 7.09 (2H, d, J = 8.2 Hz, 2 x 
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CHarom), 7.34-7.42 (2H, m, 2 x CHarom), 7.47-7.53 (1H, m, CHarom), 7.66-7.74 (2H, m, 2 x CHarom). 
13C NMR (100.6 MHz, CDCl3): δ 20.7 (pCH3), 20.9 (CH2CH2N), 24.1 (CH2CH2CH2N), 41.2 
(CH2N), 44.2 (CHC=O), 51.8 (OCH3), 56.3 (CHPh), 127.0 (2 x CHarom), 128.2 (2 x CHarom), 129.0 
(2 x CHarom), 129.1 (2 x CHarom), 132.3 (CHarom), 133.9 (Carom,quat), 137.3 (Carom,quat), 140.6 (Carom,quat), 
172.5 (C=O). MS (ES, pos mode) m/z (%): 374 (100) [M + H]+. HRMS: calcd. for C20H24NO4S+ 
[MH]+ 374.1426; found: 374.1427. 
5.2.17 Synthesis of methyl 2-arylpiperidine-3-carboxylates cis-356 and cis-357 
The synthesis of (2R,3S)-cis-methyl 2-phenylpiperidine-3-carboxylate (2R,3S)-cis-356a is 
representative. A mixture of magnesium turnings (60.0 equiv, 0.15 g, 6.43 mmol) in dry MeOH (15 
mL) was sonicated at 40 °C for 10 minutes. Subsequently, a solution of piperidine-3-carboxylate 
(2R,3S)-354a (0.04 g, 0.11 mmol) in MeOH (5 mL) was added dropwise and the resulting suspension 
was sonicated for six hours at 40 °C. Next, the reaction mixture was concentrated under reduced 
pressure to afford a white powder which was redissolved in 10 mL aqueous NH4Cl (sat.) and 
extracted with EtOAc (3 x 10 mL). The combined organic phases were dried (MgSO4), filtered, and 
evaporated in vacuo. The crude product was purified by flash chromatography to yield 0.009 g (0.04 
mmol, 37% yield) of pure (2R,3S)-methyl 2-phenyl-1-tosylpiperidine-3-carboxylate (2R,3S)-356a. 
For the synthesis of (2R,3S)-cis-methyl 2-(p-tolyl)piperidine-3-carboxylate (2R,3S)-cis-356c and 
(2S,3R)-cis-methyl 2-(p-tolyl)piperidine-3-carboxylate (2S,3R)-cis-357c, 20.0 equivalents of Mg 
was used and the reaction time was reduced to 1.5 hours. 
(2R,3S)-cis-Methyl 2-phenylpiperidine-3-carboxylate (2R,3S)-356a 
Rf = 0.15 (EtOAc/MeOH 95/5). Pale yellow oil, yield 37%. [α]D +82.5 (c 0.2, 
CHCl3). IR (cm-1): νmax 1161, 1436, 1723, 2936. 1H NMR (400 MHz, CDCl3): δ 
1.46-1.53 (1H, m, CH(H)CH2N), 1.72-2.01 (2H, m, CH(H)CH(H)CH2N), 2.04 
(1H, br s, NH), 2.11-2.22 (1H, m, CH(H)CH2CH2N), 2.81 (1H, td, J = 12.5, 3.1 
Hz, CH(H)N), 2.93-3.04 (1H, m, CHC=O), 3.30-3.39 (1H, m, CH(H)N), 3.41 (3H, s, OCH3), 3.95 
(1H, d, J = 3.5 Hz, CHPh), 7.17-7.24 (1H, m, CHarom), 7.27-7.33 (4H, m, 4 x CHarom). 13C NMR 
(100.6 MHz, CDCl3): δ 22.0 (CH2CH2N), 27.9 (CH2CH2CH2N), 44.8 (CHC=O), 47.2 (CH2N), 51.0 
(OCH3), 61.4 (CHPh), 126.0 (2 x CHarom), 126.8 (CHarom), 128.1 (2 x CHarom), 142.3 (Carom,quat), 174.0 
(C=O). MS (ES, pos mode) m/z (%): 220 (100) [M + H]+. HRMS: calcd. for C13H18NO2+ [MH]+ 







(2R,3S)-cis-Methyl 2-(p-tolyl)piperidine-3-carboxylate (2R,3S)-356c 
Rf = 0.14 (EtOAc/MeOH 95/5). Pale yellow oil, yield 52%. [α]D +87.5 (c 0.2, 
CHCl3). IR (cm-1): νmax 808, 1190, 1436, 1726, 2934. 1H NMR (400 MHz, 
CDCl3): δ 1.42-1.53 (1H, m, CH(H)CH2N), 1.75-1.99 (2H, m, 
CH(H)CH(H)CH2N), 2.11-2.20 (1H, m, CH(H)CH2CH2N), 2.31 (3H, s, pCH3), 
2.80 (1H, td, J = 12.7, 2.9 Hz, CH(H)N), 2.90-2.98 (1H, m, CHC=O), 3.29-3.36 (1H, m, CH(H)N), 
3.45 (3H, s, OCH3), 3.91 (1H, d, J = 3.4 Hz, CHPh), 7.10 (2H, d, J = 8.1 Hz, 2 x CHarom), 7.17 (2H, 
d, J = 8.1 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.0 (pCH3), 22.0 (CH2CH2N), 27.8 
(CH2CH2CH2N), 44.6 (CHC=O), 47.1 (CH2N), 51.1 (OCH3), 61.1 (CHPhMe), 125.8 (2 x CHarom), 
128.8 (2 x CHarom), 136.2 (Carom,quat), 139.3 (Carom,quat), 174.1 (C=O). MS (ES, pos mode) m/z (%): 
234 (100) [M + H]+. HRMS: calcd. for C14H20NO2+ [MH]+ 234.1489; found: 234.1491. 
(2S,3R)-cis-Methyl 2-phenylpiperidine-3-carboxylate (2S,3R)-357a 
Rf = 0.15 (EtOAc/MeOH 95/5). Pale yellow oil, yield 35%. [α]D -76.4 (c 0.1, 
CHCl3). IR (cm-1): νmax 1161, 1436, 1724, 2930. 1H NMR (400 MHz, CDCl3): δ 
1.46-1.53 (1H, m, CH(H)CH2N), 1.72-2.01 (2H, m, CH(H)CH(H)CH2N), 2.11-2.22 
(1H, m, CH(H)CH2CH2N), 2.81 (1H, td, J = 12.5, 3.1 Hz, CH(H)N), 2.93-3.04 (1H, 
m, CHC=O), 3.30-3.39 (1H, m, CH(H)N), 3.41 (3H, s, OCH3), 3.95 (1H, d, J = 3.5 Hz, CHPh), 7.17-
7.24 (1H, m, CHarom), 7.27-7.33 (4H, m, 4 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 22.0 
(CH2CH2N), 27.9 (CH2CH2CH2N), 44.8 (CHC=O), 47.2 (CH2N), 51.0 (OCH3), 61.4 (CHPh), 126.0 
(2 x CHarom), 126.8 (CHarom), 128.1 (2 x CHarom), 142.3 (Carom,quat), 174.0 (C=O). MS (ES, pos mode) 
m/z (%): 220 (100) [M + H]+. HRMS: calcd. for C13H18NO2+ [MH]+ 220.1332; found: 220.1331. 
(2S,3R)-cis-Methyl 2-(4-methoxyphenyl)piperidine-3-carboxylate (2S,3R)-357b 
Rf = 0.14 (EtOAc/MeOH 95/5). Pale yellow oil, yield 44%. [α]D -67.4 (c 0.2, 
CHCl3). IR (cm-1): νmax 1158, 1250, 1513, 1731, 2928. 1H NMR (400 MHz, 
CDCl3): δ 1.44-1.54 (1H, m, CH(H)CH2N), 1.69-1.98 (3H, m, 
CH(H)CH(H)CH2N and NH), 2.03-2.20 (1H, m, CH(H)CH2CH2N), 2.79 (1H, 
td, J = 12.6, 3.1 Hz, CH(H)N), 2.89-2.97 (1H, m, CHC=O), 3.27-3.40 (1H, m, CH(H)N), 3.45 (3H, 
s, OCH3), 3.78 (3H, s, OCH3), 3.90 (1H, d, J = 3.4 Hz, CHPhOMe), 6.83 (2H, d, J = 8.6 Hz, 2 x 
CHarom), 7.20 (2H, d, J = 8.6 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 22.0 (CH2CH2N), 
27.8 (CH2CH2CH2N), 44.6 (CHC=O), 47.1 (CH2N), 51.1 (OCH3), 55.2 (OCH3), 60.8 (CHPhOMe), 
113.5 (2 x CHarom), 127.0 (2 x CHarom), 128.5 (Carom,quat), 134.5 (Carom,quat), 174.1 (C=O). MS (ES, pos 
mode) m/z (%): 250 (100) [M + H]+. HRMS: calcd. for C14H20NO3+ [MH]+ 250.1438; found: 
250.1443. 
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(2S,3R)-cis-Methyl 2-(p-tolyl)piperidine-3-carboxylate (2S,3R)-357c 
Rf = 0.16 (EtOAc/MeOH 95/5). Pale yellow oil, yield 50%. [α]D -80.3 (c 0.3, 
CHCl3). IR (cm-1): νmax 1162, 1436, 1726, 2930. 1H NMR (400 MHz, CDCl3): δ 
1.42-1.53 (1H, m, CH(H)CH2N), 1.75-1.99 (2H, m, CH(H)CH(H)CH2N), 2.11-
2.20 (1H, m, CH(H)CH2CH2N), 2.31 (3H, s, pCH3), 2.80 (1H, td, J = 12.7, 2.9 
Hz, CH(H)N), 2.90-2.98 (1H, m, CHC=O), 3.29-3.36 (1H, m, CH(H)N), 3.45 (3H, s, OCH3), 3.91 
(1H, d, J = 3.4 Hz, CHPh), 7.10 (2H, d, J = 8.1 Hz, 2 x CHarom), 7.17 (2H, d, J = 8.1 Hz, 2 x CHarom). 
13C NMR (100.6 MHz, CDCl3): δ 21.0 (pCH3), 22.0 (CH2CH2N), 27.8 (CH2CH2CH2N), 44.6 
(CHC=O), 47.1 (CH2N), 51.1 (OCH3), 61.1 (CHPhMe), 125.8 (2 x CHarom), 128.8 (2 x CHarom), 136.2 
(Carom,quat), 139.3 (Carom,quat), 174.1 (C=O). MS (ES, pos mode) m/z (%): 234 (100) [M + H]+, 235 
(15). HRMS: calcd. for C14H20NO2+ [MH]+ 234.1489; found: 234.1487. 
5.2.18 Synthesis of (2R,3S)-cis-methyl 1-benzyl-2-phenylpiperidine-3-carboxylate 358 
To a solution of (2R,3S)-cis-methyl 2-phenylpiperidine-3-carboxylate 356a (0.18 g, 0.84 mmol) in 
dry THF (10 mL), Et3N (1.1 equiv, 0.09 g, 0.92 mmol) and benzylbromide (1.0 equiv, 0.14 g, 0.84 
mmol) were added at 0 oC. The reaction mixture was stirred at room temperature for 18 hours. 
Subsequently, the reaction mixture was quenched with 1M HCl (1 mL), and 10 mL H2O was added, 
followed by extraction with Et2O (3 x 10 mL). The organic phases were combined and washed with 
NaHCO3 (2 x 10 mL) and brine (1 x 10 mL), then dried (MgSO4). Filtration, evaporation of the 
solvent in vacuo and purification via column chromatography afforded (2R,3S)-cis-358. 
Rf = 0.49 (PE/Et2O 2/1). Pale yellow oil, yield 33%. [α]D +40.9 (c 0.2, CHCl3). IR 
(cm-1): νmax 1255 1731. 1H NMR (400 MHz, CDCl3): δ 1.52-1.62 (1H, m, 
CH(H)CH2N), 1.70-1.81 (1H, m, CH(H)CH2CH2N), 2.00-2.10 (1H, m, 
CH(H)CH2CH2N), 2.11-2.24 (2H, m, CH(H)CH(H)N), 2.92-2.98 (1H, m, CHC=O), 
2.98-3.04 (1H, m, CH2CH(H)N), 3.12 (1H, d, J = 14.3 Hz, CH(H)Ph), 3.36 (3H, s, OCH3), 3.73 (1H, 
d, J = 14.3 Hz, CH(H)Ph), 3.75 (1H, J = 5.6 Hz, NCHPh), 7.19-7.40 (10H, m, CHarom). 13C NMR 
(100.6 MHz, CDCl3): δ 22.3 (CH2CH2N), 25.2 (CH2CH2CH2N), 46.6 (CHC=O), 50.6 (CH2N), 50.9 
(OCH3), 59.4 (CH2Ph), 66.9 (NCHPh), 126.7 (CHarom), 127.3 (CHarom), 128.1 (4CHarom), 128.5 
(4CHarom), 139.3 (Carom,quat), 140.8 (Carom,quat), 173.5 (C=O). MS (ES, pos mode) m/z: 310 (100) [M + 





5.2.19 Synthesis of (2R,3R)-trans-methyl 1-benzyl-2-phenylpiperidine-3-carboxylate 
359 
To a solution of (2R,3S)-cis-methyl 1-benzyl-2-phenylpiperidine-3-carboxylate 358 (0.10 g, 0.32 
mmol) in dry THF (5 mL), potassium tert-butoxide (0.32 mmol, 0.32 mL of a 1 M solution in THF) 
and tert-butyl acetate (10 mmol, 3.2 mL) were added at room temperature. The reaction mixture was 
stirred for 48 hours at ambient temperature under nitrogen flow and subsequently was passed through 
a plug of silica gel and washed with THF followed by ethyl acetate. The eluent was evaporated and 
the crude mixture was purified by thin layer chromatography, affording trans-359. 
Rf = 0.16 (PE/Et2O 9/1). Pale yellow oil, yield 43%. [α]D -10.5 (c 0.3, CHCl3). IR 
(cm-1): νmax 1254, 1732. 1H NMR (400 MHz, CDCl3): δ 1.59-1.73 (3H, m, 
CH(H)CH(H)CH2N), 1.97-2.07 (2H, m, CH(H)CH2CH(H)N), 2.66-2.75 (1H, m, 
CHC=O), 2.82 (1H, d, J = 13.7 Hz, CH(H)Ph), 2.92-3.00 (1H, m, CH(H)N), 3.36 
(3H, s, OCH3), 3.37 (1H, d, J = 10.1 Hz, NCHPh), 3.71 (1H, d, J = 13.7 Hz, CH(H)Ph), 7.17-7.47 
(10H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 24.7 (CH2CH2N), 28.7 (CH2CH2CH2N), 51.2 
(OCH3), 52.2 (CHC=O), 52.5 (CH2N), 59.2 (CH2Ph), 69.9 (NCHPh), 126.7 (CHarom), 127.5 (CHarom), 
128.1 (2CHarom), 128.2 (2CHarom), 128.4 (2CHarom), 128.6 (2CHarom), 139.5 (Carom,quat), 141.9 
(Carom,quat), 174.5 (C=O). MS (ES, pos mode) m/z: 310 (100) [M + H]+. HRMS: calcd for C20H24NO2+ 
[MH]+ 310.1802; found: 310.1809. 
5.2.20 Synthesis of α-bromo-α-fluoro-β-lactams 363 
The synthesis of 1-benzyl-3-bromo-3-fluoro-4-phenylazetidin-2-one 363a is representative. Ethyl 
dibromofluoroacetate 34 (1.86 g, 9.2 mmol) was added to a solution of imine 362a (0.6 g, 3.1 mmol) 
in Et2O (20 mL) at -10 °C and then 1M Et2Zn in hexane (3.0 equiv, 9.2 mL) was slowly added to the 
mixture at -10 °C. The resulting mixture was stirred at the same temperature for 1 hour. The reaction 
mixture was quenched with saturated aqueous NaHCO3 (9 mL), and the mixture was filtered through 
a Celite pad and the filter cake was rinsed with a small amount of EtOAc (10 mL). The filtrate was 
extracted with EtOAc (3 x 15 mL), and then the organic phase was washed with brine (2 x 20 mL) 
and dried over MgSO4. Filtration, removal of solvent in vacuo and purification via column 
chromatography afforded 1-benzyl-3-bromo-3-fluoro-4-phenylazetidin-2-one 363a in 57% yield.  
β-Lactams 363a-e are known compounds and all spectroscopic data were in good agreement with 
reported data.[204i] 
When imine 365a was used, only ethyl trans-1-benzyl-2-fluoro-3-methylaziridine-2-carboxylate 366 
was formed. When imine 365b was used, a mixture of cis-363f, syn-367 and cis-368 was formed. 
When aldimine 27a was used, diastereomeric mixture 370 was formed in a ratio 1/1. 




Rf = 0.18 (PE/Et2O 8/2). White crystals, yield 36%. Mp 73.2-74.2 oC. IR (cm-1): 
νmax 697, 756, 969, 1777. 1H NMR (400 MHz, CDCl3): δ 2.96 (2H, t, J = 7.1 Hz, 
NCH(H)CH(H)Ph), 3.18 (1H, dt, J = 14.1, 7.1 Hz, NCH(H)CH(H)Ph), 3.89 (1H, 
dt, J = 14.1, 7.1 Hz, NCH(H)CH(H)Ph), 4.63 (1H, d, J = 10.3 Hz, CHCF), 7.05-
7.17 (4H, m, CHarom), 7.23-7.45 (6H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): 
δ 33.6 (NCH2CH2Ph), 42.4 (NCH2CH2Ph), 70.8 (d, J = 25.0 Hz, CHPh), 106.3 (d, J = 299.4 Hz, CF), 
127.0 (CHarom), 127.8 (2 x CHarom), 128.6 (2 x CHarom), 128.7 (2 x CHarom), 128.8 (2 x CHarom), 129.7 
(CHarom), 132.4 (Carom,quat), 137.5 (Carom,quat), 161.3 (C=O, d, J = 25.6 Hz). 19F NMR (376.5 MHz, 
CDCl3): δ -117.2 (CFCH, d, J = 10.3 Hz). MS (ES, pos. mode): m/z (%): 348/350 (100) [M+H]+. 
HRMS: calcd for C17H16BrFNO+ [MH]+ 348.0394; found: 348.0398. 
syn-Ethyl 2-bromo-2-fluoro-3-(phenethylamino)-3-phenylpropanoate 367 
Rf = 0.37 (PE/Et2O 8/2). (syn-5g/ unidentified prod 81/19). Pale yellow oil, 
yield 15%. IR (cm-1): νmax 697, 1144, 1257, 1764, 3028. 1H NMR (400 MHz, 
CDCl3): δ 1.12 (3H, t, J = 7.1 Hz, OCH2CH3), 2.02 (1H, br s, NH), 2.73-2.85 
(4H, m, CH2CH2Ph), 4.04-4.17 (2H, m, OCH2CH3), 4.33 (1H, d, J = 23.1 Hz, 
CHCF), 7.11-7.37 (10H, m, 10 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 
13.7 (OCH2CH3), 36.2 (NCH2CH2Ph), 48.8 (NCH2CH2Ph), 62.9 (OCH2CH3), 68.9 (CHCF, d, J = 
17.2 Hz), 100.8 (CHCF, d, J = 274.1 Hz), 126.2 (CHarom), 128.4 (2 x CHarom), 128.5 (2 x CHarom), 
128.7 (2 x CHarom), 128.8 (CHarom), 129.1 (2 x CHarom), 135.3, (Carom,quat) 139.6 (Carom,quat), 165.1 
(C=O, d, J = 25.8 Hz). 19F NMR (376.5 MHz, CDCl3): δ -127.7 (1F, d, J = 23.1 Hz, CHCF). MS 
(ES, pos. mode): m/z (%): 394/396 (100) [M+H]+. HRMS: calcd for C19H22BrFNO2+ [MH]+ 
394.0813; found: 394.0817. 
trans-Ethyl 1-benzyl-2-fluoro-3-methylaziridine-2-carboxylate 366 
Rf = 0.59 (PE/Et2O 6/1). Yellow oil, yield 37 %, purity 94%. IR (cm-1): νmax 649, 
1105, 1257, 1762. 1H NMR (400 MHz, CDCl3): δ 1.29-1.31 (6H, m, CH3CH2O 
and CH3CH), 2.32-2.44 (1H, m, CH3CH), 3.89 (1H, d, J = 13.8 Hz, CH(H)Ph), 
3.99 (1H, d, J = 13.8 Hz, CH(H)Ph), 4.25-4.36 (2H, m, CH3CH2O), 7.23-7.38 (5H, 
m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 14.1 (2C, CH3CH2O and CH3CH), 44.9 (CH3CH, d, J 
= 17.5 Hz), 52.9 (CH2Ph), 62.2 (CH3CH2O), 85.3 (CF, d, J = 257.4 Hz), 127.2 (CHarom), 127.8 (2 x 
CHarom), 128.4 (2 x CHarom), 138.0 (Carom,quat), 166 (C=O, d, J = 34.6 Hz). 19F NMR (376.5 MHz, 
CDCl3): δ -119.07 (1F, d, J = 11.1 Hz, CFCOOEt). MS (ES, pos. mode): m/z (%): 238 (100) [M+H]+. 





cis-Ethyl 2-fluoro-1-phenethyl-3-phenylaziridine-2-carboxylate 368 
Rf = 0.46 (PE/Et2O 8/2). Yellow oil, yield 11%. IR (cm-1): νmax 696, 1139, 1289, 
1703, 1732. 1H NMR (400 MHz, CDCl3): δ 1.34 (3H, t, J = 7.1 Hz, OCH2CH3), 
2.90 (2H, m, CH2CH2Ph), 3.03-3.12 (1H, m, CH(H)CH2Ph), 3.15-3.24 (1H, m, 
CH(H)CH2Ph), 4.37 (1H, d, J = 4.4 Hz, CHCF), 4.23-4.36 (2H, m, OCH2CH3), 
7.14-7.40 (10H, m, 10 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 14.2 
(OCH2CH3), 36.0 (NCH2CH2Ph), 51.2 (CHCF, d, J = 12.3 Hz), 52.8 (NCH2CH2Ph), 62.5 
(OCH2CH3), 84.8 (CHCF, d, J = 253.9 Hz), 126.3 (CHarom), 127.8 (2 x CHarom), 128.0 (CHarom), 128.1 
(2 x CHarom), 128.4 (2 x CHarom), 128.9 (2 x CHarom), 133.7 (Carom,quat) 139.1 (Carom,quat), 165.2 (C=O, 
d, J = 35.9 Hz). 19F NMR (376.5 MHz, CDCl3): δ -68.8 (1F, d, J = 4.4 Hz, CHCF). MS (ES, pos. 
mode): m/z (%): 294 (100) [M-F]-. HRMS: calcd for C19H21FNO2+ [MH]+ 314.1551; found: 
314.1553. 
Ethyl 2-bromo-2-fluoro-3-((4-methylphenyl)sulfonamido)-3-phenylpropanoate 370 
Spectral data were obtained from a mixture of two diastereomers in a 1/1 ratio 
Rf = 0.30 (PE/Et2O 1/1). Yellow amorphous solid, yield 65%. IR (cm-1): νmax 
700, 921, 1146, 1160, 1254, 1328, 1458, 1463, 1763, 3239. 1H NMR (400 MHz, 
CDCl3): δ 1.11 (3H, t, J = 7.1 Hz, OCH2CH3,isomer 1), 1.36 (3H, t, J = 7.1 Hz, 
OCH2CH3,isomer 2), 2.30 (3H, s, CH3 isomer 1, Tos), 2.31 (3H, s, CH3 isomer 2, Tos), 4.02-4.16 (2H, m, 
OCH2CH3 isomer 1), 4.28-4.37 (2H, m, OCH2CH3 isomer 2), 5.10 (1H, dd, J = 24.3, 9.3 Hz, CHCFisomer 1), 
5.11 (1H, dd, J = 22.3, 10.7 Hz, CHCFisomer 2), 5.60 (1H, d, J = 9.3 Hz, NHCHisomer 1), 5.70 (1H, d, J 
= 10.7 Hz, NHCHisomer 2), 6.99-7.28 (14H, m, 7 x CHarom,isomer 1 and 7 x CHarom,isomer 2), 7.44 (2H, 2 x 
CHarom,isomer 1), 7.53 (2H, 2 x CHarom,isomer 2). 13C NMR (100.6 MHz, CDCl3): δ 13.6 (OCH2CH3 isomer 
1), 13.8 (OCH2CH3 isomer 2), 21.4 (2 x CH3 isomer 1 and 2, Tos), 63.4 (OCH2CH3 isomer 1), 63.8 (OCH2CH3 
isomer 2), 64.0 (CHPhisomer 1, d, J = 20.8 Hz), 64.3 (CHPhisomer 1, d, J = 17.7 Hz), 97.4 (CHCFisomer 1, d, J 
= 268.7 Hz), 97.4 (CHCFisomer 2, d, J = 270.4 Hz), 127.0 and 127.1 (2 x CHarom, isomer 1 and 2), 128.3 (2 x 
CHarom, isomer 1 and 2), 128.5 (4 x CHarom, isomer 1 and 2), 128.7 (4 x CHarom, isomer 1 and 2), 129.0 (2 x CHarom, isomer 
1 and 2), 129.3 (4 x CHarom, isomer 1 and 2), 133.2 (2 x Carom,quat, isomer 1 and 2), 136.7 and 137.1 (2 x Carom,quat 
isomer 1 and 2), 143.4 (2 x Carom,quat, isomer 1 and 2), 164.0 (C=Oisomer 1, d, J = 28.8 Hz), 164.9 (C=Oisomer 2, d, J 
= 27.5 Hz). 19F NMR (376.5 MHz, CDCl3): δ -129.3 (1F, d, J = 24.3 Hz, CHCFisomer 1), -131 (1F, d, 
J = 22.3 Hz, CHCFisomer 2). MS (ES, pos. mode): m/z (%): 461/463 (100) [M+NH4]+. 
5.2.21 Synthesis of 2-fluoro-3-phenyl-1-tosylaziridine-2-carboxylates 371 and 372 
To a solution of ethyl 2-bromo-2-fluoro-3-((4-methylphenyl)sulfonamido)-3-phenylpropanoate 370 
(122.6 mg, 0.28 mmol) in CH3CN (10 mL), K2CO3 (3.0 equiv, 115.9 mg, 0.84 mmol) was added in 
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one portion. The reaction mixture was stirred for 1 hour at room temperature. Then, the solvent was 
removed in vacuo and EtOAc was added to the residue, followed by filtration. The filter cake was 
rinsed with a small amount of EtOAc and the solvents were removed in vacuo. Purification of the 
crude mixture via column chromatography afforded a mixture of 371/372 in overall yield of 30%. 
Ethyl 2-fluoro-3-phenyl-1-tosylaziridine-2-carboxylates cis-371 and trans-372 
Yellow oil, yield 12% (mixture trans/cis 34/66) and 18% (mixture trans/cis 
97/3). trans-372: Rf = 0.37 (PE/Et2O 6/4). IR (cm-1): νmax 760, 957, 1163, 1339, 
1748. 1H NMR (400 MHz, CDCl3): δ 0.99 (3H, t, J = 7.1 Hz, OCH2CH3), 2.46 
(3H, s, CH3 in Tos), 3.98-4.14 (2H, m, OCH2CH3), 4.54 (1H, d, J = 8.1 Hz, 
CHPh), 7.19-7.31 (5H, m, 5 x CHarom), 7.36 (2H, d, J = 8.2 Hz, 2 x CHarom), 7.93 
(2H, d, J = 8.2 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 13.6 
(OCH2CH3), 21.7 (CH3, Tos), 50.8 (CHPh, d, J = 19.3 Hz), 62.8 (OCH2CH3), 
84.6 (CF, d, J = 276.0 Hz), 127.2 (2 x CHarom), 128.2 (2 x CHarom), 128.3 (2 x CHarom), 128.9 (CHarom), 
129.6 (Carom,quat), 129.9 (2 x CHarom), 135.2 (Carom,quat), 145.4 (Carom,quat), 160.9 (C=O, d, J = 34.2 Hz). 
19F NMR (376.5 MHz, CDCl3): δ -165.3 (1F, d, J = 8.1 Hz, CF). MS (ES, pos. mode): m/z (%): 364 
(100) [M+H]+. HRMS: calcd for C18H19FNO4S+ [MH]+ 364.1013; found: 364.1017. 
cis-371: Rf = 0.40 (PE/Et2O 6/4). IR (cm-1): νmax 760, 957, 1163, 1339, 1748. 1H NMR (400 MHz, 
CDCl3): δ 1.44 (3H, t, J = 7.2 Hz, OCH2CH3), 2.43 (3H, s, CH3 in Tos), 4.41-4.52 (2H, m, OCH2CH3), 
4.87 (1H, d, J = 2.5 Hz, CHPh), 7.20-7.38 (5H, m, 5 x CHarom), 7.33 (2H, d, J = 8.4 Hz, 2 x CHarom), 
7.84 (2H, d, J = 8.4 Hz, 2 x CHarom). 13C NMR (100.6 MHz, CDCl3): δ 13.9 (OCH2CH3), 21.7 (CH3, 
Tos), 52.2 (CHPh, d, J = 19.3 Hz), 63.8 (OCH2CH3), 82.9 (CF, d, J = 269.1 Hz), 127.3 (2 x CHarom), 
127.7 (CHarom), 128.5 (2 x CHarom), 128.9 (CHarom), 129.2 (CHarom), 129.7 (Carom,quat), 129.8 (2 x 
CHarom), 137.1 (Carom,quat), 144.8 (Carom,quat), 162.3 (C=O, d, J = 35.3 Hz). 19F NMR (376.5 MHz, 
CDCl3): δ -161.1 (1F, d, J = 2.5 Hz, CF). MS (ES, pos. mode): m/z (%): 364 (100) [M+H]+. HRMS: 
calcd for C18H19FNO4S+ [MH]+ 364.1013; found: 364.1017. 
5.2.22 Synthesis of 1-benzyl-3-fluoro-3-iodo-4-phenylazetidin-2-ones 387 
To a solution of 3-fluoro-2-azetidin-2-one 386 (0.39 g, 1.5 mmol) in THF (8 mL), a 1M solution of 
LiHMDS in hexanes (2.0 equiv, 3.1 mL) was added dropwise at -78 °C and the reaction mixture was 
stirred at the same temperature for 45 min. Then, a solution of iodine (1.1 equiv, 0.43 g, 1.7 mmol) 
in THF (4 mL) was added slowly to the reaction mixture. The resulting mixture was stirred at -78 °C 
for 1 h and subsequently quenched with aqueous NH4Cl. The reaction mixture was poured into an 
aqueous saturated NaHCO3 and extracted with Et2O (3 x 10 mL). The organic phase was washed 
with brine (2 x 5 mL) and dried over MgSO4. Filtration, removal of the solvent in vacuo, and 




The side product trans-1-benzyl-3-fluoro-4-phenylazetidin-2-one 388, which is an isomer of starting 
cis-386, was isolated in 15% yield. 
trans- and cis-1-Benzyl-3-fluoro-3-iodo-4-phenylazetidin-2-ones 387 
Spectral data were obtained from a mixture of two diastereomers in 85/15 ratio. 
Rf = 0.40 (PE/Et2O 7/3). Yellow amorphous solid, yield 31%. IR (cm-1): νmax 696, 
1771. trans-387: 1H NMR (400 MHz, CDCl3): δ 3.91 (1H, d, J = 14.8 Hz, 
CH(H)Ph), 4.91 (1H, d, J = 14.8 Hz, CH(H)Ph), 4.95 (1H, d, J = 2.8 Hz, CHPh), 
7.08-7.48 (10H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 44.3 (CH2Ph), 
74.3 (CHPh, d, J = 23.2 Hz), 79.44 (CF, d, J = 311.9 Hz), 128.1 (CHarom), 128.4 
(4 x CHarom), 129.1 (4 x CHarom), 129.9 (CHarom), 130.9 (Carom,quat), 133.3 (Carom, 
quat), 162.3 (C=O, d, J = 24.2 Hz). 19F NMR (376.5 MHz, CDCl3): δ -130.71 
(CHCF, d, J = 2.8 Hz). MS (ES, pos. mode): m/z (%): 382 (100) [M+H]+. HRMS: 
calcd for C16H14FINO+ [MH]+ 382.0099; found: 382.0111. 
cis-387: 1H NMR (400 MHz, CDCl3): δ 3.89 (1H, d, J = 14.8 Hz, CH(H)Ph), 4.63 (1H, d, J = 11.4 
Hz, CHPh), 4.97 (1H, d, J = 14.8 Hz, CH(H)Ph), 7.08-7.48 (10H, m, CHarom). 13C NMR (100.6 MHz, 
CDCl3): δ 45.1 (CH2Ph), 69.4 (CHPh, d, J = 24.7 Hz), 90.67 (CF, d, J = 301.1 Hz), 127.6 (CHarom), 
128.4 (2 x CHarom), 128.7 (2 x CHarom), 128.9 (2 x CHarom), 129.1 (2 x CHarom), 129.8 (CHarom), 133.5 
(Carom,quat), 134.3 (Carom,quat), 162.2 (C=O, d, J = 24.3 Hz). 19F NMR (376.5 MHz, CDCl3): δ -118.4 
(CHCF, d, J = 11.4 Hz). MS (ES, pos. mode): m/z (%): 382 (100) [M+H]+. HRMS: calcd for 
C16H14FINO+ [MH]+ 382.0099; found: 382.0111. 
trans-1-Benzyl-3-fluoro-4-phenylazetidin-2-one 388 
Rf = 0.25 (PE/Et2O 7/3). Yellow oil, yield 15%. IR (cm-1): νmax 720, 1766. 1H NMR 
(400 MHz, CDCl3): δ 3.78 (1H, d, J = 14.9 Hz, CH(H)Ph), 4.47 (1H, d, J = 11.0 Hz, 
CHCHF), 4.88 (1H, d, J = 14.9 Hz, CH(H)Ph), 5.24 (1H, d, J = 54.2 Hz, CHCHF), 
7.10-7.22 (4H, m, 4 x CHarom), 7.27-7.44 (6H, m, 6 x CHarom). 13C NMR (100.6 MHz, 
CDCl3): δ 44.5 (CH2Ph), 62.5 (CHCHF, d, J = 24.0 Hz), 97.9 (CHF, d, J = 226.1 Hz), 126.8 (2 x 
CHarom), 128.1 (CHarom), 128.6 (2 x CHarom), 128.9 (2 x CHarom), 129.2 (2 x CHarom), 129.3 (CHarom), 
134.2 (Carom,quat), 134.3 (Carom,quat), 163.6 (C=O, d, J = 22.8 Hz). 19F NMR (376.5 MHz, CDCl3): δ -
189.5 (1F, d x d, J = 54.5, 11.0 Hz, CHF). MS (ES, pos. mode): m/z (%): 256 (100) [M+H]+. HRMS: 
calcd for C19H21FNO2+ [MH]+ 256.1132; found: 256.1136. 
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5.2.23 Synthesis of cis-3-bromo-3-fluoro-2-phenylazetidines 373 and trans-1-benzyl-3-
fluoro-3-iodo-2-phenylazetidine 383 
The synthesis of 3-bromo-3-fluoro-2-phenylazetidine 373a is representative. To a solution of 
aluminium(III) chloride (3.0 equiv, 0.12 g, 0.90 mmol) in 5 mL of dry Et2O was added lithium 
aluminium hydride (3.0 equiv, 0.03 g, 0.90 mmol) at 0 °C. The reaction mixture was stirred for 10 
minutes at 0 °C and was subsequently refluxed during 30 minutes. 1-Benzyl-3-bromo-3-fluoro-4-
phenylazetidin-2-one 363a (0.10 g, 0.30 mmol) in 4 mL of dry Et2O was added dropwise, and after 
the addition was complete, reflux was maintained during 4 hours. The reaction was cooled to 0 °C 
and 8 mL of water was carefully added. The aqueous phase was extracted with EtOAc (3 x 10 mL) 
and the combined organic phases were dried over MgSO4. Filtration, evaporation of solvent and 
recrystallization of the crude mixture afforded pure cis-1-benzyl-3-bromo-3-fluoro-2-
phenylazetidine 373a in 98% yield. The reaction time was shortened to 2 hours for the synthesis of 
azetidine 383. The crude oils were purified via column chromatography. 
cis-1-Benzyl-3-bromo-3-fluoro-2-phenylazetidine 373a 
Rf = 0.44 (PE/Et2O 9/1). White crystals, yield 98%. Mp 48.5-49.5 oC. IR (cm-1): 
νmax 696, 1219, 1450. 1H NMR (300 MHz, CDCl3): δ 3.43-3.62 (1H, m, 
CH(H)CFBr), 3.52 (1H, d, J = 13.1 Hz, CH(H)Ph), 3.91 (1H, t, J = 8.8 Hz, 
CH(H)CFBr), 4.02 (1H, d, J = 13.1 Hz, CH(H)Ph), 4.52 (1H, d, J = 20.2 Hz, CHN), 
7.18-7.60 (10H, m, CHarom). 13C NMR (75 MHz, CDCl3): δ 60.3 (CH2Ph), 68.1 
(CH2CFBr, d, J = 19.6 Hz), 80.4 (CHN, d, J = 20.8 Hz), 102.5 (CFBr, d, J = 291.9 Hz), 127.6 
(CHarom), 127.7 (2 x CHarom), 128.4 (2 x CHarom), 128.6 (2 x CHarom), 128.7 (CHarom), 128.8 (2 x 
CHarom), 136.8 (Carom,quat), 137.0 (Carom,quat). 19F NMR (282 MHz, CDCl3): δ -90.53 (1F, td, J = 20.2, 
8.8 Hz, CBrF). MS (ES, pos. mode): m/z (%): 320/322 (100) [M+H]+. HRMS: calcd for 
C16H16BrFN+ [MH]+ 320.0444; found: 320.0454. 
cis-1-Benzyl-3-bromo-3-fluoro-2-(4-methoxyphenyl)azetidine 373b 
Rf = 0.29 (PE/Et2O 9/1). White crystals, yield 95%. Mp 50.3-51.3 oC. IR (cm-1): 
νmax 696, 1219, 1450. 1H NMR (300 MHz, CDCl3): δ 3.49-3.58 (1H, m, 
CH(H)CFBr), 3.49 (1H, d, J = 13.2 Hz, CH(H)Ph), 3.83 (3H, s, OMe), 3.88 (1H, 
t, J = 8.8 Hz, CH(H)CFBr), 3.88 (1H, d, J = 13.2 Hz, CH(H)Ph), 4.44 (1H, d, J 
= 20.0 Hz, CHN), 6.93 (2H, d, J = 8.6 Hz, CHarom), 7.26-7.36 (5H, m, CHarom), 
7.41 (2H, d, J = 8.6 Hz, CHarom). 13C NMR (75 MHz, CDCl3): δ 55.4 (OCH3), 60.1 (CH2Ph), 67.9 
(CH2CFBr, d, J = 18.5 Hz), 80.1 (CHN, d, J = 20.8 Hz), 103.3 (CFBr, d, J = 290.8 Hz), 113.7 (2 x 
CHarom), 127.6 (CHarom), 128.6 (2 x CHarom), 128.8 (2 x CHarom), 129.1 (3 x CHarom), 136.9 (Carom,quat), 




pos. mode): m/z (%): 350/352 (100) [M+H]+. HRMS: calcd for C17H18BrFNO+ [MH]+ 350.0550; 
found: 350.0547. 
cis-1-Benzyl-3-bromo-2-(4-chlorophenyl)-3-fluoroazetidine 373c 
Rf = 0.35 (PE/Et2O 9/1). White cryst, yield 98%. Mp 68.5-69.5 oC. IR (cm-1): νmax 
697, 1222, 1488. 1H NMR (400 MHz, CDCl3): δ 3.54 (1H, d, J = 13.1 Hz, 
CH(H)Ph), 3.58 (1H, dd, J = 20.8, 9.0 Hz, CH(H)CFBr), 3.90 (1H, t, J = 9.0 Hz, 
CH(H)CFBr), 3.96 (1H, d, J = 13.1 Hz, CH(H)Ph), 4.47 (1H, J = 20.8 Hz, CHN), 
7.24-7.42 (9H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 60.2 (CH2Ph), 68.0 
(CH2CFBr, d, J = 19.2 Hz), 79.7 (CHN, d, J = 20.7 Hz), 102.0 (CF, d, J = 292.1 Hz), 127.7 (CHarom), 
128.5 (4 x CHarom), 128.8 (2 x CHarom), 129.0 (2 x CHarom), 134.4 (Carom,quat), 135.4 (Carom,quat), 136.4 
(Carom,quat). 19F NMR (376.5 MHz, CDCl3): δ -90.70 (1F, td, J = 20.8, 9.0 Hz, CBrF). MS (ES, pos. 
mode): m/z (%): 354/356/358 (100) [M+H]+. HRMS: calcd for C16H15BrClFN+ [MH]+ 354.0055; 
found: 354.0055. 
cis-1-Benzyl-3-bromo-3-fluoro-2-(4-(trifluoromethyl)phenyl)azetidine 373d 
Rf = 0.60 (PE/Et2O 9/1). White crystals, yield 85%. Mp 55.0-56.0 oC. IR (cm-
1): νmax 747, 1094, 1323. 1H NMR (400 MHz, CDCl3): δ 3.58 (1H, d, J = 13.0 
Hz, CH(H)Ph), 3.63 (1H, dd, J = 20.4, 9.5 Hz, CH(H)CFBr), 3.94 (1H, t, J = 9.5 
Hz, CH(H)CFBr), 3.98 (1H, d, J = 13.0 Hz, CH(H)Ph), 4.57 (1H, J = 20.4 Hz, 
CHPh), 7.26-7.36 (5H, m, CHarom), 7.57 (2H, d, J = 8.3 Hz, CHarom), 7.65 (2H, 
d, J = 8.3 Hz, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 60.3 (CH2Ph), 68.1 (CH2CFBr, d, J = 19.2 
Hz), 79.8 (CHN, d, J = 20.8 Hz), 101.4 (CF, d, J = 292.4 Hz), 124.2 (CF3, q, J = 272.1 Hz), 125.3 (2 
x CF3CCH, q, J = 3.8 Hz), 127.6 (CHarom), 128.0 (2 x CHarom), 128.6 (2 x CHarom), 128.8 (2 x CHarom), 
130.7 (CF3CCH, q, J = 32.4 Hz), 136.3 (Carom,quat), 140.8 (Carom,quat). 19F NMR (376.5 MHz, CDCl3): 
δ -90.58 (1F, td, J = 20.4, 9.5 Hz, CBrF), -62.48 (3F, s, CF3). MS (ES, pos. mode): m/z (%): 388/390 
(100) [M+H]+. HRMS: calcd for C17H15BrF4N+ [MH]+ 388.0319; found: 388.0320. 
cis-1-Benzhydryl-3-bromo-3-fluoro-2-phenylazetidine 373e 
Rf = 0.63 (PE/Et2O 9/1). White crystals, yield 87%. Mp 69.0-70.0 °C. IR (cm-1): 
νmax 697, 1207, 1491. 1H NMR (400 MHz, CDCl3): δ 3.57 (1H, dd, J = 21.7, 10.6 
Hz, CH(H)CF), 4.10 (1H, t, J = 10.6 Hz, CH(H)CF), 4.53 (1H, d, J = 21.7 Hz, 
CHPh), 4.71 (1H, s, CHPh2), 6.93-7.04 (3H, m, CHarom), 7.16-7.31 (8H, m, 
CHarom), 7.33-7.45 (4H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 68.0 
(CH2CF, d, J = 19.6 Hz), 75.4 (CHPh2), 80.0 (CHPh, d, J = 20.8 Hz), 103.3 (CF, d, J = 290.9 Hz), 
127.4 (CHarom), 127.5 (2 x CHarom), 127.6 (CHarom), 127.9 (2 x CHarom), 128.0 (2 x CHarom), 128.1 
(CHarom), 128.2 (2 x CHarom), 128.6 (2 x CHarom), 128.7 (2 x CHarom), 137.3 (Carom,quat), 140.1 
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(Carom,quat), 140.2 (Carom,quat). 19F NMR (376.5 MHz, CDCl3): δ -88.7 (1F, td, J = 21.7, 10.6 Hz, CBrF). 
MS (ES, pos. mode): m/z (%): 396/398 (100) [M+H]+. HRMS: calcd for C22H20BrFN+ [MH]+ 
396.0758; found: 396.0763. 
cis-3-Bromo-3-fluoro-1-phenethyl-2-phenylazetidine 373f 
Rf = 0.33 (PE/Et2O 9/1). Pale yellow oil, yield 92%. IR (cm-1): νmax 695, 1213, 
1486. 1H NMR (400 MHz, CDCl3): δ 2.69 (2H, t, J = 7.6 Hz, NCH(H)CH(H)Ph), 
2.73-2.81 (1H, m, NCH(H)CH(H)Ph), 2.92-3.00 (1H, m, NCH(H)CH(H)Ph), 3.54 
(1H, dd, J = 20.3, 9.0 Hz, CH(H)CF), 4.02 (1H, t, J = 9.0 Hz, CH(H)CF), 4.40 (1H, 
d, J = 20.3 Hz, CHPh), 7.12-7.28 (5H, m, CHarom), 7.32-7.39 (5H, m, CHarom). 13C 
NMR (100.6 MHz, CDCl3): δ 34.8 (NCH2CH2Ph), 59.1 (NCH2CH2Ph), 68.9 (CH2CFBr, d, J = 19.0 
Hz), 81.3 (CHPh, d, J = 19.9 Hz), 102.2 (CFBr, d, J = 292.1 Hz), 126.2 (CHarom), 127.5 (2 x CHarom), 
128.2 (2 x CHarom), 128.4 (2 x CHarom), 128.5 (CHarom), 128.6 (2 x CHarom), 137.2 (Carom,quat), 139.4 
(Carom,quat). 19F NMR (376.5 MHz, CDCl3): δ -89.96 (1F, td, J = 20.3, 9.0 Hz, CBrF). MS (ES, pos. 
mode): m/z (%): 334/336 (100) [M+H]+. HRMS: calcd for C17H18BrFN+ [MH]+ 334.0601; found: 
334.0606. 
trans-1-Benzyl-3-fluoro-3-iodo-2-phenylazetidine 383 
Spectral data were obtained from a mixture of trans/cis isomers in 96/4 ratio. 
Rf = 0.69 (PE/Et2O 8/2). Yellow oil, yield 78% (trans/cis 96/4). IR (cm-1): νmax 720, 
743, 1157, 1452. Trans-24: 1H NMR (400 MHz, CDCl3): δ 3.65 (1H, d, J = 12.9 
Hz, CH(H)Ph), 3.89 (1H, dd, J = 23.4, 9.8 Hz, CH(H)CF), 4.01 (1H, d, J = 12.9 Hz, 
CH(H)Ph), 4.19 (1H, dd, J = 15.7, 9.8 Hz, CH(H)CF), 5.09 (1H, d, J = 15.7 Hz, 
CHPh), 7.22-7.45 (10H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 60.9 
(CH2Ph), 70.4 (CH2CF, d, J = 22.0 Hz), 73.1 (CF, d, J = 292.4 Hz), 85.11 (CHCF, d, J = 20.7 Hz), 
127.5 (CHarom), 127.7 (2 x CHarom), 128.4 (2 x CHarom), 128.5 (2 x CHarom), 128.6 (2 x CHarom), 128.7 
(CHarom), 134.2 (Carom,quat), 137.0 (Carom,quat). 19F NMR (376.5 MHz, CDCl3): δ -120.53 (1F, dt, J = 
23.4, 15.7 Hz, CHF). MS (ES, pos. mode): m/z (%): 368 (100) [M+H]+. HRMS: calcd for 
C16H16FIN+[MH]+ 368.0306; found: 368.0317. 
5.2.24 Synthesis of syn-1-(benzylamino)-2-fluoro-1-phenylheptan-3-one 389 
To a solution of 1-benzyl-3-fluoro-4-phenylazetidin-2-one 386 (117.1 mg, 0.46 mmol) in THF (10 
mL) was added at -78 °C a 1.7M solution of n-butyllithium in hexanes (2 equiv, 0.53 mL) and the 
mixture was stirred at the same temperature for 45 minutes. The resulting mixture was added to a 
solution of iodine (1.1 equiv, 127.8 mg, 0.51 mmol) in THF (5 mL) at -78 °C. This mixture was 




NaHCO3 (10 mL) was added and the mixture was extracted with EtOAc (2 x 10 mL). The organic 
phase was washed with a saturated aqueous sodium thiosulfate (2 x 8 mL) and brine (10 mL). 
Filtration, evaporation of solvent, and purification by column chromatography afforded 1-
(benzylamino)-2-fluoro-1-phenylheptan-3-one 389 in 85% yield. 
syn-1-(Benzylamino)-2-fluoro-1-phenylheptan-3-one 389 
Rf = 0.56 (PE/Et2O 1/1). Yellow oil, yield 85%. IR (cm-1): νmax 710, 1065, 
1453, 1715, 3359. 1H NMR (400 MHz, CDCl3): δ 0.91 (3H, t, J = 7.3 Hz, 
CH3), 1.26 (1H, br. s, NH), 1.27-1.37 (2H, m, CH2CH3), 1.52-1.61 (2H, m, 
CH2CH2CH3), 2.46-2.64 (2H, m, CH2C=O), 3.47 (1H, d, J = 13.1 Hz, 
CH(H)Ph), 3.69 (1H, d, J = 13.1 Hz, CH(H)Ph), 4.11 (1H, dd, J = 28.3, 2.9 
Hz, CHNH), 4.79 (1H, dd, J = 49.2, 2.9 Hz, CHF), 7.17-7.43 (10H, m, CHarom). 13C NMR (100.6 
MHz, CDCl3): δ 13.9 (CH3), 22.2 (CH2CH3), 24.6 (CH2CH2CH3), 39.4 (CH2C=O), 50.9 (CH2Ph), 
63.0 (CHNH, d, J = 18.3 Hz), 98.5 (CHF, d, J = 191.6 Hz), 127.1 (CHarom), 121.7 (2 x CHarom), 128.0 
(CHarom), 128.2 (2 x CHarom), 128.3 (2 x CHarom), 128.8 (2 x CHarom), 138.4 (Carom,quat), 139.6 
(Carom,quat), 209.0 (C=O, d, J = 25.0 Hz). 19F NMR (376.5 MHz, CDCl3): δ -203.76 (1F, dd, J = 49.2, 
28.3 Hz, CHF). MS (ES, pos. mode): m/z (%): 314 (100) [M+H]+. HRMS: calcd for C20H25FNO+ 
[MH]+ 314.1915; found: 314.1927. 
5.2.25 Synthesis of 1-benzyl-3-fluoro-2-arylazetidine-2-carbonitriles 377 and 1-benzyl-
3,3-dimethoxy-2-arylazetidines 378 
The synthesis of 1-benzyl-3-fluoro-2-phenyl-2-carbonitrile 377a is representative. 
Method A. 
1-Benzyl-3-bromo-3-fluoro-2-phenylazetidine 373a (0.11 g, 0.34 mmol) was dissolved in dry 
DMSO (5 mL) and potassium cyanide (4.0 equiv, 0.09 g, 1.38 mmol) was added to the solution in 
one portion. The resulting mixture was heated at 100 °C and after completion of reaction (20 hours, 
TLC-monitoring) quenched with water (10 mL). This mixture was extracted with Et2O (3 x 5 mL). 
The combined organic phases were washed with brine (3 x 5 mL) and water (1 x 5 mL), and were 
dried over MgSO4. Filtration, evaporation of solvent and purification via column chromatography 
afforded 1-benzyl-3-fluoro-2-phenyl-2-carbonitrile 377a in 34% yield. 
Method B. 
In a microwave vial, 1-benzyl-3-bromo-3-fluoro-2-phenylazetidine 373a (0.20 g, 0.63 mmol) was 
dissolved in dry DMSO (6 mL) after which potassium cyanide (2.0 equiv, 0.08 g, 1.25 mmol) was 
added to the solution in one portion. The mixture was heated for 10 minutes at 125 °C with 
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microwave irradiation. After completion of the reaction (10 minutes, LC-MS monitoring), 10 mL of 
water was added and extracted with Et2O (3 x 10 mL). The organic phase was washed with brine (3 
x 5 mL) and water (1 x 5 mL), dried over MgSO4, and filtered. Removal of solvent in vacuo and 
purification via column chromatography afforded azetidine 377a in 24% yield. 
Method C. 
In a microwave vial, 1-benzyl-3-bromo-3-fluoro-2-phenylazetidine 373a (0.10 g, 0.31 mmol) was 
dissolved in dry MeOH (3 mL) and potassium cyanide (4.3 equiv, 0.09 g, 1.38 mmol) was added to 
the solution in one portion. The mixture was heated for 30 min at 100 °C with microwave irradiation. 
After completion of the reaction (30 minutes, LC-MS monitoring), MeOH was removed in vacuo 
and EtOAc (10 mL) was added to the resulting residue. The resulting suspension was filtered and the 
filter cake was rinsed with a small amount of EtOAc. Evaporation and purification of the crude 
mixture via preparative thin layer chromatography 377a and 378a in 46% and 37% yield, 
respectively. 
1-Benzyl-3-fluoro-2-phenyl-2-carbonitrile 377a 
Spectral data were obtained from a mixture of cis/trans isomers in 84/16 ratio. 
Rf = 0.51 (PE/Et2O 8/2). Yellow oil, yield 34% (method A), 24% (method B), 46% 
(method C). IR (cm-1): νmax 1180, 1359, 1449. 1H NMR (400 MHz, CDCl3): δ 
3.00-4.00 (4H, m, 2 x CH2CHFcis and trans, 2 x CH2Phcis and trans), 4.86 (1H, dt, J = 
54.5 Hz, 6.1 Hz, CHFcis), 5.29 (1H, dt, J = 55.6 Hz, 2.8 Hz, CHFtrans), 7.10-7.80 
(20H, m, 10 x CHarom,cis and 10 x CHarom,trans). 13C NMR (100.6 MHz, CDCl3): δ 
56.6 (CH2CFtrans, d, J = 23.1 Hz), 56.8 (CH2CFcis, d, J = 20.8 Hz), 57.1 (2 x 
CH2Phcis and trans), 72.0 (CCNtrans, d, J = 26.5 Hz), 72.2 (CCNcis, d, J = 18.5 Hz), 
87.9 (CFcis, d, J = 230.8 Hz), 88.8 (CFtrans, d, J = 223.8 Hz), 114.8 (CCNcis, d, J = 
6.9 Hz), 116.4 (CCNtrans, d, J = 5.8 Hz), 126.0, 127.5, 127.8, 128.6, 128.7, 128.8, 
129.1 and 129.7 (10 x CHarom,cis and trans), 135.3 (Carom,quat,cis and trans), 135.9 (Carom,quat,cis and trans). 19F NMR 
(376.5 MHz, CDCl3): δ -176.2 (1F, ddd, J = 55.3, 19.7, 7.9 Hz, CHFcis), -191.2 (1F, ddd, J = 55.3, 









Spectral data were obtained from a mixture of cis/trans isomers in 85/15 ratio. 
Rf = 0.54 (PE/Et2O 7/3). Yellow oil, yield 36%. IR (cm-1): νmax 696, 1174, 
1250, 1511, 1690. 1H NMR (400 MHz, CDCl3): δ 3.16-3.32 (1H, m, 
CH(H)CHFcis and trans), 3.42-3.54 (1H, m, CH(H)CHFtrans), 3.63 (1H, q, J = 6.6 
Hz, CH(H)CHFcis), 3.69 (1H, d, J = 12.8 Hz, CH(H)Phtrans), 3.71 (1H, d, J = 
12.7 Hz, CH(H)Phcis), 3.81 (3H, s, OCH3,trans), 3.83 (3H, s, OCH3,cis), 3.89 (1H, 
d, J = 12.8 Hz, CH(H)Phtrans), 3.91 (1H, d, J = 12.7 Hz, CH(H)Phcis), 4.82 (1H, 
dt, J = 55.2 Hz, 6.4 Hz, CHFcis), 5.25 (1H, dd, J = 55.3 Hz, 4.6 Hz, CHFtrans), 
6.91-6.99 (2H, m, 2 x CHarom,cis and trans), 7.22-7.49 (5H, m, 5 x CHarom,cis and trans), 
7.54-7.69 (2H, m, 2 x CHarom,cis and trans). 13C NMR (100.6 MHz, CDCl3): δ 55.3 
(OCH3, trans), 55.4 (OCH3,cis), 56.4 (CH2CFtrans, d, J = 23.4 Hz), 56.5 (CH2CFcis, d, J = 21.5 Hz), 56.7 
(CH2Phtrans), 56.8 (CH2Phcis), 71.6 (CCNtrans, d, J = 27.0 Hz), 74.8 (CCNcis, d, J = 17.9 Hz), 88.1 
(CHFcis, d, J = 222.1 Hz), 88.8 (CHFtrans, d, J = 230.3 Hz), 114.0 (2 x CHarom,trans), 114.3 (2 x 
CHarom,cis), 114.9 (CCNcis, d, J = 7.0 Hz), 116.4 (CCNtrans, d, J = 5.9 Hz), 127.2, 127.3, 127.6, 127.7, 
128.5, 128.7, 128.8 (7 x CHarom,cis and trans), 136.0 (Carom,quat,cis and trans), 160.7 (Carom,quat,cis and trans). 19F 
NMR (376.5 MHz, CDCl3): δ -176.7 (1F, ddd, J = 55.2, 17.9, 6.8 Hz, CHFcis), -192.2 (1F, ddd, J = 
55.3, 26.2, 20.1 Hz, CHFtrans). MS (ES, pos. mode): m/z (%): 314 (100) [M+NH4]+. 
1-Benzyl-3,3-dimethoxy-2-phenylazetidine 378a 
Rf = 0.24 (PE/Et2O 8/2). Colorless amorphous solid, yield 36%. IR (cm-1): νmax 
1046, 1239, 1508. 1H NMR (400 MHz, CDCl3): δ 2.88 (1H, d, J = 7.9 Hz, 
CH(H)C(OCH3)2), 2.96 (3H, s, OCH3), 3.23 (3H, s, OCH3), 3.46 (1H, d, J = 13.0 
Hz, CH(H)Ph), 3.55 (1H, d, J = 7.9 Hz, CH(H)C(OCH3)2), 3.91 (1H, d, J = 13.0 
Hz, CH(H)Ph), 4.22 (1H, s, CHPh), 7.17-7.59 (10H, m, 10 x CHarom). 13C NMR 
(100.6 MHz, CDCl3): δ 49.4 (OCH3), 49.7 (OCH3), 60.0 (CH2C(OCH3)2), 61.3 (NCH2Ph), 77.5 
(CHPh), 100.5 (CH2C(OCH3)2), 126.8 (CHarom), 127.7 (CHarom), 128.0 (2 x CHarom), 128.2 (2 x 










Rf = 0.27 (PE/Et2O 8/2). Colorless amorphous solid, yield 41% (method C). IR 
(cm-1): νmax 1031, 1245, 1510. 1H NMR (400 MHz, CDCl3): δ 2.86 (1H, d, J = 
8.0 Hz, CH(H)C(OCH3)2), 2.99 (3H, s, OCH3), 3.21 (3H, s, OCH3), 3.44 (1H, 
d, J = 13.2 Hz, CH(H)Ph), 3.53 (1H, d, J = 8.0 Hz, CH(H)C(OCH3)2), 3.81 
(3H, s, OCH3), 3.90 (1H, d, J = 13.2 Hz, CH(H)Ph), 4.15 (1H, s, CHN), 6.89 
(2H, d, J = 8.8 Hz, CHarom), 7.16-7.37 (5H, m, CHarom), 7.49 (2H, d, J = 8.8 Hz, CHarom). 13C NMR 
(100.6 MHz, CDCl3): δ 49.5 (OCH3), 49.8 (OCH3), 55.3 (OCH3), 59.9 (CH2C(OCH3)2), 61.3 
(NCH2Ph), 77.0 (NCH), 100.7 (CH2C(OCH3)2), 113.5 (2 x CHarom), 127.1 (CHarom), 128.3 (2 x 
CHarom), 128.8 (2 x CHarom), 129.7 (Carom,quat), 130.0 (2 x CHarom), 138.4 (Carom,quat), 159.3 (Carom,quat). 
MS (ES, pos. mode): m/z (%): 314 (100) [M+H]+. 
5.2.26 Synthesis of 1-benzyl-3-fluoro-2-arylazetidines 380 
The synthesis of 1-benzyl-3-fluoro-2-(4-methoxyphenyl)azetidine 380b is representative. To a 
solution of 1-benzyl-3-bromo-3-fluoro-2-(4-methoxyphenyl)azetidine 373b (50 mg, 0.14 mmoL) in 
THF (3 mL) was added at -90 °C a 1.4M solution of sec-butyllithium in cyclohexane (1.4 equiv, 0.14 
mL), and the reaction mixture was stirred at the same temperature for 30 min. Subsequently, 0.013 
mL of water (5.0 equiv) was added at -90 °C and the reaction was slowly warmed up to room 
temperature. Then, a saturated aqueous NH4Cl (1 mL) was added and the mixture was extracted with 
Et2O (3 x 5 mL). The organic phase was washed with brine (2 x 2 mL) and dried over MgSO4. 
Filtration, evaporation and purification by preparative thin layer chromatography afforded 1-benzyl-
3-fluoro-2-(4-methoxyphenyl)azetidine 380b in 27% yield. 
trans-1-Benzyl-3-fluoro-2-(4-methoxyphenyl)azetidine 380b 
Rf = 0.24 (PE/Et2O 4/1). Colorless oil, yield 27%. IR (cm-1): νmax 1086, 1248, 
1513. 1H NMR (400 MHz, CDCl3): δ 2.94 (1H, dt, J = 22.0, 7.3 Hz, CH(H)CHF), 
3.48 (1H, d, J = 12.8 Hz, CH(H)Ph), 3.64 (1H, q, J = 7.3 Hz, CH(H)CHF), 3.81 
(3H, s, OCH3), 3.93 (1H, d, J = 12.8 Hz, CH(H)Ph), 4.08 (1H, dd, J = 22.0, 7.3 
Hz, CHCHF), 4.78 (1H, dq, J = 57.1, 7.3 Hz, CHF), 6.89 (2H, d, J = 8.7 Hz, 2 x 
CHarom), 7.19-7.33 (5H, m, 5 x CHarom), 7.36 (2H, d, J = 8.7 Hz, 2 x CHarom). 13C NMR (100.6 MHz, 
CDCl3): δ 55.3 (OCH3), 57.5 (CH2CHF, d, J = 19.9 Hz), 61.6 (CH2Ph), 75.0 (CHCHF, d, J = 20.3 
Hz), 88.6 (CHF, d, J = 213.2 Hz), 113.9 (2 x CHarom), 127.2 (CHarom), 128.2 (2 x CHarom), 128.3 (2 x 
CHarom), 128.8 (2 x CHarom), 131.4 (Carom,quat), 137.4 (Carom,quat), 159.4 (Carom,quat). 19F NMR (376.5 
MHz, CDCl3): δ -176.1 (1F, dddd, J = 57.1, 22.0, 22.0, 7.3 Hz). MS (ES, pos. mode): m/z (%): 272 





Rf = 0.54 (PE/Et2O 4/1). Pale yellow oil, yield 30%. IR (cm-1): νmax 691, 1080, 
1250, 1514. 1H NMR (400 MHz, CDCl3): δ 2.97 (1H, dt, J = 22.1, 6.8 Hz, 
CH(H)CHF), 3.50 (1H, d, J = 12.8 Hz, CH(H)Ph), 3.60-3.69 (1H, m, CH(H)CHF), 
3.89 (1H, d, J = 12.8 Hz, CH(H)Ph), 4.11 (1H, dd, J = 22.1, 5.2 Hz, CHCHF), 
4.73 (1H, dq, J = 56.9, 5.7 Hz, CHF), 7.21-7.43 (9H, m, 9 x CHarom). 13C NMR 
(100.6 MHz, CDCl3): δ 57.7 (CH2CHF, d, J = 19.9 Hz), 61.8 (CH2Ph), 74.8 
(CHCHF, d, J = 20.4 Hz), 88.4 (CHF, d, J = 214.1 Hz), 127.3 (CHarom), 128.2 (2 x CHarom), 128.4 (2 
x CHarom), 128.6 (2 x CHarom), 128.8 (2 x CHarom), 133.6 (Carom,quat), 137.2 (Carom,quat), 137.9 (Carom,quat, 
d, J = 2.4 Hz). 19F NMR (376.5 MHz, CDCl3): δ -176.1 (1F, dddd, J = 56.9, 22.1, 22.1, 9.0 Hz). MS 
(ES, pos. mode): m/z (%): 276/278 (100) [M+H]+. 
trans-1-Benzyl-3-fluoro-2-(4-(trifluoromethyl)phenyl)azetidine 380d 
Rf = 0.57 (PE/Et2O 4/1). Colorless oil, yield 35%. IR (cm-1): νmax 1098, 1054, 
1245, 1511. 1H NMR (400 MHz, CDCl3): δ 3.02 (1H, dt, J = 22.1, 6.8 Hz, 
CH(H)CHF), 3.55 (1H, d, J = 12.8 Hz, CH(H)Ph), 3.65-3.72 (1H, m, CH(H)CHF), 
3.90 (1H, d, J = 12.8 Hz, CH(H)Ph), 4.22 (1H, dd, J = 22.1, 5.2 Hz, CHCHF), 
4.76 (1H, dq, J = 56.9, 5.7 Hz, CHF), 7.22-7.33 (5H, m, 5 x CHarom), 7.53 (2H, d, 
J = 8.3 Hz, 2 x CHarom), 7.60 (2H, d, J = 8.3 Hz, 2 x CHarom). 13C NMR (100.6 
MHz, CDCl3): δ 57.8 (CH2CHF, d, J = 19.9 Hz), 61.2 (CH2Ph), 74.8 (CHCHF, d, J = 20.4 Hz), 88.2 
(CHF, d, J = 214.6 Hz), 124.1 (CF3, q, J = 270.0 Hz), 125.4 (2 x CF3CCH, q, J = 3.8 Hz), 127.0 (2 x 
CHarom), 127.4 (CHarom), 128.4 (2 x CHarom), 128.8 (2 x CHarom), 130.1(CF3CCH, q, J = 32.3 Hz), 
137.0 (Carom,quat), 143.4 (Carom,quat). 19F NMR (376.5 MHz, CDCl3): δ -62.5 (3F, s, CF3), -176.1 (1F, 
dddd, J = 56.9, 22.1, 22.1, 9.4 Hz). MS (ES, pos. mode): m/z (%): 310 (100) [M+H]+. 
5.2.27 Synthesis of 3-(benzylamino)-2-fluoro-1-(4-methoxyphenyl)propan-1-one 382 
Sodium hydride (70 mg, 2.87 mmol, 60% dispersion in oil) was washed two times with 3 mL of 
pentane and evaporated to dryness. Dry DMSO (4 mL) was added and the mixture was stirred for 15 
min at room temperature to generate dimsyl sodium in DMSO. Then, 1-benzyl-3-bromo-3-fluoro-2-
(4-methoxyphenyl)azetidine 373b (500 mg, 1.43 mmol), dissolved in dry DMSO (5 mL), was added 
dropwise at room temperature. After the addition was completed, the mixture was stirred at 75 °C 
for 2 h. After cooling, 8 mL of water was added and the water phase was extracted with Et2O (3 x 8 
mL). The combined organic phases were dried over MgSO4 and after filtration, evaporation of the 
solvent and purification by chromatography, 3-(benzylamino)-2-fluoro-1-(4-
methoxyphenyl)propan-1-one 382 was isolated in 21% yield. 




Rf = 0.32 (PE/Et2O 2/1). Yellow oil, yield 21%, IR (cm-1): νmax 1027, 
1174, 1250, 1509, 1600, 1682, 3029. 1H NMR (300 MHz, CDCl3): δ 
3.16 (2H, dd, J = 25.3, 5.0 Hz, CH2CHF), 3.57-4.00 (3H, m, CH2Ph 
and NH), 3.89 (3H, s, OCH3), 5.72 (1H, dt, J = 49.5, 5.0 Hz, CHF), 6.93 (2H, d, J = 8.8 Hz, 2 x 
CHarom), 7.08-7.40 (5H, m, 5 x CHarom), 7.94 (2H, d, J = 8.8 Hz, 2 x CHarom). 13C NMR (75 MHz, 
CDCl3): δ 50.7 (CH2CF, d, J = 20.8 Hz), 53.6 (CH2Ph), 55.6 (OCH3), 93.3 (CF, d, J = 182.3 Hz), 
114.1 (2 x CHarom), 127.3 (CHarom), 128.2 (2 x CHarom), 128.6 (2 x CHarom), 131.2 (Carom,quat), 131.4 (2 
x CHarom), 139.6 (Carom,quat), 164.2 (Carom,quat), 194.0 (C=O, d, J = 18.5 Hz). 19F NMR (282 MHz, 
CDCl3): δ -192.23 (1F, dt, J = 49.5, 25.3 Hz, CH2CF). MS (ES, pos. mode): m/z (%): 288 (100) 
[M+H]+. 
5.2.28 Synthesis of alkyl dihydroxy(aminomethyl)propanoates 43 
The synthetic procedure is reported in a preliminary research.[50] For the synthesis of propanoate 43b, 
the reaction time was extended to 18 hours and purification was performed via column 
chromatography. CAUTION: vapors of osmium tetroxide (OsO4) are highly toxic; all work with 
osmium must be carried out in a well-ventilated fume hood. 
Ethyl 2,3-dihydroxy-2-[((4-methylbenzene)sulfonamido)methyl]propanoate 43a 
Yield 82%. Spectral data of ethyl 2,3-dihydroxy-2-[((4-
methylbenzene)sulfonamido)methyl]propanoate 43a corresponded with described data in the 
literature.[50] 
Methyl 2,3-dihydroxy-2-[(tert-butoxycarbonylamino)methyl]propanoate 43b 
Rf = 0.07 (PE/EtOAc 1/1). Colorless oil, yield 89%. IR (cm-1): νOH,NH = 3379, νC=O 
= 1710. 1H NMR (400 MHz, CDCl3): δ 1.43 (9H, s, tBu), 3.36 (1H, dd, J = 14.3, 
5.5 Hz, CH(H)NH), 3.52 (1H, dd, J = 14.3, 7.5 Hz, CH(H)NH), 3.66 (1H, dd, J = 
11.7, 5.6 Hz, CH(H)OH), 3.77 (1H, dd, J = 11.7, 8.2 Hz, CH(H)OH), 3.82 (3H, s, OCH3), 5.13 (1H, 
br s, J = 6.3, 5.0 Hz, NH). 13C NMR (100.6 MHz, CDCl3): δ 28.2 (3C, tBu), 44.3 (CH2NH), 53.1 
(OCH3), 65.1 (CH2OH), 78.3 (COH), 80.1 (C(CH3)3), 156.7 (C=O, Boc), 174.0 (C=O). MS (ES, pos. 






5.2.29 Synthesis of alkyl 2-(aminomethyl)oxirane-2-carboxylates 44 
Method A 
The synthetic procedure starting from aminodiols 43 is reported in a preliminary research.[50] For the 
synthesis of epoxide 44b a reaction time of 27 hours was applied. 
Method B 
The synthetic procedure starting from monomesylated aminodiols 400 is reported in preliminary 
research.[50] 
Ethyl 2-[((4-methylbenzene)sulfonamido)methyl]oxirane-2-carboxylate 44a 
Yield 80%. (Method B). Spectral data of ethyl 2-[((4-methylbenzene)sulfonamido)methyl]oxirane-
2-carboxylate 44a corresponded with described data in the literature.[50] 
Methyl 2-[(tert-butoxycarbonylamino)methyl]oxirane-2-carboxylate 44b 
Rf = 0.59 (PE/EtOAc 1/1). Colorless oil, yield 34% (Method A), yield 80% 
(Method B). IR (cm-1): νNH = 3385, νC=O = 1708. 1H NMR (400 MHz, CDCl3): 
δ 1.44 (9H, s, tBu), 2.94 (1H, d, J = 5.8 Hz, CH(H)O), 3.11 (1H, d, J = 5.8 Hz, CH(H)O), 3.57 (1H, 
dd, J = 14.9, 5.9 Hz, CH(H)NH), 3.78 (3H, s, OCH3), 3.76-3.86 (1H, m, CH(H)NH), 4.81 (1H, br s, 
NH). 13C NMR (100.6 MHz, CDCl3): δ 28.3 (3C, tBu), 40.3 (CH2NH), 50.2 (CH2O), 52.8 (OCH3), 
55.5 (CCH2), 79.8 (C(CH3)3), 155.8 (C=O, Boc), 169.9 (C=O). MS (ES, pos. mode): m/z (%): 176 
(100) [(M-C4H8)+H]+. HRMS: calcd for C5H10NO3+ [(M-Boc)+H]+ 132.0655; found: 132.0656. 
5.2.30 Synthesis of alkyl 2-aminomethyl-2-hydroxy-3-
(methanesulfonyloxy)propanoates 400 
The synthesis of ethyl 2-hydroxy-3-methanesulfonyloxy-2-[((4-
methylbenzene)sulfonamido)methyl]-propanoate 400a is representative. To a mixture of ethyl 2,3-
dihydroxy-2-[((4-methylbenzene)sulfonamido)methyl]propanoate 43a (107 mg, 0.34 mmol) and 
triethylamine (37 mg, 0.37 mmol) in dry THF (10 mL), a solution of methanesulfonyl chloride (46 
mg, 0.37 mmol) in dry THF (3 mL) was added dropwise at 0 °C under N2. The reaction mixture was 
stirred at room temperature for 6 hours. After completion, the resulting reaction mixture was 
quenched with water (5 mL) and extracted with EtOAc (3 × 10 mL). The combined organic extracts 
were washed with brine (2 × 5 mL) and water (5 mL). Drying (MgSO4), filtration, evaporation of the 
solvent under reduced pressure and purification by flash chromatography on silica gel (petroleum 
ether/Et2O 3/7) afforded pure compound 400a. 





Yield 97%. Spectral data of ethyl 2-hydroxy-3-methanesulfonyloxy-2-[((4-




Rf = 0.20 (PE/EtOAc 1/1). White crystals, yield 94%. Mp. 94.5-95.0 °C. IR (cm-
1): νOH,NH = 3426, νC=O = 1742, νC=O = 1693, νS=O = 1160. 1H NMR (400 MHz, 
CDCl3): δ 1.43 (9H, s, tBu), 3.06 (3H, s, SO3CH3), 3.37 (1H, dd, J = 14.2, 6.1 Hz, 
CH(H)NH), 3.57 (1H, dd, J = 14.2, 7.4 Hz, CH(H)NH), 3.85 (3H, s, OCH3), 4.04 (1H, br s, OH), 
4.34 (1H, d, J = 10.8 Hz, CH(H)OMs), 4.44 (1H, d, J = 10.8 Hz, CH(H)OMs), 4.90 (1H, br s, NH). 
13C NMR (100.6 MHz, CDCl3): δ 28.2 (3C, tBu), 37.8 (SO3CH3), 44.7 (CH2NH), 53.7 (OCH3), 71.0 
(CH2OMs), 77.2 (COH), 80.4 (C(CH3)3), 156.3 (C=O), 172.1 (C=O). MS (ES, pos. mode): m/z (%): 
228 (100) [(M-Boc)+H]+. HRMS: calcd for C6H14NO6S+ [(M-Boc)+H]+ 228.0536; found: 228.0536. 
5.2.31 Synthesis of methyl 3-amino-2-hydroxy-2-[(2,2,2-
trifluoroacetoxy)methyl]propanoate 401 
To a solution of methyl 2-[(tert-butoxycarbonyl)aminomethyl]-2-hydroxy-3-
(methylsulfonyloxy)propanoate 400b (147 mg, 0.45 mmol) in dry CH2Cl2 (2 mL) was slowly added 
trifluoroacetic acid (1 mL) at 0 ºC and then the reaction mixture was warmed up to room temperature. 
After 15 minutes, the reaction mixture was cooled down to 0 ºC, quenched by slowly adding aqueous 
saturated NaHCO3 and extracted with EtOAc (3 × 5 mL). After drying (Na2CO3), filtration and 
evaporation of the solvent under reduced pressure, the resulting crude product was dissolved in 
CH3CN and powdered K2CO3 (1.5 equiv, 93 mg, 0.66 mmol) was added in one portion. The resulting 
reaction mixture was stirred at 60 ºC for 2 h. Then the solvent was removed under reduced pressure 
and EtOAc was added. The resulting solution was filtered and the filter cake was washed with small 
portions of EtOAc. Evaporation of the solvent under reduced pressure afforded crude 401. 
Rf = 0.08 (EtOAc 100%). Pale yellow oil, yield 67% (crude). IR (cm-1): νNH 
= 3311, νC=O = 1667. 1H NMR (400 MHz, CD3OD): δ 3.51 (1H, d, J = 13.8 
Hz, CH(H)NH2), 3.61 (1H, d, J = 5.8 Hz, CH(H)O), 3.65 (1H, d, J = 13.8 Hz, 
CH(H)NH2), 3.75 (3H, s, OCH3), 3.73-3.78 (1H, m, CH(H)O). 13C NMR (100.6 MHz, CD3OD): δ 
43.2 (CH2NH), 51.8 (OCH3), 65.0 (CH2O), 77.8 (CCH2), 116.9 (CF3, q, J = 293.0 Hz), 161.7 




5.2.32 Synthesis of alkyl 2,3-bis-methanesulfonyloxy-2-(aminomethyl)propanoates 403 
The synthetic procedure is reported in a preliminary research.[50] 
For the synthesis of compound 403b dry THF was used instead of dry CH2Cl2. 
Ethyl 2,3-bis-methanesulfonyloxy-2-[((4-methylbenzene)sulfonamido)methyl]-propanoate 
403a 
Yield 27%. HRMS: calcd for C15H27N2O10S3+ [M+NH4]+ 491.0822; found: 491.0828. Spectral data 
of ethyl 2,3-bis-methanesulfonyloxy-2-[((4-methylbenzene)sulfonamido)methyl]-propanoate 403a 
corresponded with described data in the literature.[50] 
Methyl 2-[(tert-butoxycarbonylamino)methyl]-2,3-bis-(methanelsulfonyloxy)propanoate 403b 
Rf = 0.37 (PE/EtOAc 1/1). White crystals, yield 59%. Mp 104.5-106.0 oC. IR (cm-
1): νNH = 3417, νC=O = 1748, νC=O = 1712, νS=O = 1178. 1H NMR (400 MHz, 
CDCl3): δ 1.43 (9H, s, tBu), 3.12 (3H, s, SO3CH3), 3.27 (3H, s, SO3CH3), 3.68 
(1H, dd, J = 14.9, 6.5 Hz, CH(H)NH), 3.84 (3H, s, OCH3), 3.88 (1H, dd, J = 14.9, 7.4 Hz, CH(H)NH), 
4.70 (2H, s, CH(H)OMs), 5.03 (1H, br s, NH). 13C NMR (100.6 MHz, CDCl3): δ 28.2 (3C, tBu), 
37.7 (SO3CH3), 40.7 (SO3CH3), 43.3 (CH2NH), 53.7 (OCH3), 67.6 (CH2OMs), 80.4 (C(CH3)3), 86.3 
(COMs), 155.7 (C=O), 167.0 (C=O). MS (ES, pos. mode): m/z (%): 306 (100) [(M-Boc)+H]+. 
HRMS: calcd for C7H16NO8S2+ [(M-Boc)+H]+ 306.0312; found: 306.0333. 
5.2.33 Synthesis of ethyl 2-methanesulfonyloxymethyl-1-(4-
methylbenzenesulfonyl)aziridine-2-carboxylate 45a 
The synthetic procedure is reported in a preliminary research.[50] 
HRMS: calcd for C14H20NO7S2+ [MH]+ 378.0676; found: 378.0684. Spectral data of ethyl 2-
methanesulfonyloxymethyl-1-(4-methylbenzenesulfonyl)aziridine-2-carboxylate 45a corresponded 
with described data in the literature.[50] 
5.2.34 Synthesis of methyl 2-[(methanesulfonyloxy)methyl]aziridine-2-carboxylate 405 
To a solution of methyl 2-[(tert-butoxycarbonyl)aminomethyl)-2,3-bis-
(methanesulfonyloxy)propanoate 403b (70 mg, 0.17 mmol) in dry CH2Cl2 (1.5 mL) was slowly 
added trifluoroacetic acid (0.6 mL) at 0 ºC, and then the reaction mixture was warmed up to room 
temperature. After 15 minutes, the reaction mixture was cooled down to 0 ºC, quenched by slowly 
adding aqueous saturated NaHCO3 and extracted with EtOAc (3 × 5 mL). Drying (Na2CO3), filtration 
and evaporation of the solvent under reduced pressure afforded intermediate 404. Crude deprotected 
amine 404 was dissolved in CH3CN and powdered K2CO3 (3.0 equiv, 0.51 mmol, 70 mg) was added 
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in one portion. The resulting reaction mixture was stirred at 60 ºC for 1 h. Then the solvent was 
removed under reduced pressure and EtOAc (5 mL) was added. The resulting solution was filtered 
and the filter cake was washed with small portions of EtOAc. Evaporation of the solvent under 
reduced pressure and purification via preparative HPLC afforded compound 405 contaminated with 
starting material 404 (405/404 = 80/20).  
Rf = 0.10 (PE/EtOAc 1/9). Colorless oil, yield 34%. IR (cm-1): νNH = 3358, νC=O = 
1672, νS=O = 1174. 1H NMR (400 MHz, CD3OD): δ 2.00 (1H, s, CH(H)NH), 2.29 
(1H, s, CH(H)NH), 3.12 (3H, s, SO3CH3), 3.81 (3H, s, OCH3), 4.09 (1H, d, J = 11.0 Hz, CH(H)OMs), 
4.73 (1H, d, J = 11.0 Hz, CH(H)OMs). 13C NMR (100.6 MHz, CD3OD): δ 30.6 (CH2NH), 35.9 
(SO3CH3), 45.0 (CCH2), 52.2 (OCH3), 70.7 (CH2OMs), 170.7 (C=O). MS (ES, pos. mode): m/z (%): 
210 (100) [M+H]+. HRMS: calcd. for C6H12NO5S+ [MH]+ 210.0431; found: 210.0435. 
5.2.35 Synthesis of alkyl 2-aminomethyl-3-methanesulfonyloxy-2-
(trimethylsilanyloxy)propanoates 406 
The synthetic procedure is reported in a preliminary research.[50] 
Ethyl 3-methanesulfonyloxy-2-[((4-methylbenzene)sulfonamido)methyl]-2-(trimethyl-
silanyloxy)propanoate 406a 
Yield 90%. Spectral data of ethyl 3-methanesulfonyloxy-2-[((4-
methylbenzene)sulfonamido)methyl]-2-(trimethyl-silanyloxy)propanoate 406a corresponded with 
described data in the literature.[50] 
Methyl 2-[(tert-butoxycarbonylamino)methyl]-3-methanesulfonyloxy-2-(trimethylsilanyloxy) 
propanoate 406b 
Rf = 0.48 (PE/EtOAc 2/1). White crystals, yield 94%. Mp 90.3-91.3 oC. IR (cm-
1): νNH = 3351, νC=O = 1753, νC=O = 1691, νSi-C = 1249, νS=O = 1165. 1H NMR (400 
MHz, CDCl3): δ 0.19 (9H, s, Si(CH3)3), 1.44 (9H, s, tBu), 3.05 (3H, s, SO3CH3), 
3.47 (2H, d, J = 6.6 Hz, CH(H)NH), 3.79 (3H, s, OCH3), 4.30 (1H, d, J = 10.2 Hz, CH(H)OMs), 4.39 
(1H, d, J = 10.2 Hz, CH(H)OMs), 4.81 (1H, br s, NH). 13C NMR (100.6 MHz, CDCl3): δ 1.95 (3C, 
OTMS), 28.3 (3C, tBu), 37.5 (SO3CH3), 45.4 (CH2NH), 52.8 (OCH3), 70.9 (CH2OMs), 78.5 
(COTMS), 79.9 (C(CH3)3), 155.7 (C=O), 171.0 (C=O). MS (ES, pos. mode): m/z (%): 300 (100) 





5.2.36 Synthesis of ethyl 1-(4-methylbenzenesulfonyl)-3-
(trimethylsilanyloxy)azetidine-3-carboxylate 407a 
The synthetic procedure is reported in a preliminary research.[50] 
Yield 95%. Spectral data of ethyl 1-(4-methylbenzenesulfonyl)-3-(trimethylsilanyloxy)azetidine-3-
carboxylate 407a corresponded with described data in the literature.[50] 
5.2.37 Synthesis of ethyl 3-hydroxy-1-(4-methylbenzenesulfonyl)azetidine-3-
carboxylate 46a 
The synthetic procedure is reported in a preliminary research.[50] 
Yield 90%. Spectral data of ethyl 3-hydroxy-1-(4-methylbenzenesulfonyl)azetidine-3-carboxylate 
46a corresponded with described data in the literature.[50] 
5.2.38 Synthesis of ethyl 2-hydroxy-3-iodo-2-[((4-methylbenzene)sulfonamido)-
methyl]propanoate 409 
Triphenylphosphine (1.2 equiv, 0.40 mmol, 105 mg) and imidazole (1.2 equiv, 0.40 mmol, 27 mg) 
were dissolved in dry dichloromethane with stirring under nitrogen. Iodine (1.2 equiv, 0.40 mmol, 
102 mg) was added slowly and after 5 minutes a solution of the ethyl 3-hydroxy-1-(4-
methylbenzenesulfonyl)azetidine-3-carboxylate 46a (1 equiv, 0.33 mmol, 100 mg) in dry 
dichlorometane was added and the reaction mixture was stirred at room temperature for 48 hours. 
Then, the solvent was evaporated under reduced pressure. The residue was filtered through a short 
layer of silica gel eluting with ethyl acetate, and the filtrate was concentrated to give crude mixture 
of product 409 and 42a. Purification via column chromatography afforded the mixture of 409/42a in 
a ratio of 75/25. 
Spectral data were obtained from a mixture of 409/42a isomers in 75:25 ratio. 
Rf = 0.53 (PE/EtOAc 1/1). Pale yellow oil, yield 27% (calculated). IR (cm-1): νmax 
1090, 1156, 1326, 1732, 3266, 3524. 1H NMR (400 MHz, CDCl3): δ 1.32 (3H, t, J = 
7.1 Hz, OCH2CH3), 2.43 (3H, s, p-CH3), 3.14 (1H, dd, J = 12.5, 5.0 Hz, CH(H)NH), 
3.34 (1H, d, J = 10.4 Hz, CH(H)I), 3.42 (1H, d, J = 10.4 Hz, CH(H)I), 3.43 (1H, dd, J = 12.5, 8.5 
Hz, CH(H)NH), 4.18-4.35 (2H, m, OCH2CH3), 5.10 (1H, dd, J = 8.5, 5.0 Hz, NH), 7.31 (2H, d, J = 
8.5 Hz, 2 × CHarom), 7.72 (2H, d, J = 8.5 Hz, 2 × CHarom). 13C NMR (100.6 MHz, CDCl3): δ 9.6 
(CH2I), 14.1 (OCH2CH3), 21.5 (p-CH3), 48.2 (CH2NH), 63.5 (OCH2CH3), 76.0 (COH), 127.0 (2 × 
CHarom), 129.8 (2 × CHarom), 136.6 (Carom,quat), 143.8 (Carom,quat), 171.6 (C=O). MS (ES, pos. mode): 
m/z (%): 428 (100) [M+H]+. HRMS: calcd for C13H19INO5S+ [MH]+ 428.0023; found: 428.0004. 
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5.2.39 Synthesis of ethyl 3-chloro-2-hydroxy-2-[((4-methylbenzene)sulfonamido)-
methyl]propanoate 412 
To a solution of ethyl 3-hydroxy-1-(4-methylbenzenesulfonyl)azetidine-3-carboxylate 46a (0.10 g, 
0.33 mmol) in dry CH2Cl2 (4 mL), thionyl chloride (1.2 equiv, 0.03 mL, 0.40 mmol) was added 
dropwise at 0 oC and the reaction mixture was slowly warmed up to room temperature. Then 
triethylamine (1 equiv, 34 mg, 0.33 mmol) was added and the reaction was stirred at room 
temperature for 30 minutes. After completion of the reaction (TLC-monitoring), the solvent was 
evaporated and the crude mixture was purified via column chromatography (PE/EtOAc 3/1) to give 
ethyl 3-chloro-2-hydroxy-2-[((4-methylbenzene)sulfonamido)methyl]propanoate 412. 
Rf = 0.48 (PE/EtOAc 1/1). Colorless amorphous solid, yield 78 %. IR (cm-1): νmax 
1089, 1146, 1240, 1319, 1733, 3271, 3541. 1H NMR (400 MHz, CDCl3): δ 1.31 (3H, 
t, J = 7.1 Hz, OCH2CH3), 2.43 (3H, s, p-CH3), 3.12 (1H, dd, J = 12.5, 5.3 Hz, 
CH(H)NH), 3.35 (1H, dd, J = 12.5, 8.1 Hz, CH(H)NH), 3.62 (1H, d, J = 11.4 Hz, CH(H)Cl), 3.73 
(1H, d, J = 11.4 Hz, CH(H)Cl), 4.18-4.35 (2H, m, OCH2CH3), 4.83 (1H, dd, J = 8.1, 5.3 Hz, NH), 
7.32 (2H, d, J = 7.8 Hz, 2 × CHarom), 7.72 (2H, d, J = 7.8 Hz, 2 × CHarom). 13C NMR (100.6 MHz, 
CDCl3): δ 14.1 (OCH2CH3), 21.5 (p-CH3), 47.6 (CH2NH), 47.7 (CH2Cl), 63.4 (OCH2CH3), 76.9 
(COH), 127.1 (2 × CHarom), 129.9 (2 × CHarom), 136.4 (Carom,quat), 143.9 (Carom,quat), 171.2 (C=O). MS 
(ES, pos. mode): m/z (%): 336/338 (100) [M+H]+. HRMS: calcd for C13H19ClNO5S+ [MH]+ 
336.0667; found: 336.0659. 
5.2.40 Synthesis of ethyl 3-methanesulfonyloxy-1-(4-methylbenzenesulfonyl)azetidine-
3-carboxylate 413 
The synthetic procedure is reported in a preliminary research.[50] Dry THF was used as solvent instead 
of CH2Cl2. 
Yield 95%. Spectral data of ethyl 3-methanesulfonyloxy-1-(4-methylbenzenesulfonyl)azetidine-3-
carboxylate 413 corresponded with described data in the literature.[50] 
5.2.41 Synthesis of ethyl 3-azido-1-tosylazetidine-3-carboxylate 414 
To a solution of ethyl 3-methanesulfonyloxy-1-(4-methylbenzenesulfonyl)azetidine-3-carboxylate 
413 (522 mg, 1.38 mmol) in absolute DMSO (15 mL), sodium iodide (622 mg, 4.15 mmol) was 
added at room temperature and the reaction mixture was stirred for 15 minutes. Subsequently, sodium 
azide (270 mg, 4.15 mmol) was added in one portion and the solution was heated at 85 oC for 20 
hours. After cooling, the reaction mixture was poured into water (10 mL) and extracted with Et2O (3 
× 20 mL). The combined organic extracts were washed with brine (2 × 15 mL) and water (15 mL). 




product was purified by column chromatography to give ethyl 3-azido-1-tosylazetidine-3-
carboxylate 414 (96 mg, 0.30 mmol, 21%). Starting material 413 was isolated and subsequently used 
again for the synthesis of compound 414 via the above described procedure. When the reaction was 
performed with 4.0 equiv NaI and 4.0 equiv NaN3 at 110 oC for 24 h, the formation of the side product 
ethyl 2,3-diazido-2-[((4-methylbenzene)sulfonamide)methyl]propanoate 415, which can be isolated 
by flash chromatography in 5% yield, was observed. CAUTION: strict safety measurements have to 
be applied for reactions with NaN3 to avoid risk of explosions (safety shield). 
Ethyl 3-azido-1-tosylazetidine-3-carboxylate 414 
Rf = 0.23 (PE/Et2O 7/3). Yellow viscous oil, yield 56%. IR (cm-1): νN3 = 2116, νC=O = 
1732, νS=O = 1161. 1H NMR (400 MHz, CDCl3): δ 1.24 (3H, t, J = 7.1 Hz, OCH2CH3), 
2.47 (3H, s, p-CH3), 3.82 (2H, d, J = 9.8 Hz, CH(H)NCH(H)), 4.19 (2H, d, J = 9.8 Hz, 
CH(H)NCH(H)), 4.20 (2H, q, J = 7.1 Hz, OCH2CH3), 7.40 (2H, d, J = 8.2 Hz, 2 × CHarom), 7.74 (2H, 
d, J = 8.2 Hz, 2 × CHarom). 13C NMR (100.6 MHz, CDCl3): δ 13.9 (OCH2CH3), 21.6 (p-CH3), 58.2 
(CCH2), 58.4 (CH2NCH2), 63.0 (OCH2CH3), 128.4 (2 × CHarom), 130.0 (2 × CHarom), 131.2 (Carom,quat), 
144.7 (Carom,quat), 167.9 (C=O). MS (ES, pos. mode): m/z (%): 325 (100) [M+H]+. HRMS: calcd for 
C13H17N4O4S+ [MH]+ 325.0965; found: 325.0956. 
Ethyl 2,3-diazido-2-[((4-methylbenzene)sulfonamide)methyl]propanoate 415 
Rf = 0.13 (PE/Et2O 7/3). Pale yellow oil, yield 5%. IR (cm-1): νNH = 3276, νN3 = 
2106, νC=O = 1739, νS=O = 1161. 1H NMR (400 MHz, CDCl3): δ 1.33 (3H, t, J = 7.1 
Hz, OCH2CH3), 2.44 (3H, s, p-CH3), 3.16 (1H, dd, J = 13.2, 6.9 Hz, CH(H)NH), 
3.25 (1H, dd, J = 13.2, 6.9 Hz, CH(H)NH), 3.64 (1H, d, J = 12.6 Hz, CH(H)N3), 3.77 (1H, d, J = 
12.6 Hz, CH(H)N3), 4.25-4.33 (2H, m, OCH2CH3), 4.88 (1H, t, J = 6.9 Hz, NH), 7.33 (2H, d, J = 8.2 
Hz, 2 × CHarom), 7.73 (2H, d, J = 8.2 Hz, 2 × CHarom). 13C NMR (100.6 MHz, CDCl3): δ 14.1 
(OCH2CH3), 21.6 (p-CH3), 46.0 (CH2NH), 54.3 (CH2N3), 63.3 (OCH2CH3), 68.3 (CN3), 127.0 (2 × 
CHarom), 130.0 (2 × CHarom), 136.5 (Carom,quat), 144.0 (Carom,quat), 168.2 (C=O). MS (ES, pos. mode): 
m/z (%): 368 (100) [M+H]+. HRMS: calcd for C13H18N7O4S+ [MH]+ 368.1136; found: 368.1122. 
5.2.42 Synthesis of ethyl 3-amino-1-tosylazetidine-3-carboxylate 47a 
To a solution of ethyl 3-azido-1-tosylazetidine-3-carboxylate 414 (9 mg, 0.03 mmol) in EtOH (1 
mL), Pd (3 mg, 10 wt.% on carbon) was added and the reaction mixture was stirred under H2 
atmosphere (1 bar) at room temperature for 1.5 h. Subsequently, the reaction mixture was filtered 
over Celite® and the filter cake was washed with a small portion of EtOH. Evaporation of the solvent 
under reduced pressure and purification of the crude mixture by preparative TLC on silica gel 
afforded pure compound 47a.  
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Rf = 0.39 (PE/EtOAc 5/95). Yellow oil, yield 83%. IR (cm-1): νNH = 3358, νC=O = 
1730, νS=O = 1152. 1H NMR (400 MHz, CDCl3): δ 1.18 (3H, t, J = 7.1 Hz, OCH2CH3), 
1.26 (2H, br s, NH2), 2.43 (3H, s, p-CH3), 3.64 (2H, d, J = 9.0 Hz, CH(H)NCH(H)), 
4.11 (2H, q, J = 7.1 Hz, OCH2CH3), 4.15 (2H, d, J = 9.0 Hz, CH(H)NCH(H)), 7.38 (2H, d, J = 8.2 
Hz, 2 × CHarom), 7.75 (2H, d, J = 8.2 Hz, 2 × CHarom). 13C NMR (100.6 MHz, CDCl3): δ 13.9 
(OCH2CH3), 21.6 (p-CH3), 53.0 (CCH2), 62.01 (OCH2CH3), 62.04 (CH2NCH2), 128.5 (2 × CHarom), 
129.8 (2 × CHarom), 131.6 (Carom,quat), 144.3 (Carom,quat), 171.8 (C=O). MS (ES, pos. mode): m/z (%): 
299 (100) [M+H]+. HRMS: calcd for C13H19N2O4S [MH]+ 299.1060; found: 299.1068. 
5.2.43 Synthesis of 3-azido-1-tosylazetidine-3-carboxylic acid 48a 
To a solution of ethyl 3-azido-1-tosylazetidine-3-carboxylate 414 (30 mg, 0.09 mmol) in MeOH (2 
mL) was added dropwise at 0 oC 2M NaOH(aq) (2 mL), and the reaction mixture was stirred at room 
temperature for 2 h. The reaction mixture was acidified with 1M HCl aq. solution till pH = 7 and 
extracted with EtOAc (3 × 5 mL). The combined organic phases were dried (MgSO4), filtered and 
evaporated in vacuo. The crude product was purified by column chromatography to give 3-azido-1-
tosylazetidine-3-carboxylic acid 48a.  
Rf = 0.19 (PE/Et2O 1/1). Yellow oil, yield 80%. IR (cm-1): νOH = 3221, νN3 = 2108, 
νC=O = 1731, νS=O = 1157. 1H NMR (400 MHz, CDCl3): δ 2.48 (3H, s, p-CH3), 3.83 
(2H, d, J = 9.5 Hz, CH(H)NCH(H)), 4.21 (2H, d, J = 9.5 Hz, CH(H)NCH(H)), 7.40 
(2H, d, J = 8.2 Hz, 2 × CHarom), 7.74 (2H, d, J = 8.2 Hz, 2 × CHarom). 13C NMR (100.6 MHz, CDCl3): 
δ 21.7 (p-CH3), 58.2 (CCH2), 58.4 (CH2NCH2), 128.4 (2 × CHarom), 130.0 (2 × CHarom), 131.2 
(Carom,quat), 144.7 (Carom,quat), 168.5 (C=O). MS (ES, pos. mode): m/z (%): 297 (100) [M+H]+. HRMS: 
calcd for C11H11N4O4S- [M-H+] 295.0507; found: 295.0516. 
5.2.44 Synthesis of methyl N-(tert-butoxycarbonyl)-3-hydroxyazetidine-3-carboxylate 
46b 
A mixture of magnesium powder (33 mg, 1.37 mmol) in dry MeOH (1 mL) was stirred at room 
temperature for 10 min. The reaction mixture was cooled down to 0 oC and a solution of ethyl 3-
hydroxy-1-(4-methylbenzenesulfonyl)azetidine-3-carboxylate 46a (41 mg, 0.13 mmol) in dry MeOH 
(2 mL) was added dropwise. Subsequently, the resulting suspension was allowed to warm up to room 
temperature. After 16 h, a second portion of magnesium powder (16 mg, 0.68 mmol) was added. The 
suspension was stirred for another 2 h at room temperature. Subsequently, the reaction mixture was 
cooled down to 0 oC and Et3N (14 mg, 0.14 mmol) was added dropwise followed by addition of a 
solution of di-tert-butyl dicarbonate (31 mg, 0.14 mmol) in MeOH (0.5 mL). The ice bath was 
removed and the resulting suspension was stirred at room temperature for 3 h. Subsequently, the 




dissolved in aqueous NH4Cl and extracted with EtOAc (3 × 5 mL). The combined organic phases 
were dried (MgSO4), filtered and evaporated in vacuo. The purification of the crude mixture by 
preparative TLC on silica gel afforded pure methyl N-(tert-butoxycarbonyl)-3-hydroxyazetidine-3-
carboxylate 46b. CAUTION: strict safety measurements have to be applied for Mg-promoted 
reactions to avoid risk of violent reactions, fires or explosions (safety shield). 
Rf = 0.27 (PE/Et2O 3/7). Colorless oil, yield 54%. IR (cm-1): νOH = 3387, νC=O = 1740, 
νC=O = 1675. 1H NMR (400 MHz, CDCl3): δ 1.46 (9H, s, tBu), 3.63 (1H, s, OH), 3.90 
(3H, s, OCH3), 4.01 (2H, d, J = 9.9 Hz, CH(H)NCH(H)), 4.26 (2H, d, J = 9.9 Hz, 
CH(H)NCH(H)). 13C NMR (100.6 MHz, CDCl3): δ 28.3 (3C, tBu), 53.6 (OCH3), 60.8 (CH2NCH2), 
69.2 (CCH2), 80.1 (C(CH3)3), 156.1 (C=O), 174.0 (C=O). MS (ES, pos. mode): m/z (%): 132 (100) 
[(M-Boc)+H]+. HRMS: calcd for C5H10NO5+ [(M-Boc)+H]+ 132.0655; found: 132.0656. 
Compounds 46c, 417 and 418 were formed as a side products during the optimization of N-
deprotection reaction of ethyl 3-hydroxy-1-(4-methylbenzenesulfonyl)azetidine-3-carboxylate 46a 
(See table 17). The spectral data of the pure isolated compounds are given below:  
Methyl 3-hydroxy-1-(4-methylbenzenesulfonyl)azetidine-3-carboxylate 46c 
Rf = 0.15 (PE/Et2O 3/7). White crystals, yield 15%. Mp 105.5-106.5 ºC. IR (cm-1): 
νOH = 3410, νC=O = 1739, νS=O = 1156. 1H NMR (400 MHz, CDCl3): δ 2.47 (3H, s, p-
CH3), 3.55 (1H, s, OH), 3.80 (3H, s, OCH3), 3.82 (2H, d, J = 9.2 Hz, CH(H)NCH(H)), 
4.17 (2H, d, J = 9.0 Hz, CH(H)NCH(H)), 7.39 (2H, d, J = 8.2 Hz, 2 × CHarom), 7.75 (2H, d, J = 8.2 
Hz, 2 × CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.6 (p-CH3), 53.8 (OCH3), 61.8 (CH2NCH2), 
67.8 (CCH2), 128.4 (2 × CHarom), 129.8 (2 × CHarom), 131.3 (Carom,quat), 144.3 (Carom,quat), 173.1 (C=O). 
MS (ES, pos. mode): m/z (%): 286 (100) [M+H]+. HRMS Calcd for C12H16NO5S+ [MH]+ 286.0744; 
found: 286.0751. 
1-(tert-Butoxycarbonyl) methyl 3-[(tert-butoxycarbonyl)oxy]azetidine-3-carboxylate 417 
Rf = 0.50 (PE/Et2O 1/1). Yellow oil, yield 8%. IR (cm-1): νC=O = 1743, νC=O = 1706. 
1H NMR (400 MHz, CDCl3): δ 1.45 (9H, s, tBu), 1.50 (9H, s, tBu), 3.84 (3H, s, 
OCH3), 4.09 (2H, d, J = 10.1 Hz, CH(H)NCH(H)), 4.38 (2H, d, J = 10.1 Hz, 
CH(H)NCH(H)). 13C NMR (100.6 MHz, CDCl3): δ 27.6 (3C, tBu), 28.3 (3C, tBu), 53.1 (OCH3), 
57.6, 73.3 (CCH2), 80.4 (C(CH3)3), 84.2 (C(CH3)3), 151.2 (C=O), 155.9 (C=O), 169.3 (C=O). MS 
(ES, pos. mode): m/z (%): 220 (100) [(M-C8H16)+H]+. HRMS: calcd for C5H10NO3+ [(M-2xBoc)+H]+ 
132.0655; found: 132.0657. 
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Methyl 3-[(tert-butoxycarbonyl)oxy]-1--(4-methylbenzenesulfonyl)azetidine-3-carboxylate 27 
Rf = 0.33 (PE/Et2O 1/1). Pale yellow oil, yield 5%. IR (cm-1): νC=O = 1740, νS=O = 
1160. 1H NMR (400 MHz, CDCl3): δ 1.45 (9H, s, tBu), 2.48 (3H, s, p-CH3), 3.70 
(3H, s, OCH3), 4.00 (2H, d, J = 9.7 Hz, CH(H)NCH(H)), 4.26 (2H, d, J = 9.7 Hz, 
CH(H)NCH(H)), 7.39 (2H, d, J = 8.3 Hz, 2 × CHarom), 7.75 (2H, d, J = 8.3 Hz, 2 × CHarom). 13C NMR 
(100.6 MHz, CDCl3): δ 21.7 (p-CH3), 27.5 (3C, tBu), 53.2 (OCH3), 58.6 (CH2NCH2), 72.1 (CCH2), 
84.5 (C(CH3)3), 128.4 (2 × CHarom), 129.9 (2 × CHarom), 131.7 (Carom,quat), 144.5 (Carom,quat), 151.4 
(C=O), 168.2 (C=O). MS (ES, pos. mode): m/z (%): 330 (100) [(M-C4H8)+H]+. HRMS: calcd for 



























The discovery of non-proteinogenic amino acids among natural products has significantly increased 
interest in this class of compounds as they may possess interesting biological activity and could also 
serve as valuable building blocks in the synthesis of new classes of bioactive compounds as well as 
for the synthesis and design of peptides. Some natural non-proteinogenic amino acids were proposed 
as neurotoxic compounds which play a role in neurodegenerative diseases. The misincorporation of 
some non-proteinogenic amino acids into proteins in place of canonical amino acids causes toxic 
effect and has been implicated in the pathophysiology of a wide range of diseases, including 
amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. In that respect, the synthesis of new 
derivatives of non-proteinogenic α- and β-amino acids, including acyclic and cyclic scaffolds, was 
the subject of the present research. 
In the first part of this PhD thesis, iminoacetates i were used for (asymmetric) synthesis of non-
proteinogenic diamino acid derivatives (Scheme 110). The condensation of iminoacetates i with 1-
(methylenamino)pyrrolidine ii, N-sulfinyl imidates iii and 3,3-dichloroketimines iv afforded adducts 
v/vi, viii and ix, respectively. Unfortunately, further transformations of the mixture vb/vib towards 
the desired amino acid derivatives vii could not be realized due to instability of the adducts. Adduct 
ixa was tested as a possible precursor for the asymmetric synthesis of aziridine-2-carboxylic acid 






In the next part of the research, the synthesis of 3-chloroazetidine-2-carboxylic acid xvi from 
enantiomerically pure 2-arylazetidines xiv was attempted (Scheme 111). The latter azetidines were 
synthesized via an earlier described procedure based on a Mannich-type reaction of methyl α-chloro-
N-sulfinyl acetimidate across aromatic aldimines. However, the oxidation of the 2-aryl substituent 
failed, giving the ring opened product xvii (only xviib was isolated). Nucleophilic substitution of 
chloride to an azido group could also not be achieved (Scheme 111). 
 
Scheme 111 
A modification of the aromatic substituent to a 3,5-dimethoxyphenyl moiety was investigated to 
facilitate the oxidation process. However, the selectivity and efficiency of the key step involving the 
formation of imidate xx (Scheme 112) dropped significantly when aldimine xix was used as starting 
material. Subsequent N-sulfinyl deprotection, en route towards the corresponding azetidine, afforded 
undesired amide xxi (R = NH2) as main product instead of ester xxi (R = OMe). 
 
Scheme 112 
Furthermore, the use of δ-chloro N-sulfinyl imidates xxiv in the addition reaction across aromatic 
aldimines led to the synthesis of new chiral β-aryl-δ-chloro-substituted β-amino acid derivatives xxv 
and xxvi as potential building blocks of enantiopure functionalized piperidines (Scheme 113). 





Diastereomers xxv and xxvi were separated and selected derivatives were subjected to further 
transformations (Scheme 114). The base-promoted cyclization of imidates xxv and xxvi afforded 
piperidines xxvii and xxviii. The latter were N-deprotected leading to the formation of amides (xxix 
and xxx) or esters (xxxiii and xxxiv). Hofmann rearrangement of the amides xxix and xxx provided 
the enantiomerically pure 3-amino-2-arylpiperidines xxxi and xxxii. The N-detosylation of esters 






The N-benzyl protection of the cis-piperidine-3-carboxylate xxxv and subsequent treatment with a 
base afforded the trans-derivative xxxviii (Scheme 115). 
 
Scheme 115 
In the third part of this PhD, fluorinated azetidines were synthesized and their reactivity was 
investigated. The synthesis of key precursor cis-xliv was performed via Reformatsky-type reaction 
of dibromofluoroacetate xxxix and aldimines xliii (Scheme 116). The formation of adducts xlv and 
aziridines xlvi was observed in some cases. When aldimine xix, bearing an electron-withdrawing 
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group at nitrogen, was subjected to the condensation with acetate xxxix, adduct xl was obtained 
which was further cyclized towards aziridines xli and xlii. 
 
Scheme 116 
The reduction of cis-β-lactams xliv was accomplished using chloroalane in Et2O, affording cis-2-
aryl-3-bromo-3-fluoroazetidines xlvii, exclusively (Scheme 117). In the next step, the reactivity of 
the fluorinated azetidines xlvii was investigated (Scheme 117). The unexpected nucleophilic attack 
at the C-2 position of the azetidine ring afforded 2-aryl-2-cyano-3-fluoroazetidine xlviii and side 
product xlix, when the reaction was performed in methanol. Furthermore, the azetidines xlvii were 
used in a halogen-lithium exchange strategy. When water was used as an electrophile, trans-2-aryl-
3-fluoroazetidines l were formed. Other electrophilic reagents did not lead to the desired substitution. 
The treatment of azetidine xlvii (R2 = 4-MeOC6H4) with NaH in DMSO followed by aqueous work-






Furthermore, the influence of substrate structure on the reactivity of 3-fluorinated azetidines xlvii 
was investigated. Thus, trans-3-fluoro-3-iodo-2-phenylazetidine lv was prepared via reduction of β-
lactam liv (Scheme 118). Despite several attempts, the nucleophilic substitution of iodide in azetidine 
lv using sodium azide in different solvents was not successful. 
 
Scheme 118 
In the last part of this PhD thesis, aminodiols lx were elaborated towards small membered amino 
acid derivatives bearing an aziridine, azetidine and epoxide scaffold. The starting aminodiols lx were 




The cyclization of aminodiol lxb under Mitsunobu conditions afforded epoxide lxvib (Scheme 120). 
A more efficient synthesis of epoxides lxvi was accomplished via a monomesylation/cyclization 
sequence. When bismesylated aminodiols lxii were treated with potassium carbonate, the cyclization 
towards aziridine lxva occurred smoothly but prior N-Boc deprotection was necessary in order to 
obtain aziridine lxvb. The tertiary hydroxyl group of monomesylated substrates lxi was TMS-
protected, affording mesylates lxiii. Only N-Tos protected mesylate lxiiia was cyclized to the 
azetidine lxiva. The O-deprotection and subsequent mesylation of the hydroxyl group of azetidine 
lxiva afforded mesylate lxviii. Azetidine lxviii was elaborated towards the 3-azidoazetidine lxix, 
while reduction or hydrolysis of the latter afforded the 3-aminoazetidine-3-carboxylate lxx or 
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azetidine-3-carboxylic acid lxxi, respectively. Additional transformation of azetidine lxvii towards 
N-Boc protected azetidine lxxii was performed via an N-detosylation/N-protection sequence. 
 
Scheme 120 
In conclusion, this PhD work resulted in the preparation of diverse acyclic and cyclic non-
proteinogenic amino acid derivatives such as aziridines, epoxides, azetidines and piperidines with 
different types of substitution, including some enantiomerically enriched compounds. 
Some of the established synthetic approaches provide great potential in the synthesis of various 














De ontdekking van niet-proteïnogene aminozuren in natuurlijke producten deed de belangstelling 
voor deze klasse van verbindingen aanzienlijk toenemen. Naast een mogelijk interessante 
biologische activiteit, kunnen ze een waardevolle rol spelen als bouwstenen bij de synthese van 
nieuwe klassen van bioactieve verbindingen en bij de synthese en het ontwerp van peptiden. 
Sommige natuurlijk voorkomende niet-proteïnogene aminozuren worden beschouwd als 
neurotoxische verbindingen met een rol in neurodegeneratieve ziektes. De foutieve incorporatie van 
een aantal niet-proteïnogene aminozuren in plaats van de canonieke aminozuren in eiwitten brengt 
toxische effecten teweeg en is betrokken bij de pathofysiologie van een brede waaier ziekten, zoals 
amyotrofische laterale sclerose (ALS) en de ziekte van Alzheimer. Vanuit dit oogpunt was de 
synthese van nieuwe derivaten van niet-proteïnogene α- en β-aminozuren, waaronder acyclische en 
cyclische derivaten, een relevant onderwerp voor het huidige onderzoek. 
In het eerste deel van dit proefschrift werden iminoacetaten i gebruikt voor de (asymmetrische) 
synthese van niet-proteïnogene diaminozuurderivaten (Schema 1). De condensatie van iminoacetaten 
i met 1-(methyleenamino)pyrrolidine ii, N-sulfinyl imidaten iii en 3,3-dichloorketiminen iv gaf de 
adducten v/vi, viii en ix, respectievelijk. Verdere omzettingen van het mengsel v/vi naar de gewenste 
aminozuurderivaten vii kon jammerlijk niet worden gerealiseerd vanwege de instabiliteit van de 
adducten. Adduct ixa werd getest als een mogelijke precursor voor de asymmetrische synthese van 







In het volgende deel van dit onderzoek werd de synthese van 3-chloorazetidine-2-carbonzuur xvi 
vanuit enantiomeer zuivere 2-arylazetidines xiv beoogd (Schema 2). De azetidines xiv werden 
gesynthetiseerd via een eerder beschreven procedure op basis van een Mannich-type reactie van 
methyl α-chloor-N-sulfinyl acetimidaat en een aromatisch aldimine. De oxidatie van de 2-
arylsubstituent mislukte, waardoor het geringopend product xvii (alleen xviib werd geïsoleerd) 
bekomen werd. De nucleofiele substitutie van het chlooratoom met een azidogroep was evenmin 
succesvol (Schema 2). 
 
Schema 2 
De wijziging van de aromatische substituent naar een 3,5-dimethoxyfenyl-groep werd geëvalueerd 
om de oxidatie te vergemakkelijken. Echter, hierdoor daalde de selectiviteit en de efficiëntie van de 
vorming van imidaat xx (Schema 3) aanzienlijk wanneer aldimine xix werd gebruikt als 
uitgangsmateriaal. Daaropvolgende N-sulfinyl ontscherming, om het overeenkomstige azetidine te 
bekomen, leverde het ongewenste amide xxi (R = NH2) als hoofdproduct in plaats van het ester xxi 
(R = OMe). 
 
Schema 3 
Het gebruik van δ-chloor-N-sulfinyl imidaten xxiv in de additiereactie met aromatische aldiminen 
leidde tot de synthese van de nieuwe, chirale β-aryl-δ-chloor-gesubstitueerde β-aminozuurderivaten 
xxv en xxvi als mogelijke bouwstenen voor enantiomeer zuivere, gefunctionaliseerde piperidinen 
(Schema 4). 





Diastereomeren xxv en xxvi werden gescheiden en geselecteerde derivaten werden gebruikt voor 
verdere transformaties (Schema 5). De base bevorderde ringsluiting van imidaten xxv en xxvi leidde 
tot piperidinen xxvii en xxviii. Deze laatste werden N-ontschermd tot de amiden (xxix en xxx) of 
esters (xxxiii en xxxiv). Hofmann-omlegging van de amiden xxix en xxx gaf de enantiomeer zuivere 
3-amino-2-arylpiperidinen xxxi en xxxii. De N-detosylering van de esters xxxiii en xxxiv gaf 






De N-benzyl bescherming van cis-piperidine-3-carboxylaat xxxv en de daaropvolgende behandeling 
met een base leverde het trans-derivaat xxxviii op (Schema 6). 
 
Schema 6 
In een derde luik van dit doctoraat werden gefluoreerde azetidinen gesynthetiseerd en werd hun 
reactiviteit onderzocht. De synthese van de belangrijkste precursor cis-xliv gebeurde via een 
Reformatsky-type reactie met dibroomfluoracetaat xxxix en aldiminen xliii (Schema 7). De vorming 
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van adducten xlv en aziridinen xlvia,b werd geobserveerd in sommige gevallen. Wanneer aldimine 
xixa, voorzien van een elektronenzuigende groep op het stikstofatoom, werd onderworpen aan een 
condensatiereactie met acetaat xxxix, werd adduct xl verkregen, dat werd gecycliseerd tot aziridines 
xli and xlii. 
 
Schema 7 
De reductie van cis-β-lactam xliv werd bewerkstelligd met behulp van chlooralaan in Et2O en gaf 
uitsluitend aanleiding tot cis-2-aryl-3-broom-3-fluorazetidines xlvii (Schema 8). In de volgende stap 
werd de reactiviteit van de verkregen gefluoreerde azetidines xlvii onderzocht (Schema 8). Een 
onverwachte nucleofiele aanval trad op aan de C-2 positie van de azetidinering, wat aanleiding gaf 
tot 2-aryl-2-cyaan-3-fluorazetidine xlviii en nevenproduct xlix wanneer de reactie werd uitgevoerd 
in methanol. Azetidines xlvii werden ook gebruikt in een halogeen-lithium-uitwisselingsstrategie. 
Wanneer water werd gebruikt als elektrofiel, werden trans-2-aryl-3-fluorazetidines l gevormd. 
Andere elektrofiele reagentia leidden niet tot de gewenste substitutie. De behandeling van azetidine 
xlvii (R2 = 4-MeOC6H4) met NaH in DMSO, gevolgd door een waterige opwerking bewerkstelligde 






Vervolgens werd de invloed van de substraatstructuur op de reactiviteit van 3-gefluoreerde azetidines 
xlvii onderzocht. Aldus werd trans-3-fluor-3-jood-2-fenylazetidine lv bereid via de reductie van β-
lactam liv (Schema 9). Ondanks verschillende pogingen, faalde de nucleofiele substitutie van het 
joodatoom in azetidine lv gebruik makende van natriumazide en dit in verschillende solventen. 
 
Schema 9 
In het laatste deel van dit proefschrift werden aminodiolen lx verder omgezet tot aminozuurderivaten 
voorzien van een aziridine, azetidine of epoxide-eenheid. De benodigde aminodiolen lx werden 
gesynthetiseerd uit gefunctionaliseerde allylamines lix via een OsO4 gekatalyseerde dihydroxylering 
(Schema 10). 





De ringsluiting van aminodiol lxb onder Mitsunobu-condities gaf epoxide lxvib (Schema 11). Een 
efficiëntere synthese van epoxiden lxvi werd bekomen via een 
monomesylering/ringsluitingssequentie. Wanneer bisgemesyleerde aminodiolen lxii met 
kaliumcarbonaat behandeld werden, ging de ringsluiting tot aziridine lxva vlot door, alhoewel een 
voorafgaande N-Boc-ontscherming noodzakelijk was om aziridine lxvb te verkrijgen. De tertiaire 
hydroxylgroep van monogemesyleerde substraten lxi werd TMS-beschermd, met als resultaat 
mesylaten lxiii. Alleen het N-Tos beschermde mesylaat lxiiia werd gecycliseerd tot het azetidine 
lxiva. De O-ontscherming en daaropvolgende mesylering van de hydroxylgroep van azetidine lxiva 
gaf mesylaat lxviii. Azetidine lxviii werd verder omgezet tot 3-azidoazetidine lxix. Reductie of 
hydrolyse van het laatstgenoemde azetidine leverde het 3-aminoazetidine-3-carboxylaat lxx of het 
azetidine-3-carbonzuur lxxi, respectievelijk. Een extra transformatie van azetidine lxvii tot het N-






Samengevat, resulteerde dit onderzoek in de synthese van verschillende acyclische en cyclische niet-
proteïnogene aminozuurderivaten zoals aziridinen, epoxiden, azetidinen en piperidines met 
verschillende substituties, waaronder ook enkele enantiomeer aangerijkte verbindingen. Enkele van 
de ontwikkelde synthetische protocollen hebben een groot potentieel in de synthese van verschillende 
biologisch relevante verbindingen.    
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